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Mature blood cells perform a variety of tasks, involving the transport of oxygen to all tissues by 
erythrocytes (red blood cells), clotting of blood mediated by thrombocytes (platelets) and the 
defense against infectious agents by leukocytes (white blood cells). Most of these cells have a life span 
of only hours to weeks. This implicates that the adult human hematopoietic system must be capable 
of producing billions of blood cells each day during the life of an individual. In case of an event such 
as infection or bleeding, the demand for specific blood cells is even greater and production has to 
increase further. Considering the important tasks of the mature blood cells, an insufficient quantity 
or quality of these cells, as occurs in myelodysplastic syndromes, may have profound consequences. 
Hematopoiesis
Although hematopoietic cells perform a variety of functions, all differentiated blood cells originate 
from the same hematopoietic stem cell (HSC) population (Figure 1)1-4. By definition, HSCs have 
the ability to self-renew and to give rise to progeny that can develop into mature blood cells. In 
the past, the first step of differentiation was thought to involve the choice between the lymphoid 
cell lineage (giving rise to T-cells, B-cells and NK-cells) and the myeloid cell lineage (giving rise 
to erythrocytes, platelets, granulocytes and monocytes). More recently, experiments using mouse 
models indicated that lymphoid progenitor cells maintain the ability to produce myeloid cell types5-9. 
This phenomenon also seems to apply to adult human hematopoiesis, although the potential of the 
different progenitors may not be identical to murine blood cell formation10. The extent to which 
“cross-over” between the original myeloid and lymphoid lineages occurs in physiological conditions 
in the adult human body, is not known and the current models of hematopoiesis will be subject to 
further adjustments in the future. 
Figure 1 
The hematopoietic stem cell (HSC) gives rise to all 
blood cells. The path of differentiation that the he-
matopoietic cells follow to become one of the ma-
ture blood cell types, is still subject of study. Recent 
experiments suggested the existence of a multilym-
phoid progenitor that gives rise to B-cells and NK-
cells as well as dendritic cells and macrophages10. 
HSC hematopoietic stem cell; CMP common my-
eloid progenitor; MLP multilymphoid progenitor; 
MEP megakaryocyte-erythroid progenitor; GMP 
granulocyte-monocyte progenitor; MDP mono-
cyte-dendritic cell progenitor.
Although the route from HSC to specialized blood cell is not fully elucidated yet, it is clear that the 
direction in which the cells develop is influenced by both intrinsic and extrinsic factors. Within the 
bone marrow a limited number of specialized niches exist in which the HSCs reside. The interaction 
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between HSCs and their niche is thought to balance the quiescence and self-renewal of HSCs as well 
as control their differentiation11. Signaling pathways including Notch and Wnt appear to be involved 
in these interactions11-16. In order to guide proliferation and differentiation of HSCs and progenitor 
cells, hematopoietic growth factors mediate signals via receptors on the surface of these cells17. Some 
growth factors act at early stages of hematopoiesis and stimulate differentiation towards multiple 
cell types, whereas others stimulate a specific cell lineage. Examples of the first group are Stem Cell 
Factor (SCF) and IL-3, which stimulate the proliferation of HSCs and progenitor cells. Examples of 
more lineage-specific growth factors are erythropoietin (Epo), which promotes the proliferation of 
erythroid progenitor cells, and granulocyte colony stimulating factor (G-CSF), which stimulates the 
production of neutrophils. After binding of growth factors to their receptors, signals are passed by 
activation of kinases, for example of the Janus kinase family (JAKs), initiating a cascade of secondary 
events that eventually lead to changes in cell survival, proliferation and differentiation. In addition to 
these extracellular signals, hematopoietic cell fate is influenced by a network of transcription factors. 
As the cells differentiate, specific transcription factors must be expressed at a certain level, whereas 
other transcription factors must be switched off. Changes in the balance between transcription 
factors can change the fate of the cell. For example, Pax5 drives differentiation towards B-cells at the 
expense of other cell lineages18;19. The transcription factor PU.1 activates myeloid- or B-cell specific 
gene expression, depending on the presence of other transcription factors, while genes associated 
with erythroid, NK- or T-cell development are repressed20-23. C/EBPα suppresses both lymphoid and 
erythroid development, favoring myeloid differentiation24. Considering the important influence that 
transcription factors exert on cell development, their expression must be tightly regulated. Epigenetic 
changes are thought to play an important part in this regulation and have recently been the subject 
of many studies. Epigenetics is defined as the study of heritable changes in gene activity that cannot 
be explained by changes in the DNA sequence itself. Epigenetic regulation includes processes such 
as DNA methylation and histone tail modifications (Box 1). Although these modifications can be 
preserved during cell division, the epigenetic marks may also change. The genomic regions in which 
histone tail modifications and DNA methylation are present, the combined presence of various 
modifications and the extent of modification (e.g. di- or trimethylation of lysines) influence the 
expression of HSC and cell lineage associated genes and thereby play a role in directing cell fate. 
It has been suggested that HSCs contain a permissive chromatin structure, in which repressive 
and activating modifications may occur alone or together near the same genes and additional 
cofactors must be present to induce an effect on gene transcription. This epigenetic plasticity may be 
progressively reduced in differentiating cells25-28.
Hematopoietic malignancies
If a defect in the HSC or an early hematopoietic progenitor cell (HPC) arises that disturbs the finely 
balanced process of hematopoiesis mentioned above, this cell may obtain a proliferative advantage 




DNA is the same in all somatic cells of 
a human being (although exceptions 
exist; consider DNA rearrangement 
in lymphocytes). However, these so-
matic cells perform a variety of functi-
ons. This can be explained by changes 
in the activity of specific sections of 
DNA. The changes in DNA transcrip-
tion through modulation of chromatin 
is defined as epigenetics.  
 
Chromatin can be modified in a num-
ber of ways. Two important ways are 
methylation of DNA and modification 
of histones.  DNA methylation of cyto-
sines within gene regulatory DNA se-
quences can influence the transcription 
of the related gene(s). It is associated 
with a closed and less accessible confi-
guration of the chromatin. In general, 
repression of the associated gene occurs 
either directly or through concomitant 
epigenetic events, such as recruitment 
of repressive protein complexes. DNA methylation is catalyzed by the family of DNA me-
thyltransferases (DNMTs). The methylation patterns can be maintained when cells divide, 
although changes may occur. 
         
Histone tail modifications include phosphorylation, acetylation, methylation, sumoylation and 
ubiquitylation. These modifications can lead either to activation or repression of the associated 
genes. Acetylation and methylation of histones were among the first covalent modifications to 
be described. Acetylation occurs mainly at lysine residues in the amino termini of histones H3 
and H4 and leads to activation. Acetylation is mediated by histone acetyltransferases (HATs) 
and reversed by histone deacetylases (HDACs). Methylation of histone H3 at certain positions 
(K4, K36, K79) results in activation, whereas this process leads to gene repression when other 
loci are affected (H3K9, H3K27, H4K20). Histone methyltransferases are responsible for these 
modifications and include e.g. MLL proteins (H3K4 methylation) and EZH2 (H3K27 methy-
lation). Multiple histone demethylases have been described, such as the JmjC (jumonji)-con-
taining family. These epigenetic chan-
ges to DNA and histones appear to be 
interrelated, for example, after DNA 
methylation occurs, MeCP2 (methyl-
CpG binding protein 2) can be recrui-




characteristics of the malignancy that arises depends on the stage of hematopoiesis in which the 
defect occurs and its potential to influence differentiation into specific lineages. Hematopoietic 
malignancies are grouped into myeloid and lymphoid diseases. Since the research described in this 
thesis mainly focuses on myeloid malignancies, in particular myelodysplastic syndromes, these will 
be discussed here. According to the latest World Health Organization (WHO) classification, myeloid 
malignancies are subdivided into myeloproliferative neoplasms (MPN), myelodysplastic syndromes 
(MDS), an intermediate entity with features of both MPN and MDS (MPN/MDS), acute myeloid 
leukemia (AML) and myeloid/lymphoid neoplasms with eosinophilia and defects of the PDGFRA , 
PDGFRB or FGFR genes29. The prominent morphological feature of MPN is proliferation of one or 
more of the myeloid lineages. The bone marrow is hypercellular and patients have increased numbers 
of mature hematopoietic cells in their blood. The majority of MPN have now been associated with 
specific aberrations that involve genes encoding protein kinases, particularly JAK2, that transmit 
extracellular signals leading to stimulation of proliferation. Like MPN, myelodysplastic syndromes 
are characterized by increased proliferation as well. However, increased cell death of the defective 
cells occurs simultaneously, leading to an ineffective hematopoiesis with cytopenias in the peripheral 
blood. Moreover, cells show dysplastic morphological features. Although multiple large chromosomal 
aberrations have been found in the DNA of bone marrow cells from MDS patients, until recently, 
defects of specific genes have been described in only a minority of patients, which will be discussed 
later. This is in sharp contrast to AML, where a variety of genes have been found to be affected in 
a substantial number of patients. In AML differentiation of hematopoietic cells along one or more 
lineages is completely blocked at a certain stage of differentiation.
Myelodysplastic Syndromes
The term myelodysplastic syndromes refers to a wide variety of malignant hematopoietic disorders. 
Dysplastic features of the erythroid, granulocytic, monocytic or megakaryocytic blood cell lineages 
is one of the main characteristics of these diseases, however they are not specific for MDS. Due to 
the lack of a clear common denominator, a variety of names has been used to describe (a subtype 
of) MDS. “Refractory anemia”, for example, referred to the fact that patients with MDS did not 
respond to the therapies commonly used to treat anemia, and the names “smoldering leukemia” 
or “preleukemia” were used because some patients with MDS eventually developed acute myeloid 
leukemia. The French-American-British (FAB) classification, published in 1976 and revised in 1982, 
was designed to help define MDS based on morphological examination of the blood and bone 
marrow (Table 1)30;31. The clinical phenotype of patients with refractory anemia (RA) or refractory 
anemia with ringed sideroblasts (RARS) was found to be more chronic and less aggressive than that 




French-American British (FAB) Classification of myelodysplastic syndromes (1982)30;31
based on:
percentage of blasts in blood (<1%, 1-5%, >5%) and bone marrow (<5%, 5-20%, 20-30%)
presence or absence of ring sideroblasts
presence or absence of Auer rods
number of (pro)monocytes (above or below 1.0x109/l)
categories:
refractory anemia (RA)
refractory anemia with ring sideroblasts (RARS)
refractory anemia with excess of blasts (RAEB)
refractory anemia with excess of blasts in transformation (RAEB-t)
chronic myelomonocytic leukemia (CMML)
Thus, this classification provided tools to diagnose MDS and predict its clinical course and has been 
used for many years. However, several pitfalls remained. The FAB classification did not take into 
account the number of cell lineages affected by cytopenias and/or dysplasia. In addition, the FAB 
defined entity of chronic myelomonocytic leukemia (CMML) was shown to possess features that 
were characteristic of myeloproliferative disorders as well as MDS33;34. RAEB-t , the most aggressive 
MDS subtype, was defined by an increased percentage of blasts in the blood (>5%) or bone marrow 
(20-30%) or the presence of Auer rods. The importance of this category was questioned later, since 
the prognostic impact of the presence of Auer rods was less important than previously thought35. 
Moreover, the clinical relevance of distinguishing patients with dysplasia and 20-30% blasts (RAEBt) 
or more than 30% blasts (AML with dysplasia) seemed to be limited. The presence of cytogenetic 
aberrations was not included in the FAB classification. To attempt to improve the existing methods 
for risk assessment in MDS, the International Prognostic Scoring System (IPSS) was developed 
in 1997 (Table 2)36. In this system, the percentage of blasts, the number of cytopenias and the 
presence of cytogenetic abnormalities was taken into account, leading to a risk score correlating 
with the prognosis of the patient. The IPSS score was often used in combination with the FAB 
classification. In 2001 the WHO proposed modified criteria to distinguish MDS subtypes which 
should replace the FAB classification (Table 3)37-39. The WHO classification redefines CMML as a 
myeloproliferatieve/myelodysplastic neoplasm (MPN/MDS) and MDS with 20-30% blasts in the 
bone marrow as AML. It recognizes dysplastic changes in the granulocytic and megakaryocytic 
lineages in addition to dysplastic changes of the erythroid cell line and defines the group of refractory 
anemia with multilineage dysplasia (with or without ringed sideroblasts) in addition to the group 
of refractory anemia. Cases with anemia, low blast counts and an isolated deletion of the long arm 
of chromosome 5 were categorized as a separate entity. Although this classification more precisely 
distinguished MDS subtypes, several difficulties remained. For example, the group of patients 
with a cytopenia of one cell lineage but multilineage dysplasia cannot be clearly categorized. Other 
ways to classify these patients have been proposed40. In 2008, the WHO classification was revised 
and a new subgroup named refractory cytopenia(s) with unilineage dysplasia (RCUD, comprising 
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refractory anemia, refractory neutropenia and refractory thrombocytopenia) was added29. Although 
this revision does not solve all problems in classification, it further refines the MDS subtypes. Several 
newer risk-scoring systems that take additional parameters into account have been published or are 
being developed at this moment41-44. For example, the WHO classification-based prognostic scoring 
system (WPSS)41 takes into account karyotypic abnormalities and transfusion dependency, and can 
be used to estimate survival and risk of progression towards AML at any time during the course of 
the disease. 
Table 2
International Prognostic Scoring System (IPSS) (1997)36
based on:
percentage of blasts in the bone marrow (<5%, 5-10%, 11-19%, 20-30%)
number of cytopenias (0-1 versus 2-3)
cytogenetic abnormalities 
 - good: no abnormalities, -Y, del(5q), del(20q)
 - poor: 3 or more abnormalities, chr 7 abnormalities







World Health Organization (WHO) classification of myelodysplastic syndromes (2001)37;38
based on:
percentage of blasts in blood (<1%, 1-5%, >5%) and bone marrow (<5%, 5-9%, 10-19%)
number of cytopenias (anemia versus  bicytopenia or pancytopenia)
number of cell lineages affected by dysplasia (erythroid dysplasia versus multilineage dysplasia)
presence or absence of ring sideroblasts
presence or absence of Auer rods
presence of an isolated del(5q)
categories:
refractory anemia (RA)
refractory anemia with ring sideroblasts (RARS)
refractory anemia with multilineage dysplasia (RCMD)
refractory anemia withmultilineage dysplasia and ring sideroblasts (RCMD-RS)
refractory anemia with excess of blasts (RAEB-1 and RAEB-2, depending on percentage of blasts)
myelodysplastic syndrome unclassified (MDS-U)
myelodysplastic syndrome with isolated del (5q)
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Pathogenesis of myelodysplastic syndromes
Diagnosing MDS and subdividing patients into prognostically relevant groups would be facilitated 
by thorough knowledge of the origin of these diseases. The pathogenesis of MDS is complex and 
may differ depending on the MDS subtype. Several factors that may influence MDS development 
have been studied, including disorders in the regulation of programmed cell death and immune 
responses and (epi) genetic abnormalities. 
Deregulation of programmed cell death
One of the hallmarks of MDS is ineffective hematopoiesis resulting in peripheral cytopenias. 
Increased cell death has been hypothesized to contribute to the failure to produce sufficient mature 
blood cells. During the transformation of MDS to AML, cell death in the immature bone marrow 
cells may be reduced, causing a proliferative advantage of these cells. Different forms of cell death 
have been distinguished45;46; apoptosis, autophagy-associated cell death and necrosis. Apoptosis is 
an ordered process of cellular destruction which is executed by specific enzymes (caspases) that are 
present in cells in an inactive form, but become activated when cells are at the end of their normal 
life span, when they are damaged or when they encounter various types of stress, including chemical 
exposure, viral infection or irradiation (Box 2). The main morphological feature of apoptosis is 
shrinkage of the cell and condensation and fragmentation of DNA in its nucleus. Apoptosis can 
be triggered by intracellular signals, such as DNA damage, and extracellular signals, such as those 
mediated via the death receptors on the cell membrane. Autophagy is a process which targets cellular 
proteins and organelles for degradation in lysosomes. Autophagy is a protective mechanism to allow 
cell survival during the initial stages of starvation and other forms of stress by maintaining production 
of ATP (energy) and eliminating damaged proteins and organelles that accumulate during stress. 
The role of autophagy in cell death is controversial. It is not clear if autophagy can continue to 
the point of caspase-independent cell death without signs of apoptosis. Some genes that have been 
implicated in regulation of apoptosis, such as BCL2 and TP53, have been linked to regulation 
of autophagy as well45. The third type of cell death is necrosis. In general, necrosis is regarded as 
accidental (not programmed) cell death. More recently it has been suggested that regulated forms of 
necrosis exist, mediated by, for example, TNFα. The various forms of cell death can be studied using 
techniques such as electron microscopy (all types of cell death), TUNEL/ISEL assays (apoptosis) 
and determination of expression of cell death-associated proteins (e.g. caspases in apoptosis). In 
most studies, the observation of cytopenias in MDS despite an often hypercellular bone marrow 
has been attributed to defects in the regulation of apoptosis. On examination of the bone marrow 
of MDS patients, increases in apoptotic markers have been described47-54. Several studies indicated 
that apoptosis was increased in particular in the indolent forms of MDS, whereas the aggressive 
phenotype was characterized by lower levels of apoptotic markers. However, conflicting results have 
been published. The methods used to determine the level of apoptosis, the cell lineages studied 
and the selection of patients may have led to these controversies. Deregulation of expression of 
specific proteins that are involved in the execution of apoptosis have been described. For example, 
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it has been reported that expression of BCL2 is decreased in the smoldering MDS cases and/or 
increased in the aggressive phenotype compared to the expression in normal bone marrow52;55-58. 
However, as mentioned above, BCL2 has been implicated in autophagy as well59. Signs of increased 
autophagy, such as double-membraned autophagic vacuoles, have been found in bone marrow of 
patients suffering from MDS60. Thus, deregulation of programmed cell death seems to play a role in 
the development of MDS. Stimulation of proliferation of the hematopoietic cells with growth factors 
such as Epo, G-CSF or Thrombopoietin (TPO) can limit the detrimental effects of hematopoietic 
cell death in some patients.
Box 2
Apoptosis or programmed cell death of the mammalian cell is regulated by specialized 
enzymes, particularly caspases. Caspases are present in the cell in an inactive form and can be 
activated via an extrinsic or intrinsic route (Figure). The initiator caspases (most importantly 8 
and 9) translate an intra- or extracellular death signal into proteolytic activity targeting effector 
caspases. Effector caspases (most importantly 3 and 7) in turn are responsible for the subsequent 
proteolytic events that result in destruction of the cell. Under normal circumstances, apoptosis 
is initiated when the cell receives either an extracellular or intracellular death signal. Examples 
of extracellular death signals are binding of TNFα to its receptor and exposure of the cell to 
granzyme B produced by cytotoxic T-cells or NK-cells. Activation of a death receptor leads 
to cleavage of initiator caspase 8 and, subsequently, effector caspases 3 and 7. Granzyme B 
activates caspases 3 and 9 in the cytoplasm. An important intracellular death signal is the 
presence of DNA damage. Upon this signal, the mitochondrial membrane potential is altered, 
resulting in the release of cytochrome-c and apoptotic peptidase activator 1 (APAF1). These 
proteins recruit initiator caspase 9 to form a protein complex called the apoptosome. The 
apoptosome can induce effector caspase 3, which subsequently leads to cleavage of caspase 7. 
16
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Deregulation of immune responses
T-cells are in general not regarded as part of the malignant clone in MDS61-64. However they may affect 
the development of the disease. Apoptosis can be induced by a T-cell mediated attack on the bone 
marrow cells of MDS patients. Increased production of cytokines and an increased expression of death-
signal mediating receptors, such as Fas, on hematopoietic cells have been found in MDS65-68. After 
recognition of antigens on the outer membrane of target cells, proliferation of T-cells can result in 
clonal or oligoclonal T-cell expansions. Antigens may consist of novel peptides that are not expressed 
in healthy cells. Alternatively, the expression of known antigens may be increased, eliciting an immune 
response. Although skewing of the T-cell receptor repertoire has been shown to occur in the healthy 
elderly population as well, it is increased in MDS patients independent of their age, in particular in 
the CD8+ cells69-72. Activated cytotoxic T-cell subsets also seem to be increased in MDS compared to 
healthy controls63;71;73. In addition, a high number of T-helper 17 cells are present in low-risk MDS 74. 
Th17 cells are thought to induce the production of inflammatory cytokines and increased numbers 
may contribute to the auto-immune response seen in MDS. Alternatively, the response elicited by 
these Th17 cells and also cytotoxic T cells may prevent further disease progression. A subset of MDS 
patients are responsive to treatment with anti-thymocyte-globuline (ATG) and/or cyclosporine75-79. 
ATG has been shown to induce loss of oligoclonally expanded T-cell populations that are responsible 
for suppression of bone marrow cells80;81. In addition to the changes in cytotoxic and helper T cells, 
increased amounts of CD4+CD25highFoxp3+ regulatory T-cells (Treg) have been found in patients with 
more aggressive forms of MDS, suggesting that Treg-mediated immune suppression during these disease 
stages may allow continuing expansion of the malignant cells82;83. Furthermore, disease progression 
may occur due to expression of proteins on the MDS cell membrane that suppress activated T-cells. 
For example, B7-H1 on the MDS cell membrane has been suggested to interact with PD1 on the 
activated T-cells84. Not only T-cells, but also other cells of the immune system have been associated 
with MDS. For example, NK-cell function in MDS patients is altered 85;86. In conclusion, the number 
and activation status of various immune cells may influence the development and course of MDS, not 
only by induction of apoptosis but also by other mechanisms.
Epigenetic abnormalities in MDS
Epigenetic changes are increasingly recognized as important mechanisms by which gene 
transcription is regulated. Aberrant DNA methylation of genes involved in cell-cycle regulation, 
apoptosis and differentiation has been shown In various types of cancer. In MDS, hypermethylation 
of a number of genes has been reported (Table 4). Hypermethylation of some of these genes has 
been shown to correlate with a poor prognosis and worse response to therapy87;88. One of the most 
studied genes is CDKN2B (p15INK4B), a cyclin-dependent kinase (CDK) inhibitor that controls 
cell cycle progression. Silencing of this gene by methylation may contribute to uncontrolled cell 
growth. CDKN2B is frequently methylated in patients with high-risk MDS compared to low-risk 
patients89;90. In patients without CDKN2B methylation, methylation was often acquired at the time 
of progression to leukemia. More recently, global methylation patterns in MDS patients have been 
the focus of several studies 91-93. The results show that hypermethylation in MDS is not restricted to a 
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small subset of genes. Römermann et al. showed that an increase in global methylation could already 
be found in low-risk MDS patients and it was further increased in the high-risk patient group91. 
Table 4
Hypermethylated genes in MDS 
Gene  Location References
CALCA Calcitonin 11p15.2 155;156
CDH1 E-cadherin 16q22.1 88;157-159
CDH13 H-cadherin 16q23.3 88
CDKN2B (p15) Cyclin-dependent kinase inhibitor 2B 9p21 89;90;157;159-168
CTNNA1 Catenin 5q31 110;169
DAPK Death-associated protein kinase 9q34.1 158;159;170;171
DDIT3 DNA-damage-inducible transcript 3 12q13.1-13.2 172
ER Estrogen receptor 6q25.1 88;157
FHIT Fragile histidine triad gene 3p14.2 173;174
GRAF Rho GTPase activating protein 26 5q31 175;176
HIC1 Hypermethylated in cancer 1 17p13.3 87;157
ID4 Inhibitor of DNA binding 4 6p22.3 177
KLF11 Kruppel-like factor 11 2p25 178
MEG3 maternally expressed 3 14q32 179
NOR1 Organic solute carrier partner 1 1p34.3 88
NPM2 Nucleophosmin 2 8p21.3 88
OLIG2 Oligodendrocyte lineage transcription factor 2 21q22.11 88
PGR progesterone receptor 11q22 88
RASSFIA Ras association (RalGDS/AF-6) domain family member 1 3p21.3 180
RB1 Retinoblastoma 1 13q14.2 167
RIL Reversion-induced LIM protein 5q31.1 88;181
SNRPN small nuclear ribonucleoprotein polypeptide N 15q11.2 179
SOCS1 Suppressor of cytokine signaling 1 16p13.13 159;180;182;183
Subsequent studies confirmed the aberrant methylation of promoter regions in high risk MDS 
patients and provided large numbers of differentially methylated genes in MDS patients compared 
to healthy controls92;93. In healthy cells DNA methylation is required for maintaining silence in 
nonexpressed and noncoding regions of the genome. The cause of the aberrant methylation patterns 
in MDS is not clear. As mentioned before, DNA methylation is regulated at several levels, for example 
by DNA methyltransferases (DNMTs, box1). Overexpression of DNMT1 and DNMT3A/B has 
been shown in bone marrow biopsies of MDS patients94. However, expression of DNMTs was not 
aberrant when isolated hematopoietic cells were studied, although correlations between DNMT 
subtypes and promoter methylation of specific genes in MDS were found95. Recently, mutations in 
DNMT3A have been described in MDS, but the functional consequences of these mutations are 
not yet clear96;97. Although DNA methylation is associated with gene silencing, methylation itself is 
not sufficient to repress transcription. Other epigenetic changes, such as histone modifications are 
involved as well (box 1). Studies focusing on changes in the histone code in MDS have not been 
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performed yet. Changes in specific proteins directly or indirectly involved in histone modifications 
have been reported. For example, defects involving the MLL gene occasionally occur in MDS 
patients. MLL is a known chromatin modifier and has been implicated in H3K4 methylation among 
other activities. In addition, in a small minority of patients with MDS a chromosomal translocation 
involving the EVI-1 gene occurs. Aberrant expression of EVI-1 in MDS has been detected as well. 
The mechanisms by which EVI-1 contributes to MDS pathogenesis have  not been fully elucidated 
yet. Recently it was shown that EVI-1 interacts with the histone methyltransferase SUV39H1. 
SUV39H1 catalyzes the addition of trimethyl groups to lysine 9 of histone 3 (H3K9me3) 98;99. In this 
way, aberrations of EVI-1 could influence the histone code. Similar direct or indirect mechanisms 
that result in epigenetic modifications may apply to other MDS cases. The discovery of aberrations 
in DNA methylation provided the basis for the application of pharmaceutical compounds which 
modify this process. DNMT inhibitors replace normal nucleotides in the DNA (and RNA) and 
bind DNMTs, which leads to degradation of the latter, thus preventing DNA methylation by 
these proteins during subsequent cell divisions. As mentioned previously, DNA methylation is also 
dependent on changes in histone modifications. HDACs cause histone deacetylation leading to 
a repressive state of the chromatin, as does DNA methylation. HDAC inhibitors counteract this 
mechanism. Treatment with DNMT inhibitors has shown overall response rates (hematological 
improvement, partial/complete response) in 20-60% of MDS patients (reviewed in 100). HDAC 
inhibitors as monotherapy have shown lower response rates. Combinations of both compounds (and 
of these compounds with other drugs used in MDS) are being evaluated as well.  
Genetic abnormalities in MDS
As mentioned before, MDS is not characterized by one or several well-defined genetic defects, as is 
the case for chronic myelogenous leukemia. In fact, the genetic background of MDS appears highly 
heterogeneous, as is its clinical phenotype. Karyotype analysis is routinely used in MDS diagnostics 
and has revealed a multitude of abnormalities. These include deletions, duplications, inversions 
and translocations, of which deletions are clearly the most common abnormalities, leading to the 
hypothesis that loss of tumor suppressor genes is an important mechanism in MDS pathogenesis. 
At diagnosis, karyotype analysis of hematopoietic cells reveals (a) cytogenetic defect(s) in 
approximately 50% of patients (Figure 2). The number of abnormalities per patient varies and 
correlates with prognosis101. Deletions of (a part of) chromosomes 5, 7 and 20 and trisomy of 
chromosome 8 occur most frequently (Figure 3)101. In line with the hypothesis that deletions may 
result in loss of a tumor suppressor gene, many studies have focused on finding the targeted gene(s) 
on chromosomes 5, 7 and 20. In order to find genes of interest, the chromosomal areas affected by 
these deletions have been compared between patients, defining commonly deleted regions (CDRs). 
On chromosome 5, two distinct CDRs have been described. The most distal region lies on 5q33.1 
and contains approximately 40 genes and 3 microRNAs102. This CDR was defined by analyzing 
patients with the 5q-syndrome, characterized by anemia and an isolated del(5q). The proximal 
CDR is located on 5q31 and has been associated with both MDS and AML that progressed from 
MDS103-106. Recently, the gene encoding ribosomal S14 protein (RPS14) on 5q33.1 was implicated 
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in the pathogenesis of the 5q- syndrome. Knockdown of this gene with approximately 60% was 
shown to cause a block in erythroid differentiation of cultured human hematopoietic cells, a 
phenotype that could be rescued by re-introduction of the gene107. In addition, overexpression of 
RPS14 in cells of patients with 5q-syndrome promoted erythroid differentiation. The remaining 
RPS14 gene in 5q-syndrome patients did not appear to be affected by mutations, microdeletions 
or hypermethylation107. Mice with a deletion of part of the 5q33.1 CDR in hematopoietic cells, 
containing RPS14 among other genes, show features of 5q-syndrome108. This effect appears to be 
at least in part mediated by activation of the tumor suppressor protein p53. Loss of RPS14 may 
not however explain all features of the 5q-syndrome and it is likely that other genes or microRNAs 
are involved as well. Indeed, miR-145 and miR-146, the first located in the 5q33.1 CDR, have 
been implicated in the thrombocytosis, neutropenia and megakaryocytic dysplasia that can be seen 
in 5q-syndrome109. The second CDR on 5q31 carries several genes that have been implicated in 
MDS pathogenesis, including CTNNA1110, HSPA9111;112 and EGR1113. The alpha catenin CTNNA1 
was found to be expressed at much lower levels in primitive hematopoietic cells of individuals 
with a 5q deletion than in other MDS patients or healthy controls. CTNNA1 expression by the 
remaining allele in the HL-60 cell line that carries a 5q deletion was reported to be suppressed by 
both promoter methylation and histone deactetylation110. A mutated ortholog of HSPA9 in zebrafish 
was shown to cause defects in hematopoiesis including apoptosis and dysplasia112. EGR1 deficiency 
in mice caused a myeloproliferatieve disorder with features of myelodysplasia after treatment with 
N-ethyl nitrosurea to induce secondary genetic defects113. These results indicate that multiple genes 
on 5q31 are probably responsible for the MDS phenotype. Several other genes on chromosome 
5q that are located outside the CDRs, but still are affected in multiple patients, have also been 
implicated in MDS development. Genes located within CDRs on the other commonly deleted 
chromosomes, 7 and 20, have not been similarly implicated in the pathogenesis in MDS. Several 
Figure 2101
Number of cytogenetic abnormalities in MDS 
patients (karyotype analysis)
Figure 3101
Distribution of most common cytogenetic 
abnormalities in MDS patients
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CDRs on chromosome 7 have been described, including cytobands 7q22, 7q31-33 and 7q36114-120. In 
many patients multiple CDRs are affected, suggesting that the combined effect of several critically 
deleted genes is important. On chromosome 20, a CDR has been reported on 20q11-20q13 121-126. As 
is the case for chromosome 7, the genes located on chromosome 20 that are responsible for (part of) 
the MDS phenotype have not been identified yet. 
Although large chromosomal aberrations do not directly provide insight into the pathogenesis of 
MDS, the detection of these defects has improved MDS diagnostics since they provide evidence of 
clonal disease. In addition, their presence influences prognosis (Table 5) and can predict response 
to therapy, for example in case of patients with 5q- syndrome, who respond well to treatment with 
lenalidomide127. Unlike these large chromosomal aberrations, balanced translocations can more 
easily provide specific information concerning the affected genes. However, various chromosomal 
translocations in MDS have been found in single or only a few cases, mostly therapy-related MDS, 
and are often not the primary cytogenetic defect. Several genes that are recurrently found to be 
involved in translocations are listed in Table 6. Recently, a novel gene, IER3 was implicated in 
MDS pathogenesis after it was found to be involved in a translocation between chromosomes 6 and 
9. Expression of IER3, located on 6p21 was lost due to the translocation. IER3 is involved in the 
regulation of apoptosis. Its expression was subsequently shown to be more than four-fold increased 
or decreased in more than half of MDS patients without 6p21 abnormalities compared to healthy 
controls128.
Table 5
Prognostic impact of cytogenetic aberrations in MDS184 
Risk Group Good Intermediate 1 Intermediate 2 Poor
Percentage of 
patients
73% 6% 9% 12%
Median survival with 
supportive care
55 months 29 months 15 months 8 months
Cytogenetics normal karyotype  +8 -7 > 3 abnormalities
del(5q) del(11q) 3 abnormalities t(5q)
 -Y any 3q abnormality
del(20q) del(7q)
 +21 t(11q23)












Genes recurrently involved in translocations in MDS    
Gene   Function Examples of translocations References
















MLL Mixed lineage leukemia Methyltransferase t(11;16)(q23;p13.3), 
t(11;17)(q23;q25)
190;191
PRDM16 PR-domain containing 16 Transcription factor t(1;21)(p36;q22), t(1;3)
(p36;p21)
192;193





As has been discussed in the previous section, (epi)genetic defects such as disturbed methylation 
patterns and chromosomal deletions and duplications may contribute to MDS pathogenesis. 
However, they often affect many genes, complicating the search for those that are critically involved 
in this process. Aberrations of specific genes, such as the JAK2 mutations in MPN, have been found 
in MDS, although they occur in a minority of cases (Table 7). Mutations in the RAS family of genes 
(N-RAS, K-RAS, H-RAS) were among the first recurring mutations identified in MDS129;130. RAS 
proteins are involved in regulation of signaling pathways that are implicated in cell proliferation and 
survival. In healthy cells, RAS proteins are activated after binding of growth factors or cytokines to 
plasma membrane receptors with tyrosine kinase activity. In case of RAS mutations, the signaling 
cascade is constitutively activated, leading to uncontrolled cell growth. Alternatively, mutations of 
the receptors on the plasma membrane, such as FLT3, CSF1R and KIT may have similar effects. 
RAS and FLT3 mutations in MDS are associated with a higher risk of disease progression131-133. Also, 
RAS mutations are more common in the group of chronic myelomonocytic leukemias (CMML), 
which are now classified as MPN/MDS. The detection of recurrent RAS mutations in MDS has lead 
to the application of farnesyl transferase inhibitors. The specific inhibition of the enzyme farnesyl 
transferase by these drugs interferes with the transfer of a farnesyl moiety to substrates such as 
RAS proteins. This modification is required in the normal processing of RAS proteins. Clinical 
responses to these drugs have been seen in MDS, though do not seem to be related to RAS mutation 
status, indicating additional mechanisms of action (reviewed in 134). Clinical trials in high-risk 
MDS patients with inhibitors directed against FLT3 are ongoing. Mutations in other genes involved 
in signal transduction, such as PTPN11 and JAK2, have been described but are rare in MDS. In 
contrast, JAK2 mutations occur frequently (~50%) in refractory anemia with ring sideroblasts and 
thrombocytosis (RARS-T)135;136. RARS-T is now classified as MPN/MDS. Aberrations of genes 
that are not (directly) involved in signal transduction have been studied as well. TP53, a tumor 
suppressor gene that is known to be mutated in a wide variety of malignancies, has been studied 
elaborately in MDS. Mutations in TP53 are found in about 5-15% of patients and are associated 
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Harvey rat sarcoma viral oncogene 
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FLT3 Fms-related tyrosine kinase 3 13q12 Signal transduction <1-4% 138;207 208-211 
PTPN11 Protein tyrosine phosphatase, non-receptor type 11 12q24 Signal transduction <1-2
212-214
JAK2 Janus kinase 2 9p24 Signal transduction <1-5% 138;215;216








TP53 Tumor protein p53 17p13.1
Apoptosis, DNA 
repair, cell cycle 
regulation
5-15% 204;220-225
CDKN2A Cyclin-dependent kinase inhibitor 2A 9p21 Cell cycle regulation <1%
226-228
RUNX1 Runt-related transcription factor 1 21q22.3 Transcription factor 3-8% 138;139;229
CEBPalpha CCAAT/enhancer binding protein (C/EBP), alpha 19q13.1 Transcription factor <1-4%
230;231
WT1 Wilms tumor 1 11p13 Transcription factor <1% (AML 
post MDS)
138;232
ASXL1 Additional sex combs like 1 20q11.1 Chromatin 
modification
10-20% 138;144;145
MLL Mixed-lineage leukemia 11q23 Methyltransferase 2-3% 211
DNMT3A DNA methyl transferase 3A 2p23 Methyltransferase 3-8% 96;97
NPM1 Nucleophosmin 5q35 Nucleocytoplasmic 
transport
<1-5% 138;233
CBL Cas-Br-M (murine) ecotropic retroviral transforming sequence 11q23.3
E3 ubiquitin ligase,   
signal transduction
1-7% 138;234
IDH1 Isocitrate dehydrogenase 1 2q33.3 Metabolic pathways 2-4% 138;235-237
















In addition to mutations, TP53 can also be affected by other processes, such as a deletion of 
chromosome 17/17p, which occurs in approximately 5% of patients (Figure 3). Also, TP53 can 
be indirectly involved in MDS pathogenesis as was shown for example in a mouse model of 
5q-syndrome108.  Similarly, the transcription factor RUNX1 (AML1) can be affected in multiple 
ways. RUNX1 is important in normal hematopoiesis and its function may be compromised in MDS 
by translocations involving its locus on chromosome 21 and by mutations. As applies to several other 
mutated genes in MDS, RUNX1 mutations are detected more frequently in high risk MDS138;139. 
Mutations in several other transcription factors, CEBPA and WT1, are known to occur in MDS, 
but at a low frequency. On the contrary, overexpression of WT1 is detectable in patients with MDS 
and correlates with a worse prognosis140;141. Mutations in NPM1, that occur in approximately 30% 
of AML patients, are detected in only a minority of MDS patients. However, since NPM1 is located 
on chromosome 5q, haploinsufficiency of this gene may also play a role in the pathogenesis of 
MDS142. NPM1 has been associated with a number of cellular processes, one of which is regulation 
of the p53 pathway143. Recently, mutations in several other genes have been identified in MDS. 
The mutational frequency of some of these (BCL, IDH1 and IDH2) seems low, whereas mutations 
of the gene ASXL1 were detected in 10-20% of MDS patients138;144;145. ASXL1 is a member of the 
group of polycomb genes that are involved in regulation of transcription.  ASXL1 was found to be 
a member of a repressive complex containing histone H1.2146. However, it was also shown to have 
transcriptional activating properties147. In mice haploinsufficiency of ASXL1 did not cause MDS, 
although hematopoiesis was affected148. This may be explained by the fact that the mutants used 
were not identical to the mutated genes found in MDS patients. Alternatively secondary defects are 
required to cause a clear phenotype.  
In conclusion, a variety of cytogenetic defects has been found in hematopoietic cells of patients 
with MDS. Their discovery has improved understanding of MDS pathogenesis and has let in 
some instances to the application of specific pharmaceutical compounds in the treatment of MDS. 
However, in the majority of patients the genetic background of MDS remains unknown, mainly 
because only large or no genetic defects are detected.
Diagnosing and treating patients with MDS
Patients with MDS usually present with symptoms caused by anemia or, less often, another cytopenia. 
Morphological examination of the blood and bone marrow lays the foundation of the diagnosis of 
MDS, however, is often not sufficient for a definitive diagnosis. Dysplasia of at least 10% of the 
cells of the erythroid, monocytic, granulocytic or megakaryocytic lineage is the cardinal feature 
of MDS. Dysplasia includes features such as multinuclear erythroid precursors, hyposegmentation 
and hypogranulation of neutrophils and hypolobulation of megakaryocytes. The interpretation of 
dysplasia is complicated by the fact that it has many causes besides MDS. These include infections 
(e.g. parvovirus B19), drugs and toxic substances (e.g. chemotherapy, G-CSF), nutritional deficiencies 
(vitamine B12, folic acid) and congenital disorders (e.g. congenital dyserythropoiesis). In addition to 
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dysplasia, other morphological features are important, such as the number of blasts (very immature 
hematopoietic cells) in the blood and bone marrow and the presence of ringed sideroblasts. Apart 
from their role in diagnosing MDS, features like the presence of hypolobulated megakaryocytes 
and thrombocytosis may also indicate the possible presence of a specific MDS subtype, in this 
case 5q-syndrome. In addition, morphological characteristics are the main determinants of the 
classification of MDS in prognostically relevant groups. In some cases, particularly those with 
an increased number of blasts, the diagnosis of MDS can be made if the required 10% dysplasia 
is present and other causes of dysplasia have been excluded or are unlikely. In the other cases 
cytogenetic examination of the hematopoietic cells can provide further diagnostic information. As 
mentioned previously, karyotype analysis reveals chromosomal aberrations in approximately 50% 
of patients. Since the presence of these aberrations has prognostic implications as well, karyotype 
analysis is usually performed in all MDS patients. Occasionally, cytogenetic defects are found in 
patients with (a) cytopenia(s) without morphological abnormalities149, requiring careful evaluation. 
Another way to confirm a suspected diagnosis of MDS is by histological examination of the bone 
marrow, which may exclude causes of non-MDS dysplasia and provide additional information on 
cellularity, clustering of blasts and fibrosis. In addition to the clinical characteristics, morphological 
and histological examination, other techniques such as flow cytometry and molecular genetic assays 
may facilitate a diagnosis of MDS. However, these techniques are not yet routinely used. By use 
of combinations of flow cytometric markers, dysplasia of the erythroid and myeloid cells can be 
evaluated 150;151. In addition, aberrant expression of markers (increased or decreased expression of 
normal markers or expression of lineage-infidelity markers) has been shown to have prognostic 
implications152;153. Further standardization and validation of the flow cytometric parameters used to 
distinguish MDS from other hematopoietic disorders will facilitate the diagnostic process of MDS 
in the future. Recently, the results of the implementation of flow-cytometry in the diagnosis of MDS 
in the Netherlands have been published154.
The routine application of molecular genetic techniques for example to detect mutated genes is 
limited by the fact that the mutations identified thus far are not specific for MDS and occur in only 
a minority of patients. Due to the limitations of the assays available for diagnosing MDS, a number 
of patients remains with a diagnosis of ‘possible MDS’ and requires accurate follow-up to evaluate 
the clinical course. Once the diagnosis of MDS has been established and an estimation of the 
prognosis has been made using the classification systems described before, several treatment options 
may be considered. Hematopoietic stem cell transplantation remains the only potentially curative 
treatment for MDS. Only a minority of patients are treated by stem cell transplantation, due to 
the toxicity of this treatment and the lack of available donors. Other treatment options include 
supportive therapy, such as erythrocyte transfusions and G-CSF and disease-modifying therapy. 
Disease-modifying therapies include for example ATG and lenalidomide. Most disease-modifying 
therapies are currently subject of extensive investigation to determine which patients are most likely 
to respond and to what extent combination therapy (for example a hypomethylating agent with an 
HDAC inhibitor) benefits patients.
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Outline of this thesis
As discussed in the previous section, MDS is a heterogeneous group of diseases, complicating 
diagnosis, estimation of prognosis and development and proper application of novel treatment 
modalities. Improving insight into the pathogenesis of MDS and defining the biological pathways 
that are commonly disturbed in these patients could improve the quality of MDS patient care. The 
first part of this thesis focuses on deregulation of a biological pathway that is not thought to be 
the primary defect leading to MDS, but has often been related to development of the devastating 
cytopenias: apoptosis. This study aims at defining commonly deregulated apoptosis-related genes 
in isolated hematopoietic cells of MDS patients with various clinical phenotypes (chapter 2). The 
second part of this thesis describes the search for genetic defects that are potentially causally involved 
in the development of the malignant clone in MDS. The results of genome-wide analysis of genetic 
defects using single-nucleotide polymorphism (SNP) arrays (Box 3) in hematopoietic cells isolated 
from MDS patients is described in chapter 3. The identification of recurrent aberrations in the 
Ten-eleven-translocation-2 (TET2) gene in MDS that resulted from this analysis is described in 
chapter 3 as well. In chapter 4, the presence of TET2 aberrations is studied in other hematopoietic 
malignancies than MDS, namely acute myeloid and lymphoid leukemia in children. In chapter 5 
we return to the SNP-array analysis described in Chapter 3 and explore another commonly affected 
region of the genome in MDS, leading to the discovery of recurrent aberrations in the Enhancer-
of-Zeste-homolog-2 (EZH2) gene. Finally, chapter 6 provides an overview and discussion of the 




Single nucleotide polymorphism (SNP) arrays allow the detection of deletions and 
amplifications in the DNA as well as areas showing loss-of-heterozygosity. SNP-array analysis 
starts with cleaving DNA isolated from cells into smaller fragments using a restriction enzyme 
(e.g. nspI, which cuts DNA at the recognition site 5’…RCATG*Y…3’/3’…Y*GTACR…5’). 
Subsequently, linkers are ligated to the DNA fragments, allowing primers to bind for the 
subsequent amplification by PCR. The amplified DNA fragments are purified, fragmented 
further by DNAse I and labeled. The labeled DNA is then hybridized to the SNP-array. The 
SNP-array contains oligonucleotide probes corresponding to DNA sequences containing 
SNPs. If the labeled DNA contains a specific SNP, the DNA will bind to the probe. If not, 
the DNA will be removed by several washing steps. By fluorescently labeling the bound 
DNA and scanning the array, the amount of DNA and the presence of specific SNPs can be 
determined. One of the advantages of SNP-array analysis and also array-comparative genomic 
hybridization (array-CGH) is the higher resolution compared to conventional karyotyping. 
Also, no dividing cells are necessary to perform the analysis. A disadvantage is that balanced 
chromosomal aberrations cannot be detected. Only SNP-array analysis allows the detection of 
copy-number neutral loss of heterozygosity due to mitotic recombination. 
 karyotyping array-CGH SNP-array
Sample cells in metaphase DNA DNA
Resolution low
high (depending on 
no. of probes)
high (depending on 
no. of probes)
Detection of:  
small subclones possibly no no
copy number abnormalities yes yes yes
balanced chromosomal aberrations yes no no
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Although the vast majority of patients with a myelodysplastic syndrome (MDS) suffer from 
cytopenias, the bone marrow is usually normocellular or hypercellular. Apoptosis of hematopoietic 
cells in the bone marrow has been implicated in this phenomenon. However, in MDS it remains 
only partially elucidated which genes are involved in this process and which hematopoietic cells 
are mainly affected. We have employed sensitive real-time PCR technology to study a large set of 
apoptosis-related genes and gene families in the immature CD34+ and the differentiating erythroid 
and monomyeloid bone marrow cells. Several genes were found to be differentially expressed between 
patients and controls in more than one cell fraction, most importantly the BIK (BCL2-interacting 
killer) gene. Although different patient groups, based on the IPSS scoring system, and healthy 
controls could not be distinguished based on the overall expression pattern of these apoptosis-related 
genes, the differential expression of specific genes in MDS patients and controls may contribute to 
changes in the cell’s sensitivity to cell death and thus increased apoptosis.
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Introduction
Myelodysplastic syndromes (MDS) represent a heterogeneous group of malignant hematopoietic 
disorders that are characterized by dysplasia in the myeloid, megakaryocytic and/or erythroid 
cell lineages. The clinical course of MDS is highly variable. Whereas some patients suffer from 
smoldering cytopenias, others rapidly develop a more aggressive disease eventually resulting in acute 
myeloid leukemia. The WHO classification and International Prognostic Scoring system (IPSS) 
recognize the heterogeneity of MDS and divide patients into subgroups based on characteristics such 
as the amount of blasts in the bone marrow and the number of cytopenias. 
Although cytopenias are present in the peripheral blood of the vast majority of MDS patients, the 
bone marrow is usually normocellular or hypercellular. Apoptosis of hematopoietic cells in the bone 
marrow has been implicated in this phenomenon. Several studies have shown signs of increased 
apoptosis in MDS bone marrow using techniques such as in situ end labeling (ISEL) of fragmented 
DNA/ TUNEL assay 1, electron microscopy 2, flowcytometry using annexin V staining 3, 4 and 
measurement of mitochondrial membrane potential 4. The percentage of cells affected by apoptosis 
differs between studies, possibly due to the use of different techniques and the heterogeneity of the 
clinical samples studied. In most, but not all studies apoptosis markers are particularly elevated in the 
more indolent cases of MDS, whereas apoptosis is reduced or at normal levels in the more aggressive 
cases. This led to the hypothesis that apoptosis is initially increased in MDS due to either primary 
defects of the apoptotic pathway or in response to oncogenic stress. During the advanced stages 
of MDS, this response may be lost as result of further transformation of the malignant cells. The 
presence of apoptosis has been studied in whole bone marrow and in several bone marrow fractions, 
such as CD34+ cells. Depending on the study, increased apoptosis parameters were found in the 
CD34+ cell fraction of all MDS patients4, 5 or only in patients with the more indolent phenotype3. 
Others described that apoptosis is mainly increased in the more committed myeloid, erythroid and/
or megakaryocytic lineages2, 6.
Apoptosis is a tightly regulated process that involves many proteins. The differential regulation 
of some of these proteins, such as Fas7, 8, FLIP 9, 10, BCL-2 and BCL-2-related proteins3, 11-14, TNF 
proteins and their receptors 15-17, IAPs 18, 19 and caspases 14, 20 has been the subject of studies in 
MDS patients. Most of these studies focused on only one or a few apoptosis-related genes and were 
performed in either whole bone marrow or the CD34+ cell fraction.
Based on the results of these previous studies, we expected that different patterns of apoptosis-
related gene expression can be distinguished in healthy hematopoietic cells and those of low-risk and 
high-risk MDS patients. To gain insight into these expression patterns, we have employed sensitive 
real-time PCR technology to study 93 apoptosis-related genes and gene families in both CD34+ 




Isolation of hematopoietic cell fractions
Hematopoietic cell fractions were isolated from the bone marrow of 23 patients and 10 healthy 
controls (Supplementary Table 1). Three different hematopoietic cell fractions were sorted, CD34+ 
cells (immature hematopoietic cells), CD71+ erythroid precursors and CD13/33+ mono-myeloid 
precursors. According to the IPSS score 4 low , 11 int-1, 4 int-2 and 4 high risk patients were included. 
In most cases we were able to isolate all three subfractions from the same patient (Supplementary 
Table 1). As a control, the expression of several genes related to erythroid differentiation (TFRC, 
GYPA, GYPB, GYPC, SPTB, SPTA1, EBP41, EBP42 and HBB) was measured in all fractions and 
shown to be highly upregulated in CD71+ cells (data not shown). 
Unsupervised cluster analysis separates different bone marrow fractions but does not 
differentiate MDS patients and controls
Unsupervised hierarchical cluster analysis was performed based on the expression of 93 apoptosis-
related genes. These included members of the TNF (Receptor) Family, BCL-2 Family, IAPs, 
Caspases, CARD Family, TRAF family and others (Supplementary Table 2). The analysis showed 
a clear clustering of the three hematopoietic cell fractions, indicating different patterns of apoptosis-
related gene activity in these cell fractions (Figure 1). Unexpectedly, within each cell fraction, 
patients and healthy controls could not be distinguished based on the global expression pattern 
of these apoptosis-related genes (Figure 1). Also low-risk MDS and high-risk MDS patient groups 
could not be distinguished using this approach. 
Figure 1: Unsupervised hierarchical cluster 
analysis of all samples based on apoptosis-
related gene expression profile.
Cell fractions are shown in the first column: 
CD34+ cells (blue), CD71+ cells (green), 
CD13/33+ cells (red). The second column shows 
patients and controls: controls (purple), low risk 
MDS (light blue), high risk MDS (orange)
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Differential expression of apoptosis-related genes in MDS patients and controls
Analysis of individual genes revealed several genes that were differentially expressed between patients 
and controls in more than one cell fraction: BIK, TNFRSF19 and TNFRSF7 (CD34+ and CD71+ 
fractions) and MDM2 (CD71+ and CD13/33+ fractions). (Table 1, Figure 2) Of these genes, only 
the pro-apoptotic BIK gene showed a significantly increased expression after correction of p-values 
for multiple testing. The analyses were repeated after the MDS patients were divided into low-
risk and high-risk groups. As was the case for the comparison between all patients and controls, 
differential expression was detected of TNFRSF19, RALBP1 and TNFRSF7 in the CD34+ fraction, 
BIK, DAPK1, BNIPL, TNFSRF10A, and CARD9 in the CD71+ group and TNFSRF13B and 
MDM2 in the CD13/33+ fraction. In addition, several other genes  mainly showed differences in 
expression between the low-risk and high-risk MDS patients and not between patients and controls 
(Supplementary Table 3). The apoptosis-related genes TNFRSF4, BIK and TNFRSF13B showed 
the most prominent differences in expression between the different patient groups and controls. 
Although several pro-apoptotic genes showed increased expression in low-risk MDS patients and 
anti-apoptotic genes reduced expression, no clear correlation was seen between the known effect of 
the genes studied (pro- or anti-apoptotic) and the MDS subtype.
Table 1A: Differentially expressed genes in the CD34+ cell fraction in MDS patients versus controls
Gene p-value effect on apoptosis Ratio of median expression in patients/ controls
TNFRSF19 0.006 pro 0.2
TNFRSF7 0.013 pro 0.1
BIK 0.016 pro 0.6
RIPK2 0.020 pro 1.5
CARD11 0.035 pro 0.6
RALBP1 0.047 anti 2.9
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Table 1B: Differentially expressed genes in the CD71+ cell fraction in MDS patients versus controls
Gene p-value effect on apoptosis Ratio of median expression in patients/ controls
BIK 0.001* pro 203
BNIPL 0.004 pro 0.1
DAPK1 0.020 pro 3.6
BBC3 0.015 pro 3.0
EDA2R 0.015 pro 49
TNFRSF10A 0.015 pro 3.9
CARD9 0.018 pro 1.6
CASP9 0.018 pro 7.0
DAPK1 0.012 pro 3.3
MDM2 0.020 anti 1.8
TNFSRF19 0.020 pro 0.2
TNFRSF7 0.022 pro 0.2
TNFRSF10B 0.028 pro 6.2
BCL2L10 0.032 anti 2.1
BAG3 0.035 anti 3.1
TNFRSF10D 0.044 anti 2.9
Table 1C: Differentially expressed genes in the CD13/33+ cell fraction in MDS patients versus controls
Gene p-value effect on apoptosis Ratio of median expression in patients/ controls
MDM2 0.004 anti 1.7
TNFRSF13B 0.005  - 0.01
FADD 0.035 pro 1.7
*indicates significant difference (p<0.05) using p-value for multiple testing
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Discussion
Up- or downregulation of various apoptosis-related genes in MDS has been shown in the past. We 
have studied the expression of a large set of genes and gene families that have been associated with 
apoptosis in three different FACS isolated hematopoietic cell fractions. Using sensitive real-time 
PCR analysis followed by unsupervised clustering analysis of the measured gene expression levels, 
we were able to distinguish the CD34+, CD71+ and CD13/33+ cell fractions. Unexpectedly, global 
patterns of gene expression could not distinguish healthy controls and low risk and high risk MDS 
patients, but analysis of the expression of single genes identified a limited number of genes that were 
differentially expressed between these groups. Deregulation of the expression of some of these genes 
has been implicated in MDS before. Increased expression of TNFRSF10A (TRAIL-R1) in MDS 
has been described, though not specifically in the CD71+ population 16. Differential expression of 
other genes, such as TP53 and BCL2, that have previously been implicated in MDS, could not be 
confirmed. Differences between our study and those of others could be due to the bone marrow 
fractions studied and the selection of patients. The BIK (BCL-2 interacting killer) gene showed the 
most prominent differences in expression between MDS patients and controls. BIK is thought to 
mediate apoptosis signaling to mitochondria. Although mutations of BIK have been found in B-cell 
lymphomas 21, little is known about the role of BIK in myeloid malignancies. In a study examining 
gene expression in acute myeloid leukemia, BIK was found to be upregulated in AML samples 
compared to controls 22. However, the differences in expression were dependent on the cytogenetic 
abnormalities of the patients. 
We conclude that, although apoptosis has been found to be disturbed in MDS, the overall expression 
pattern of a large number of apoptosis-related genes is not grossly disturbed in MDS. When single 
genes were analyzed, the expression of BIK appeared to be the most prominently differentially 
expressed gene. Further functional studies into the possible role of BIK in MDS are therefore 
warranted.
Figure 2: Expression of BIK in MDS patients 
and controls 
BIK expression in ‘low risk’ patients, ‘high risk’ 
patients and controls. The expression of BIK is 
depicted relative to the housekeeping gene GAP-





Bone marrow from MDS patients (n=23) and healthy controls (n=10) was collected after informed 
consent. Patients diagnosed at the Radboud University Nijmegen Medical Centre belonging 
to all different WHO and IPSS categories were included. Patient characteristics are shown in 
Supplementary Table 1. Mononuclear cells were isolated from the bone marrow by density gradient 
centrifugation using Ficoll 1.077 g/mL (Pharmacia Biotech, Uppsala, Sweden) and viably frozen in 
liquid nitrogen until further use. 
Cell sorting and RNA isolation
After thawing, hematopoietic cell subtypes were isolated by fluorescence activated cell sorting 
(FACS) using monoclonal antibodies directed against CD45 and the side scatter profile. In addition, 
monoclonal antibodies directed against CD34, CD13, CD33 and CD71 were used. Gating on 
forward and side scatter was used to exclude dead cells and debris. RNA was isolated from three 
subfractions, the CD34+ stem/progenitor cells, the CD13/33+ mono/myeloid cells and the CD71+ 
erythroid cells.
Gene expression analysis
In a first set of patients and controls, the expression of 180 different apoptosis-related genes was 
measured simultaneously by real-time PCR employing a 384 Microfluidic Card (Applied Biosystems). 
The genes measured and the corresponding assay numbers are shown in Supplementary Table 2. 
cDNA obtained from the CD34+ (patients n=13, controls n=5), CD71+ (patients n=12, controls n=4) 
and CD13/33+ (patients n=11, controls n= 5) cell fractions was analyzed. Based on the expression 
pattern of these genes, a selection of 93 genes was used to perform a similar expression analysis in 
an additional group of CD34+ (patients n=8, controls n=5), CD71+ (patients n=9, controls n=5) and 
CD13/33+ cells (patients n=8, controls n=5). The relative expression of the apoptosis-related genes 
was calculated by measuring the housekeeping gene GAPDH. Relative expression values less than 
1x10-6 were set to 1x10-6 to avoid bias introduced by including values reaching the limit of detection 
of the real-time PCR assay. In addition to the apoptosis-related genes, the expression of several genes 
implicated in erythroid differentiation (TFRC, GYPA, GYPB, GYPC, SPTB, SPTA1, EBP41, EBP42 
and HBB) was determined to check whether these genes indeed showed highest expression in the 
CD71+ cell fraction. The erythroid genes were only used as controls and not included in subsequent 
statistical analyses.
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Statistical analysis
Microfluidic card log-scale values were imported into Partek (Partek Genomic Suite software, version 
6.5; Partek Inc., St. Louis, MO). Principle Component Analysis (PCA) showed a clear distinction 
between the three different tissues and thus the dataset was split accordingly into three separate 
groups. In each group expression differences between donors and patients was calculated using the 
non-parametric Mann-Whitney U-test. For statistical analysis, patients from the IPSS low and int-1 
risk groups were combined in a ‘low risk MDS’ group and patients from the IPSS int-2 and high-risk 
groups in a ‘high-risk MDS’ group. Corresponding P-values were corrected for multiple testing by 
random permutations. The Kruskall-Wallis-test was used to identify differences between the ‘low 
risk MDS’, ‘high-risk MDS’ and control groups.  In case of a p-value< 0.05, posthoc analysis was 
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Supplementary Table 1: Patients and controls







patient 1 RA RCMD low normal 3 5.7 2.1 CD34, CD13/33
patient 2 RA RCMD low normal 1 7.0 1.9
CD34, CD71, 
CD13/33
patient 3 RA RCMD low normal 1 3.8 5.8
CD34, CD71, 
CD13/33
patient 4 RARS RCMD-RS low normal 1 2.4 2.1
CD34, CD71, 
CD13/33
patient 5 RA RA int-1 46,XY, -20, +mar [10] 3 6.2 2.6
CD34, CD71, 
CD13/33
patient 6 RARS RARS int-1 normal 2 6.0 3.6 CD34, CD71  
patient 7 RARS RARS int-1 47,XY,+8[4]/46,XY[6] 2 5.6 2.4
CD34, CD71, 
CD13/33
patient 8 RARS RCMD-RS int-1 normal 1 3.4 0.7 CD71
patient 9 RAEB RAEB-1 int-1 normal 6 6.0 0.2
CD34, CD71, 
CD13/33
patient 10 RAEB RAEB-1 int-1 normal 9 7.5 4.5
CD34, CD71, 
CD13/33
patient 11 RAEB RAEB-1 int-1 47,XX,+8[7]/46,XX[3] 6 6.5 28.1
CD34, CD71, 
CD13/33
patient 12 RAEB RAEB-1 int-1 normal 8 7.7 0.5
CD34, CD71, 
CD13/33
patient 13 RAEB RAEB-1 int-1 normal 5 5.6 1.9 CD34, CD71  
patient 14 RAEB RAEB-1 int-1 normal 6 4.0 1.0
CD34, CD71, 
CD13/33
patient 15 RAEB RAEB-1 int-1 normal 5 3.8 1.7 CD71, CD13/33
patient 16 RAEB RAEB-2 int-2 normal 4 6.6 2.5
CD34, CD71, 
CD13/33
patient 17 RAEB-t RAEB-2 int-2 normaal 12 5.9 21.6
CD34, CD71, 
CD13/33
patient 18 RAEB-t RAEB-2 int-2 complex 10 6.6 12.1
CD34, CD71, 
CD13/33
patient 19 RAEB-t AML int-2 normal 21 6.7 2.5
CD34, CD71, 
CD13/33
patient 20 RAEB-t RAEB-2 high complex 11 4.0 0.6 CD34, CD71 
patient 21 RAEB RAEB-2 high 47,XY, +11 [5] / 46,XY [15] 12 6.2 1.0 CD34, CD13/33
patient 22 RAEB-t AML high normal 22 4.8 0.6
CD34, CD71, 
CD13/33






control 10        CD34, CD13/33
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Supplementary Table 2: Genes and assay numbers
Gene NM number Assay number Assay
BAX NM_138761.2 Hs00180269_m1 1,2
BBC3 NM_014417.2 Hs00248075_m1 1,2
BCL2A1 NM_004049.2 Hs00187845_m1 1,2
BCL2 NM_000633.2 Hs00153350_m1 1,2
BCL2L10 NM_020396.2 Hs00368095_m1 1,2
BCL2L11 NM_138621.2 Hs00197982_m1 1,2
BCL2L12 NM_138639.1 Hs00369327_m1 1,2
BCL2L13 NM_015367 Hs00209789_m1 1
BCL2L14 NM_030766.1 Hs00373302_m1 1,2
BCL2L1 NM_001191 Hs00169141_m1 1,2
BCL2L1 NM_138578.1 Hs00236329_m1 1,2
BCL2L2 NM_004050 Hs00187848_m1 1
BID NM_197966.1 Hs00609630_m1 1,2
BIK NM_001197.3 Hs00154189_m1 1,2
BLK NM_001715.2 Hs00176441_m1 1,2
BNIP1 NM_001205.1 Hs00241824_m1 1,2
BNIP2 NM_004330.1 Hs00188939_m1 1,2
BNIPL NM_138278.2 Hs00414503_m1 1,2
BOK NM_032515.3 Hs00261296_m1 1,2
HRK NM_003806.1 Hs00705213_s1 1,2
BAD NM_032989 Hs00188930_m1 1
BAG1 NM_004323 Hs00185390_m1 1
BAG2 NM_004282.2 Hs00188716_m1 1,2
BAG3 NM_004281.3 Hs00188713_m1 1,2
BAG4 NM_004874 Hs00362193_m1 1
BAG5 NM_004873 Hs00191644_m1 1
BAK1 NM_001188 Hs00832876_g1 1
BCL10 NM_003921 Hs00184839_m1 1
BCL3 NM_005178 Hs00180403_m1 1
BCLAF1 NM_014739 Hs00602256_m1 1
BECN1 NM_003766 Hs00186838_m1 1
BMF NM_033503 Hs00372938_m1 1
BNIP3L NM_004331 Hs00188949_m1 1
C19orf6 NM_033420 Hs00364301_m1 1
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Gene NM number Assay number Assay
MCL1 NM_021960 Hs00172036_m1 1
MCL1 NM_182763 Hs00766187_m1 1
PMAIP1 NM_021127 Hs00560402_m1 1
CARD10 NM_014550.3 Hs00367225_m1 1,2
CARD11 NM_032415.2 Hs00260906_m1 1,2
CARD12 NM_021209.3 Hs00368367_m1 1,2
CARD14 NM_024110 Hs00364499_m1 1
CARD15 NM_022162.1 Hs00223394_m1 1,2
CARD4 NM_006092 Hs00196075_m1 1
CARD6 NM_032587.2 Hs00261581_m1 1,2
CARD8 NM_014959.1 Hs00209095_m1 1,2
CARD9 NM_052813.2 Hs00364485_m1 1,2
NOL3 NM_003946.3 Hs00358724_g1 1,2
RIPK2 NM_003821.5 Hs00169419_m1 1,2
APAF1 NM_181861 Hs00559441_m1 1
C10orf97 NM_024948 Hs00227894_m1 1
C9orf89 NM_032310 Hs00260439_m1 1
COPl NM_052889 Hs00430993_m1 1
NALP1 NM_033004 Hs00248187_m1 1
PYCARD NM_145183 Hs00203118_m1 1
CASP3 NM_032991.2 Hs00234387_m1 1,2
CASP5 NM_004347.1 Hs00237061_m1 1,2
CASP6 NM_032992.2 Hs00154250_m1 1,2
CASP7 NM_033338.4 Hs00169152_m1 1,2
CASP8AP2 NM_012115.2 Hs00201640_m1 1,2
CASP8 NM_033356.2 Hs00154256_m1 1,2
CASP9 NM_032996.1 Hs00154260_m1 1,2
PACAP NM_016459.3 Hs00414907_m1 1,2
CASP10 NM_32974 Hs00154268_m1 1
CASP14 NM_012114 Hs00201637_m1 1
CASP1 NM_03329 Hs00169146_m1 1
CASP2 NM_032982 Hs00154242_m1 1
CASP4 NM_001225.3 Hs00426677_m1 1
CASP8 NM_033356.2 Hs00236278_m1 1
CIDEC NM_022094.2 Hs00535723_m1 1,2
CIDEA NM_198289 Hs00154455_m1 1
Supplementary Table 2: Genes and assay numbers (vervolg)
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CIDEB NM_014430 Hs00205339_m1 1
CRADD NM_003805.3 Hs00187009_m1 1,2
EDARADD NM_080738.2 Hs00369830_m1 1,2
FADD NM_003824.2 Hs00538709_m1 1,2
LRDD NM_018494 Hs00388035_m1 1
MADD NM_130470 Hs00366249_m1 1
TRADD NM_003789 Hs00182558_m1 1
DEDD2 NM_032998 Hs00370206_m1 1
DEDD NM_133328 Hs00172768_m1 1
BIRC3 NM_182962.1 Hs00154109_m1 1,2
BIRC7 NM_139317.1 Hs00223384_m1 1,2
BIRC8 NM_033341.3 Hs00364262_s1 1,2
BIRC1 NM_004536 Hs00244967_m1 1
BIRC2 NM_001166 Hs00357350_m1 1
BIRC4BP NM_017523 Hs00213882_m1 1
BIRC4 NM_001167 Hs00236913_m1 1
BIRC5 NM_001012271 Hs00153353_m1 1
BIRC6 NM_016252 Hs00212288_m1 1
ABL2 NM_005158 Hs00246861_m1 1,2
ABL2 NM_007314 Hs00270858_m1 1,2
ATM NM_138292.3 Hs00175892_m1 1,2
CHEK1 NM_001274.2 Hs00176236_m1 1,2
CHEK2 NM_001005735.1 Hs00200485_m1 1,2
DUSP2 NM_004418.2 Hs00358879_m1 1,2
GADD45A NM_001924.2 Hs00169255_m1 1,2
MDM1 NM_017440.2 Hs00220015_m1 1,2
MDM2 NM_002392.2 Hs00242813_m1 1,2
PARK2 NM_013987.1 Hs00247755_m1 1,2
TP53BP1 NM_005657.1 Hs00152943_m1 1,2
TP53 NM_000546.2 Hs00153349_m1 1,2
TP73 NM_005427.1 Hs00232088_m1 1,2
TP73L NM_003722.3 Hs00186613_m1 1,2
ABL1 NM_005157 Hs00245445_m1 1
AKT1 NM_001014431 Hs00178289_m1 1
GADD45B NM_015675 Hs00169587_m1 1
P53AIP1 NM_022112 Hs00223141_m1 1
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PARC NM_015089 Hs00292746_m1 1
PERP NM_022121 Hs00751717_s1 1
PIN1 NM_006221 Hs00749260_s1 1
PPM1D NM_003620 Hs00186230_m1 1
PTEN NM_000314 Hs00829813_s1 1
RCHY1 NM_001008925 Hs00295839_m1 1
RFWD2 NM_022457 Hs00375437_m1 1
RPA3 NM_002947 Hs00366098_m1 1
TP53BP2 NM_005657.1 Hs00610488_m1 1
PDCD1 NM_005018.1 Hs00169472_m1 1,2
PDCD4 NM_145341.2 Hs00377253_m1 1,2
PDCD5 NM_004708.2 Hs00270435_m1 1,2
FAS NM_152871.1 Hs00531110_m1 1,2
TNFRSF10A NM_003844.2 Hs00269491_m1 1,2
TNFRSF10B NM_147187.1 Hs00366272_m1 1,2
TNFRSF10C NM_003841.2 Hs00182570_m1 1,2
TNFRSF10D NM_003840.3 Hs00174664_m1 1,2
TNFRSF11A NM_003839.2 Hs00187189_m1 1,2
TNFRSF11B NM_002546.2 Hs00171068_m1 1,2
TNFRSF13B NM_012452.2 Hs00234859_m1 1,2
TNFRSF17 NM_001192.2 Hs00171292_m1 1,2
TNFRSF18 NM_148901.1 Hs00188346_m1 1,2
TNFRSF19 NM_018647.2 Hs00218634_m1 1,2
TNFRSF1B NM_001066.2 Hs00153550_m1 1,2
TNFRSF25 NM_148965.1 Hs00237054_m1 1,2
TNFRSF4 NM_003327.2 Hs00533968_m1 1,2
TNFRSF7 NM_001242.3 Hs00154297_m1 1,2
TNFRSF8 NM_152942.2 Hs00174277_m1 1,2
TNFRSF9 NM_001561.4 Hs00155512_m1 1,2
CD40 NM_152854 Hs00374176_m1 1
FAF1 NM_131917 Hs00169544_m1 1
FBF1 NM_001080542.1 Hs00384673_m1 1
LTBR NM_002342 Hs00158922_m1 1
TNFRSF12A NM_016639 Hs00171993_m1 1
TNFRSF13C NM_052945 Hs00606874_g1 1
TNFRSF14 NM_003820 Hs00187058_m1 1
TNFRSF19L NM_032871 Hs00262701_m1 1
Supplementary Table 2: Genes and assay numbers (vervolg)
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TNFRSF1A NM_001065 Hs00533560_m1 1
TNFRSF21 NM_014452 Hs00205419_m1 1
EDA2R NM_021783.2 Hs00222305_m1 1,2
TRAF1 NM_005658.3 Hs00194638_m1 1,2
TRAF6 NM_145803.1 Hs00377558_m1 1,2
TRAIP NM_005879.2 Hs00183394_m1 1,2
TANK NM_133484 Hs00370305_m1 1
TIFA NM_052864 Hs00385268_m1 1
TRAF2 NM_021138 Hs00184186_m1 1
TRAF3 NM_145726 Hs00237035_m1 1
TRAF3IP2 NM_147200 Hs00210113_m1 1
TRAF4 NM_145751 Hs00188755_m1 1
TRAF5 NM_145759 Hs00182979_m1 1
TRAF7 NM_032271 Hs00260228_m1 1
TTRAP NM_016614 Hs00213282_m1 1
AVEN NM_020371.2 Hs00220565_m1 1,2
ENDOG NM_004435.2 Hs00172770_m1 1,2
ICEBERG NM_021571.2 Hs00253674_s1 1,2
AIF1 NM_001623 Hs00610419_g1 1
CYC1 NM_001916 Hs00357717_m1 1
DIABLO NM_138930 Hs00219876_m1 1
HTRA2 NM_013247 Hs00234883_m1 1
DFFB NM_001004285.1 Hs00237077_m1 1,2
DFFA NM_213566 Hs00189336_m1 1
DAPK1 NM_004938 Hs00234480_m1 1,2
DAPK1 NM_004938.2 Hs00234489_m1 1,2
DAPK2 NM_014326.3 Hs00204888_m1 1,2
DAPK3 NM_001348.1 Hs00154676_m1 1,2
RALBP1 NM_006788.3 Hs00183639_m1 1,2
RIPK1 NM_003804.3 Hs00169407_m1 1,2
RIPK3 NM_006871.3 Hs00179132_m1 1,2
RIPK4 NM_020639 Hs00221005_m1 1
DAP NM_004394 Hs00234397_m1 1
DAXX NM_001141969.1 Hs00154692_m1 1
MIB1 NM_020774 Hs00379185_m1 1
BFAR NM_016561 Hs00275423_m1 1
CFLAR NM_003879 Hs00236002_m1 1
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Ratio of median expression in:
gene p-value effect on apoptosis
low risk MDS/ 
controls
high risk MDS/ 
controls
high risk MDS/ 
low risk MDS
TNFRSF4 0.0023** anti   0.2* 0.9     4.4**
TNFRSF19 0.0070 pro 0.3   0.1* 0.2
RALBP1 0.031 anti   3.6* 0.9 0.3
TNFRSF7 0.046 pro   0.2*   0.1* 0.4
TRAIP 0.050 pro 1.3 0.4   0.3*
BNIP1 0.050 anti 1.9 0.8   0.4*
Supplementary Table 3b: Differentially expressed genes in the CD71+ cell fraction (patients vs low-risk MDS 
vs high-risk MDS)
Ratio of median expression in:
gene p-value effect on apoptosis
low risk MDS/ 
controls
high risk MDS/ 
controls
high risk MDS/ 
low risk MDS
BIK 0.003 pro    215*    203* 0.9
DAPK1 0.006 pro 2.5   6.8* 2.8
DAPK1 0.008 pro 2.4   10.8*   4.5*
BNIPL 0.013 pro   0.1*   0.1* 0.5
TNFRSF10A 0.015 pro 3.2   8.1* 2.5
CARD9 0.017 pro 1.3   3.3* 2.6
BCL2L10 0.043 anti 1.1   3.4* 3.0
Supplementary Table 3c: Differentially expressed genes in the CD13/33+ cell fraction (patients vs low-risk 
MDS vs high-risk MDS)
Ratio of median expression in:
gene p-value effect on apoptosis
low risk MDS/ 
controls
high risk MDS/ 
controls




  0.2*   0.0*   0.0*
MDM2 0.011 anti   1.6*   2.0* 1.2
DAPK2 0.015 pro 0.5 1.9   3.9*
TNFRSF10C 0.029 anti 0.5 1.7   3.5*
CARD6 0.042 anti 0.9 2.3   2.5*
* indicates significant difference (p<0.05) in expression after posthoc analysis
** indicates significant difference (p<0.05) using p-value for multiple testing
Supplementary Table 3a: Differentially expressed genes in the CD34+ cell fraction (patients versus low-risk 
MDS versus high-risk MDS)
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Myelodysplastic syndromes (MDS) represent a heterogeneous group of neoplastic hematopoietic 
disorders1. Several recurrent chromosomal aberrations have been associated with MDS, but the 
genes affected have remained largely unknown. To identify relevant genetic lesions involved in the 
pathogenesis of MDS, we performed SNP-array-based genomic profiling and genomic sequencing 
in 102 individuals with MDS and identified acquired deletions and missense and nonsense muta-
tions in the TET2 gene in 26% of these individuals. Using allele-specific assays, we detected TET2 
mutations in most of the bone marrow cells (median 96%). In addition, the mutations were encoun-
tered in various lineages of differentiation including CD34+ progenitor cells, suggesting that TET2 
mutations occur early during disease evolution. In healthy tissues, TET2 expression was shown to 
be elevated in hematopoietic cells with highest expression in granulocytes, in line with a function in 
myelopoiesis. We conclude that TET2 is the most frequently mutated gene in MDS known so far.
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Introduction
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by dysplasia 
of the myeloid, megakaryocytic and/or erythroid lineages. The clinical course varies from a 
smoldering disease to a more acute manifestation with bone marrow failure. In about 30% of 
cases acute myeloid leukemia (AML) develops, but most affected individuals eventually die from 
complications of bone marrow failure. Diagnosis of MDS is often difficult as many conditions (such 
as infection or medication) may give rise to cytopenias and dysplasias without clonal disease. Using 
karyotyping and fluorescent in situ hybridization (FISH), chromosomal aberrations can be found 
in approximately 60% of cases2-4 but information on specific target genes is scarce. Mutations in 
NRAS have been described in 10-15% of the patients, as well as mutations in TP53 (5-10%), FLT3 
(2-5%), and RUNX1/AML1 (2-10%)5. Recently, haploinsufficiency of RPS14 has been implicated 
in impaired erythropoiesis in individuals suffering from MDS with 5q-aberrations6, 7. Several SNP 
array-based genomic profiling studies have been performed yielded various chromosomal regions of 
interest8-12. The aim of this study was to identify novel genes that are recurrently affected in MDS. 
Results and discussion
DNA from bone marrow cells of 102 MDS patients was hybridized to Affymetrix 250k SNP-
arrays. Genomic profiles were analyzed for copy number abnormalities and copy-neutral loss of 
heterozygosity (LOH), also referred to as uniparental disomy (UPD). Regions showing acquired 
UPD usually extend to one of the telomeres and are believed to harbor homozygously mutated genes. 
In line with known cytogenetic data, we frequently observed aberrations affecting chromosomes 5, 
7, 8 and 20 (Figure 1, Supplementary Table 1). In addition, microdeletions on chromosome 21 
involving RUNX1 were present in three subjects (Supplementary Figure 1). Segmental telomeric 
UPD was seen on chromosomes 1, 4, 6, 7 and 17 (Figure 1 and Supplementary Table 2); a 
homozygous mutation of TP53 was detected within the homozygous region in the individual with 
UPD17p (Supplementary Figure 2). UPD was particularly frequent on chromosome 4q. Notably, 
chromosomal aberrations involving 4q have been described9-13, but no specific target gene in this 
region has yet been implicated in MDS. Therefore, we set out to identify the target gene(s) on 
chromosome 4.
Five individuals with MDS carried large aberrations on the long arm of chromosome 4, of which 
four (UPN 52, 73, 74 and 100) showed UPD of the 4q arm and one (UPN 7) showed a mono-
allelic deletion (Figure 2a). None of these abnormalities was observed in a cohort of 1015 healthy 
controls that we use as an in-house control panel for SNP-array studies. In one patient (UPN 44) 
a microdeletion (<850 kb) was present at 4q24, which was validated by FISH (Figure 2b). Two 
genes are located within this microdeletion, the pyrophosphatase gene PPA2 and the ten-eleven-
translocation gene TET2 (KIAA1546, FLJ20032). Genomic sequencing did not reveal any mutation 
in PPA2, but the remaining copy of TET2 harbored a nonsense mutation in most cells, introducing 
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Figure 1: Copy number changes and uniparental disomy in MDS patients.
Overview of all genetic aberrations found with 250k SNP array analysis in 102 MDS cases. Each line represents a different 
subject. Blue lines are large (> 20Mb) telomeric regions of (acquired) uniparental disomy, red lines represent deletions, and 
green lines are copy-number gains. 
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a premature stop codon (Figure 2c and Table 1). Both the 4q24 microdeletion and the nonsense 
mutation were absent in non-neoplastic T-lymphocytes of the same individual (Figures 2a and 2c), 
indicating that both anomalies were acquired. To establish whether the other five subjects with 4q24 
abnormalities also carried TET2 mutations, we sequenced this gene and found that all five carried 
bi-allelic anomalies of TET2 (Table 1 and Figure 3). We conclude that TET2 is the target gene in 
MDS-affected individuals with 4q24 abnormalities. 
To reveal the overall frequency of TET2 mutations in MDS, we subsequently sequenced the gene 
in all cases from our cohort. Common single nucleotide polymorphisms (SNPs) present in public 
databases and/or detected in a cohort of 104 healthy Dutch controls were excluded (Supplementary 
Table 3). In total, we found TET2 aberrations in 27 out of 102 subjects with MDS (26%, Table 1). To 
investigate whether the mutations were acquired, we analyzed germ-line DNA from T-cells wherever 
Figure 2: TET2 is recurrently affected in MDS.
(a) Genomic profile of chromosome 4 in patient 44 showing a 850-kb microdeletion on 4q24, encompassing the PPA2 and 
TET2 genes. This deletion was absent in the T cells of the same individual. Five other subjects carried larger aberrations on 4q, 
including a deletion (red bar) or uniparental disomy (UPD; blue bars) 
(b) Validation of the 4q24 microdeletion in subject 44 by fluorescent in situ hybridization, showing presence of the 4q24 locus 
(green signal) on only one of the two chromosomes 4 (red centromere probe) in a metaphase of bone marrow cells.
(c) Sequence analysis of DNA from the lymphocyte-depleted cell fraction of patient 44 reveals a C > T conversion at position 
1147 of the TET2 gene in the remaining 4q24 allele leading to a premature stop codon (TAA). The mutation was found to be 





Table 1: Characteristics of TET2 mutations. 









44 RAEB RAEB-2 int-2 normal no 4q24.23 Q383X hemizygous acquired






50 RA RCMD low normal no no Q417X heterozygous acquired






59 RAEB RAEB-1 int-2 -7 no no R506X heterozygous acquired




73 RAEB RAEB-1 int-1 +8
4q12-
q35.2
no W1291R homozygous acquired
75 RAEB RAEB-1 int-1 normal no no









79 RARS RCMD-RS int-1 normal no no G1913D heterozygous acquired
81 RA RCMD int-1 normal no no Q574fsX5 heterozygous N/A










87 RA RA low normal no no Q847fsX24 heterozygous N/A










98 RA RA low normal no no P555fsX10 heterozygous N/A
100 RA RCMD low normal
4q22.3-
q35.2
no H682fsX10 homozygous N/A




102 RA RCMD low normal no no R1261L† heterozygous N/A






104 RAEB-t AML high Complex***  No  no S826fsX14 heterozygous N/A
7 RAEB-t RAEB-2 int-2 complex no 4q23-q35.2 P1962L† heterozygous** N/A






11 RARS RCMD-RS int-1 +8 no no H1881Q† heterozygous N/A
36 RARS RCMD-RS low normal no no T996fsX12 heterozygous N/A
74 RAEB-t AML MLD high normal
4q23-
q35.2
no Q1170fsX55 homozygous N/A
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available (10/27). In all cases examined, the mutations were restricted to the nonlymphoid cells, 
indicating that they were acquired. Nonsense and frameshift mutations leading to premature stop 
codons were scattered throughout the TET2 coding sequence, with preference for the N-terminal 
and middle moieties of the protein (Fig. 3). Notably, all missense mutations leading to amino acid 
substitutions and in-frame deletions clustered in two distinct regions (Figure 3). Alignment of TET2 
orthologues from different species showed that these regions are highly conserved (Supplementary 
Figure 3). In addition, these regions were found to be conserved in the human TET2 paralogues 
TET1 and TET3 (Supplementary Figure 4), indicating that they represent functionally important 
domains.
Notably, it was very recently found that TET2 mutations in myeloproliferative neoplasms target both 
multipotent and committed progenitor cells, suggesting that TET2 has an important regulatory role 
for TET2 in myelopoiesis14. To gain further insight into its function, we studied TET2 expression 
in various cell types. First, we determined whether the different splice variants that are predicted by 
genome databases are expressed. Three isoforms were shown to be expressed, of which isoforms 2 
and 3 lack the C-terminal part of the protein, including the two highly conserved regions (Figure 
4a and Supplementary Figure 5). TET2 showed a broad expression pattern in different tissues, 
with a 10-100 fold higher expression in hematological cells, particularly in granulocytes (Figure 4b). 
In addition, TET2 expression was upregulated during all-trans retinoic acid induced granulocytic 
differentiation of the promyelocytic cell line NB4 (Figure 4c), underscoring its proposed role in 
myeloid differentiation. To compare the expression of TET2 in MDS cases and healthy controls, 
we isolated CD34+ cells, CD13+/33+ myelo-monocytic cells and CD71+ erythroid cells from bone 
marrow, and mature granulocytes from peripheral blood. TET2 expression was comparable between 
most fractions from MDS cases and controls, but was significantly decreased in the granulocytes 
from MDS cases (Figure 4d, p<0.01). This decreased TET2 expression was observed in all MDS-
affected individuals, irrespective of the TET2 mutation status. As all subjects with MDS showed 
morphological defects of the mature granulocytes (Supplementary Table 4), the decreased TET2 
expression levels may be caused by a disturbed or incomplete granulocytic differentiation in the 
MDS cells, thereby further linking TET2 expression to myeloid differentiation.
Subject 44 later progressed to AML. Notably, in the leukemic blasts, the 4q24 deletion and the 
nonsense TET2 mutation were retained, but an additional 7q deletion (associated with poor 
Table 1: Characteristics of TET2 mutations. 









44 RAEB RAEB-2 int-2 normal no 4q24.23 Q383X hemizygous acquired






50 RA RCMD low normal no no Q417X heterozygous acquired






59 RAEB RAEB-1 int-2 -7 no no R506X heterozygous acquired




73 RAEB RAEB-1 int-1 +8
4q12-
q35.2
no W1291R homozygous acquired
75 RAEB RAEB-1 int-1 normal no no









79 RARS RCMD-RS int-1 normal no no G1913D heterozygous acquired
81 RA RCMD int-1 normal no no Q574fsX5 heterozygous N/A










87 RA RA low normal no no Q847fsX24 heterozygous N/A










98 RA RA low normal no no P555fsX10 heterozygous N/A
100 RA RCMD low normal
4q22.3-
q35.2
no H682fsX10 homozygous N/A




102 RA RCMD low normal no no R1261L† heterozygous N/A






104 RAEB-t AML high Complex***  No  no S826fsX14 heterozygous N/A
7 RAEB-t RAEB-2 int-2 complex no 4q23-q35.2 P1962L† heterozygous** N/A






11 RARS RCMD-RS int-1 +8 no no H1881Q† heterozygous N/A
36 RARS RCMD-RS low normal no no T996fsX12 heterozygous N/A
74 RAEB-t AML MLD high normal
4q23-
q35.2
no Q1170fsX55 homozygous N/A
*  In 27 of 102 individuals with MDS, aberrations of TET2 were observed in bone marrow cells. Uniparental disomy 
(UPD), amplifications and deletions at 4q24 were analyzed using SNP-arrays. Genomic sequencing of the protein coding 
region and splice donor and acceptor sites revealed nonsense, missense and insertion/deletion mutations leading to an amino 
acid deletion and substitution or to a frameshift resulting in a stopcodon after 2-77 aminoacids (indicated as fsX followed 
by the number of aminoacids18). Sequence aberrations were classified as heterozygous, homozygous or hemizygous by analy-
zing the intensity of the base pair signal in the sequence reaction. Whenever possible, purified T cells were analyzed to assess 
whether the observed mutations were acquired. UPN,  unique patient number. N/A, not analyzed due to lack of sufficiently 
available T cells. Nucleotide positions of the mutations are indicated in Supplementary Table 5. 
* *   Sequencing showed both the missense as well as the wild type sequence (albeit with lower signal intensity). As the SNP array 
showed loss of one allele, the wild type sequence might have arisen from remaining non-clonal bone marrow cells.
***   Including deletion of chromosome 4 in 2/39 cells analyzed by conventional karyotyping.
†   Although these missense mutations were not present in our cohort of healthy controls and did result in changes of conserved 
amino acids (Supplementary Figures 3 and 4), it cannot be excluded that they represent rare SNPs, since germ-line mate-
rial of these patients was not available.
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prognosis in MDS) plus a gain on chromosome 11q were acquired at the time of AML progression 
(Supplementary Figure 6). This indicates that the bi-allelic TET2 inactivation represented an 
earlier event than the aberrations on 7q and 11q. To further address whether TET2 mutations 
represent early or late events in the course of the disease, we conducted allele-specific, quantitative 
assays for the different mutations in 25 of 27 cases (Figure 5a, Supplementary Tables 5a and 5b 
and Supplementary Figures 7 and 8). Although in five cases the allelic burden was between 56 and 
70%, in most patients with mono-allelic mutations, the mutant allele was present in the majority 
(>70%) of the cells, suggesting that the mutation was an early event (overall range: 56-100%, 
median 96%). In cases with more than one TET2 mutation, at least one mutant allele was present 
in most of the cells whereas the second mutation was present in variable percentages (range 22-
100%, median 80%) showing that acquisition of a second mutation may lead to further expansion of 
double-positive subclones. In one subject (UPN46), three different TET2 mutations were detected 
in 96%, 43% and 44% of the cells respectively, suggesting that two different subclones, each with a 
different second mutation, had arisen from the initial mutant clone. 
Next, we determined in which bone marrow cells the TET2 mutants were expressed. To this 
end, we isolated RNA from CD71+ erythroid precursors, CD13/33+ myelomonocytic cells and 
CD34+ progenitor cells from the bone marrow of seven MDS-affected individuals with a TET2 
mutation. In all cases, mutant TET2 was found to be present in all subfractions tested. Of note, 
we detected a second mutation in patient UPN 77 in the CD34+ and CD13/33+ cells, but not in 
the CD71+ cells (which represented <10% of the total bone marrow cells)(Supplementary Figure 
9 and Supplementary Table 6a and 6b). This observation further indicates that TET2 mutations 
represent early events, and that second mutations in TET2 may occur in subclones arising at later 
stages of disease development. 
Figure 3: Localization of TET2 mutations.
Localization of all TET2 mutations detected in 27 individuals with MDS shown at the protein level. Missense mutations are 
indicated by dark gray squares, nonsense and frameshift mutations in light gray squares. All missense mutations are located in 
one of the conserved protein regions. These conserved regions are present in isoform 1, but absent in isoforms 2 and 3. UPN, 
unique patient number (corresponding to Table 1); AA, amino acid.
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Figure 4: Expression of three TET2 isoforms in various cells and tissues.
(a) Schematic representation of the exon structure of three isoforms of TET2 as confirmed by RT-PCR. Location of the (shared) 
start codons and the stop codons are indicated. The translated region is indicated in black. AA, amino acid.
Expression of TET2 isoforms was measured by isoform-specific quantitative PCR. Expression is depicted relative to the house-
keeping gene GAPDH. The mean expression of TET2 isoforms is indicated. (b) Expression was determined in various tissues 
(pooled RNA) and hematopoietic cell fractions. The expression is significantly higher in granulocytes than in other hematopoietic 
cells (indicated by an asterisk).(c) The promyelocytic cell line NB4 before and after induction of granulocytic differentiation 
using all-trans retinoic acid (ATRA, 10-6 M). The difference in time is statistically significant (p<0.05). d) Expression in vari-
ous hematopoietic subfractions of MDS cases and controls. In the CD13/33 fraction, expression of isoform 2 was significantly 
different in cases compared to controls. In the granulocyte fraction, expression of all three isoforms was significantly decreased. An 





TET2 mutations occurred in all subtypes defined by the International Prognostic Scoring System 
(IPSS), but were more frequent in the low (41%) and int-1 risk categories (27%) as compared to 
the int-2 (13%) and high risk (14%) groups (Figure 5b). TET2 mutations were significantly less 
common in patients with multiple cytopenias or high blast cell counts (Figure 5b). Monoallelic 
or biallelic mutation status and the mutant allelic burden did not significantly correlate with MDS 
subcategory (Figures 5a and Supplementary Table 5), overall survival or progression to AML in 
this cohort (data not shown), but to properly address this point, a larger prospective study is needed. 
Figure 5: Correlation of TET2 mutation status and allelic burden with clinical phenotype.
(a)  Allelic burden of the identified TET2 mutations (and deletion in case of UPN 44). In case of multiple mutations in a single 
individual, the allelic burden of all mutations is shown by different bars. Data are sorted based on an increasing allelic 
burden. 
(b)  The incidence of TET2 mutations is shown in the four IPSS subgroups. As the IPSS is determined by the cytogenetic fin-
dings, cytopenias and amount of bone marrow blasts, these subgroups are shown separately. Also, patients with a normal 
karyotype and with one or more aberrations are distinguished. As shown, the frequency of TET2 mutations varies between 
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To assess whether TET2 is affected in a wider range of myeloid malignancies, we sequenced TET2 in 
a cohort of individuals with de novo AML (n=32) (Supplementary Table 7). TET2 mutations were 
indeed detected in 6 of 32 patients and co-occurred with various other cytogenetic and molecular 
aberrations, including PML-RAR translocations and NPM1 mutations. Together with the above 
mentioned observation that TET2 mutations occur in myeloproliferative disease as well, our data 
suggest a general role for this gene in myeloid malignancies.
In conclusion, we have identified TET2 as the most frequently mutated gene in MDS thus far 
known. As in all cases at least one, and in many cases two alleles were affected, loss of function 
seems to be the most probable mechanism by which these mutations contribute to the malignant 
transformation of bone marrow cells, thereby defining TET2 as a previously undescribed tumor-
suppressor gene in MDS.
Methods
Patients and healthy controls
Bone marrow (n=102) and blood (n=10) from MDS patients and blood from healthy controls 
(n=104) were collected after informed consent. Consecutive patients from the Radboud University 
Nijmegen Medical Center Nijmegen (n =83) belonging to all different WHO and IPSS categories 
and cytogenetic subgroups were included. A second cohort of karyotypically normal patients from 
the University Hospital Leuven (n=19) was also included. Patient characteristics are shown in 
Supplementary Table 8. Cells were frozen in liquid nitrogen until further use. DNA was extracted 
from FACS-sorted lymphocyte-depleted bone marrow (patients, n=41), Ficoll density gradient 
isolated mononuclear cells from bone marrow (patients, n= 61), or white blood cells after NH4Cl lysis 
(controls, n=104). In addition, in a subset of patients (n=10) DNA was extracted from T-cells isolated 
from peripheral blood by FACS sorting of CD3+/CD19-/CD45+ cells. In case only limited amounts 
of cells were available, in vitro expansion of polyclonal T-cells was performed. For this purpose, cells 
were cultured in IMDM and 10% Human Serum for 7-14 days in medium containing IL-2 (100 
IU/ml) and beads coated with anti-CD3 and anti-CD28 (Dynabeads, Invitrogen). After culture, the 
purity of the T-cells was measured using CD3 and CD45 surface markers. To ensure high purity, 
sorting of the CD3+ cells by FACS was performed. DNA was isolated using Qiagen spin-columns 
and its quality was checked on gel and by using a nanodrop ND-1000 spectrophotometer analysis.
Granulocytes were isolated after 1077 Ficoll density gradient centrifugation and erythrocyte lysis. The 
other cell subtypes were isolated by FACS sorting using monoclonal antibodies directed against CD4 
and CD8 (T-cells), CD14 (monocytes), CD19 (B-cells), CD71 (erythroid cells), CD34 (progenitor 
cells), CD56 (NK-cells), CD13/33 (mono/myeloid-cells). Pooled RNA from all other tissues was 
commercially obtained (Clontech). NB4 cells were cultured in RPMI medium supplemented with fetal 
bovine serum and penicilline/streptomycine and exposed to 10-6 M all-trans retinoic acid (ATRA)(n = 3).
Bone marrow (n=21) and blood (n=11) of AML patients were collected after informed consent. 
Patients were diagnosed in the Radboud University Nijmegen Medical Center (n=25) or the Leiden 
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University Medical Centre (n=7). We included patients of all FAB subtypes. Since AML M3 
represents an important subgroup of AML, characterized by the PML-RAR translocation and its 
unique sensitivity to ATRA, a relatively large cohort of M3 patients was examined. 
SNP-array analysis
Affymetrix 250k SNP arrays were hybridized according to the protocol provided by the manufacturer 
(Gene Chip Mapping 500K Assay manual). Briefly, 250 µg of total genomic DNA was digested using 
the Nsp I restriction enzyme and ligated to adaptors. A single primer that recognizes the adaptor 
sequence was used to amplify adaptor ligated DNA fragments. The amplified DNA was purified, 
digested with DNase I and labeled with biotin. Subsequently, samples were hybridized to GeneChip 
Human mapping 250k arrays (Affymetrix). The arrays were washed and stained by streptavidin-
phycoerythrin conjugates using the Affymetrix GeneChip Fluidics Station 450. Subsequently, the 
arrays were scanned with the Affymetrix GeneChip Scanner 3000 to obtain the fluorescence intensity 
data. Analysis of data, including quality control, was performed with the Genotyping Analysis 
Software GTYPE (Affymetrix). Copy number analysis was performed using the public domain 
CNAG software package15. Next to visual inspection, the Hidden Markov Model (HMM) available 
within the CNAG software package was used to score the copy number aberrations. An overview 
plot was made using the Genome-Wide Viewer available at https://bioinformatics.cancerresearchuk.
org/ ~cazier01/GWA_View.html. For the analysis of DNA from the T-cell fraction, the mononuclear 
MDS fraction, and an AML diagnosis sample from patient UPN44, the Affymetrix SNP6.0 arrays, 
containing 1.8 million SNPs and copy number probes, were used. Genotypes were generated using 
Birdseed analysis software implemented in the Affymetrix Genotyping Consule v2.1. To exclude 
those regions that show normal copy number variation all detected copy number aberrations were 
compared to those present in paired T-cells (n=8), our in-house panel of copy-number variations 
in healthy controls (currently containing 1015 individuals), as well as those previously reported in 
270 unaffected HapMap individuals16 and the Database of Genomic Variants (http://projects.tcag.
ca/variation). Copy number neutral loss of heterozygosity (LOH) was defined as areas consisting of 
stretches of >70 sequentially homozygous SNPs. The regions thus defined were ordered based on size 
and location (i.e. interstitial or telomeric). 
FISH analysis
DNA from BAC clones RP11-449G2 and RP11-542F11 (BACPAC Resources, Oakland, USA), 
both spanning the TET2 gene, were labelled with biotin and immunocytochemically stained with 
FITC. As a reference, a Cy3-labeled chromosome 4 centromeric probe was used (Vysis Inc.). Visual 
examination of the slides was performed using a Zeiss Axiophote-2 microscope equipped with 
appropriate filters. Twenty metaphases were examined. Digital images were captured using a high-
performance Leica DC 350FX camera coupled to Leica CW 4000 software package.
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Sequence analysis 
Sequence analysis was performed on PCR-amplified genomic DNA fragments spanning the entire 
coding region of all three TET2 isoforms (for primer sequences, see Supplementary Table 9). All 
intron-exon boundaries were included to identify possible splice site aberrations. All products were 
sequenced bi-directionally and sequence variations were confirmed by an independent PCR and 
sequencing procedure starting from the original patient DNA. To analyze whether the observed 
mutations were acquired, DNA from T-cells, if available, was isolated from patients showing sequence 
variations in TET2 (n=10). To further minimize the chance that putative mutations represent SNPs, 
the observed mutations were compared with known ESTs. Moreover, TET2 was sequenced in a 
group of 104 healthy Dutch controls. 
Determination of allele burden
To establish the allele burden of TET2 mutations, pyrosequencing (PSQ) reactions were performed 
in patients with missense mutations and single basepair deletions/insertions according to the protocol 
of the manufacturer, with minor modifications17. Briefly, ratios of single-nucleotide missense and 
nonsense mutations relative to the wild-type sequence were determined using a Pyrosequencer 
PSQ96MA platform (Biotage AB, Uppsala, Sweden). Mutation-specific PSQ primer combinations 
were developed in-house, using dedicated ‘PSQ Assay Design’ software (Isogen Life Science). 
Mutation-specific PSQ primer sequences are shown in Supplementary Table 9. All PSQ reactions 
were performed in duplicate. 
Genescan analysis was performed in MDS patients with TET2 microdeletions consisting of two or 
more nucleotides found by sequencing (n=4) and in patients with single basepair deletions/insertions 
where pyrosequencing was unsuccessful (n =3). The primers used for genescan analysis are shown in 
Supplementary Table 9. Briefly, 50 PCR cycles were performed using unlabeled primers, followed by 
15 cycles with a labeled forward or reverse primer (conditions: 5 min. at 95°C, 50/15 cycles of 30 s at 
95°C, 30 s at 55°C and 1 min at 72°C, followed by 10 min at 72°C). 1 µl of each PCR product was 
analyzed using the 3730 DNA analyzer (Applied Biosystems) and Peak Scanner Software (Applied 
Biosystems).
Splice-variant analysis
To confirm the expression of the TET2 splice-variants described in databases (TET2 Isoform 1: 
NM_001127208 / UniRef100Q6N021. Isoform 2: NM_017628 / UniRef100Q6N021-2. Isoform 
3: UniRef100_Q6N021-3), primer pairs were designed covering all relevant, isoform specific, exon-
exon boundaries (for primer sequences, see Supplementary Table 9). PCR was performed on cDNA 




To assess the mRNA expression of TET2 in different hematopoietic cell fractions and tissues, specific 
PCR primers and probes were designed that discriminate between the three different isoforms of 
TET2 (Supplementary Table 9). Quantitative PCR was performed using an Applied Biosystems 
Taqman 7900HT machine. Quantities were normalized using GAPDH expression as a reference 
and calculated using the 2∆CT method. 
Statistical analysis
The occurrence of TET2 mutations in different patient subgroups was determined. Error bars 
show the standard deviation. P-values were calculated using a Pearson chi square test (4x2 and 
3x2 tables) or a two-tailed Fisher exact test. Statistical analysis of TET2 expression in NB4 cells 
during differentiation was performed with ANOVA using repeated measures. Statistical analysis of 
TET2 expression in various cellular subsets was performed with ANOVA using univariate analysis. 
P-values <0.05 were considered statistically significant.
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Supplementary Figure 1: RUNX1 deletions detected by 250k SNP-array analysis 
In three MDS patients (UPN 47, 26, 97) a microdeletion was detected on chromosome 21 using 250k SNP-array based 
analysis. The minimal overlapping region contained (part of ) RUNX1 as the only affected gene, as indicated below. RUNX1 
is known to be affected by mutations in 2-10% of MDS patients. The upper graph shows the genomic profile on chromosome 
21 of patient 47. The red boxes indicate the location of the deletions in patients 26 and 97. In patient 97, 9 genes were deleted 
including RUNX1. In the other two patients only part of RUNX1 was deleted. The exact locations of the deletions is listed in 
Supplementary Table 1. Although cryptic translocations cannot be excluded, no evidence was obtained for translocations invol-
ving RUNX1 upon karyotype analysis (n=3). RUNX1-RUNX1T1 PCR was performed on RNA of patient 47. There was no 
evidence for a RUNX1-associated translocation. 
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Supplementary Figure 2: TP53 mutation detection in a patient with UPD on chromosome 17p
(a) 250k SNP-array analysis of chromosome 17 of UPN 68 showing no copy number changes (in red). Green lines below the 
ideogram represent heterozygous SNP calls, which are nearly absent on the p-arm of chromosome 17, representing segmental 
UPD (indicated by a blue line). (b) Sequence analysis of the TP53 gene, which is located on 17p13.1, shows a homozygous 
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Drosophila-melanog.      1 ----------MENAGEQARCLDAIIEIAFAVRANGACESENEPGVCSSYLAARLAPGPGDKERNS-NLPARIVGFICMALCDTYYAYQIN 
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Homo-sapiens            22 P-PICQTEPLAT--KLQNGSPLPERAHPEVNGDTKWHSFKSYYGIPCMKGSQNSRV---------------------------------- 
Pan-troglodytes        162 P-PICQTEPLAT--KLQNGSPLPERAHPEVNGDTKWQSFKSYYGIPCMKGNQNSRV---------------------------------- 
Canis-lupus-fam.       140 PSPNCQTEPLAL--KLQNGSPLTERPYPEVNGDTKWQSFKSYHGIPHMKRSQNSRV---------------------------------- 
Rattus-norvegicus       49 PSPVSHTEPLAV--KLQNGSPLAERPHPEVNGDTKWQSFQSYYGIPHMKGSQSSHE---------------------------------- 
Macaca-mulatta          22 P-PICQTEPLAT--KLQNGSPVPERSHPEVNGDTKWQSFKSYYGIPHMKGSQNSRV---------------------------------- 
Mus-musculus            22 PSPISHTEPLAV--KLQNGSPLAERPHPEVNGDTKWQSSQSCYGISHMKGSQSSHE---------------------------------- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio             29 KISATQQTDFLT--KHQNGDQSPE--------------------------VLSQQK---------------------------------- 
Monodelphis-domest.    125 PGKIPPSKTLEKENKCENGVLAVSKEHIVETEKETDQ--SQEKVISTDNEEDPIVV---------------------------------- 
Ornithorhynchus-anat.    1 ------------------------------------------------------------------------------------------ 
Bos-taurus               6 FEG-TSILLPHCPLCLASNRQ--GHSK--------------------------------------------------------------- 
Xenopus-trop.            5 PAP-VPHVLPQDVYEFPDDQESLGRLR--------------------------------------------------------------- 
Gallus-gal.            132 PRKAAAQKKLETKEKHEQALAVVEEKNVEASEKVLEQNLAQDELASLPVEDIPCSV---------------------------------- 
Tetraodon-nig.         203 PRPRVRHSPPWLPLRLHHHRRDSGSDRRLREAHWDARPDALLHGEFPASASALVSVGRPNAPSVSQNPRLLDDVSFHPCVRFKRWEAERI 
Culex-pip.              74 PSPNTTTGGAAGPP---N-------VVQSSQLVTVSGAQTG------------------------------------------------- 
Aedes-aegypt.           62 PSPNTTTGAVAAATGTSN-------VVQSSQLVTVSGAQTG------------------------------------------------- 
Apis-mellif.           361 QICKMRRCEKLTEKKSYRKIARQVSTPDSAPAGLGSPQTGIGGLQQHQQQAQQQSQQTLHQPD--------------------------- 
Nasonia-vitripen.        1 ------------------------------------------------------------------------------------------ 
Anopheles-gam.          48 PSPNTTTPATPNVQQVPGQQQQQQQQQQQQQLVTVSGAQQPGTAAPPTAASTASAAHNNSNGV--------------------------- 
Drosophila-melanog.     80 PYGHYTHHWRKQSRARKN-------STKANKLNAAAASATSPRLSPVPAATLLPQQSPN------------------------------- 
 
 
Homo-sapiens            75 ---------------------------------------------------------------------------------------SPD 
Pan-troglodytes        215 ---------------------------------------------------------------------------------------SPD 
Canis-lupus-fam.       194 ---------------------------------------------------------------------------------------SPD 
Rattus-norvegicus      103 ---------------------------------------------------------------------------------------SPD 
Macaca-mulatta          75 ---------------------------------------------------------------------------------------SPD 
Mus-musculus            76 ---------------------------------------------------------------------------------------SP- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio             57 ---------------------------------------------------------------------------------------VPA 
Monodelphis-domest.    179 ---------------------------------------------------------------------------------------TSD 
Ornithorhynchus-anat.    1 ------------------------------------------------------------------------------------------ 
Bos-taurus              30 ---------------------------------------------------------------------------------------RVK 
Xenopus-trop.           31 ---------------------------------------------------------------------------------------VSE 
Gallus-gal.            188 ---------------------------------------------------------------------------------------AEE 
Tetraodon-nig.         293 LSFIPPDGNFRLLSYHVSSQNLVAIPVYVKHNITFREGSSQGRFDLTLGPKQTMGKGVESVLVSSQLPRGVLNVSLNPSQGTYTFDPVTK 
Culex-pip.             105 ----------------------------------------------------------------------------------------VN 
Aedes-aegypt.           96 ----------------------------------------------------------------------------------------VN 
Apis-mellif.           424 ---------------------------------------------------------------------------------------PMQ 
Nasonia-vitripen.        1 ----------------------------------------------------------------------------------------MQ 
Anopheles-gam.         111 ---------------------------------------------------------------------------------------LLA 
Drosophila-melanog.    132 ----------------------------------------------------------------------------------------TT 
 
 
Homo-sapiens            78 FTQESRGYSKCLQNGGIKRTVSEPSLSG-------------LLQIKKLKQDQKANGERRNF----------------------------- 
Pan-troglodytes        218 FTQESRGYSKCLQNGGIKRTVSEPSLSG-------------LLQIKKLKQDQKANGERRNF----------------------------- 
Canis-lupus-fam.       197 FIQEGRGYSRCLQNGGIKRTVSEPSLSG-------------LHQNKKLKQDQKANGERNNF----------------------------- 
Rattus-norvegicus      106 FIHEGRGYSGCLQNGGIKRTVSEPSLSG-------------LHLNTKLTLDQKAKGESNNF----------------------------- 
Macaca-mulatta          78 FIQESRGYSKCLQNGGIKRTVSEPSLSG-------------LLQIKKLKQDQKANGERCNF----------------------------- 
Mus-musculus            78 --HEDRGYSRCLQNGGIKRTVSEPSLSG-------------LHPNKILKLDQKAKGESNIF----------------------------- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio             60 NLQGIFDQSMFGMKGQMKHALSEQALLD-------------FHQTKTLVNG--------------------------------------- 
Monodelphis-domest.    182 ALP----SKENGQAVEDPITSITTHSSLP------------TQTSETLEENCKCEGQFFEK--------------LLNDSSDTVRT---- 
Ornithorhynchus-anat.    1 ------------------------------------------------------------------------------------------ 
Bos-taurus              33 VYSQMVGPQMFKDLLEFRLLQ-NQKGPVS------------------------------------------------------------- 
Xenopus-trop.           34 MPAELNGGGGGGSAAAFAMELPEQSNKKR------------------------------------------------------------- 
Gallus-gal.            191 PAATCAGQEEEGEIPETKNSVPSTQVADDNT---------AVSEVEYEHEDLPCEPTLVDLNASSAAEAFVEDAALVLPSSDSITTSEST 
Tetraodon-nig.         383 MLSWDVGKINPQKLPSLKGTMSLQAGASKPD---------ENPTINIQFKIQQMAISGLKV------------------NRLDMYGEKYK 
Culex-pip.             107 LLASQPTQALQQQQQQVAQTNPGLTQQ---------------QQSAPQQQAPQQTPQQVPT----------------------------- 
Aedes-aegypt.           98 ATLLASNNASQPLQQQQQQQ---LAQQ---------------SQLQQQQQTPQQQQQQVPT----------------------------- 
Apis-mellif.           427 QSKDNLNPAAN------QQTGALRNGN---------------PPPPVVSISPGVMPFYGDS----------------------------- 
Nasonia-vitripen.        3 QAKDSLNPAAGQQQQQQQQAGPLRNGNP--------------APAPVVSMSPGVMPFYGDG----------------------------- 
Anopheles-gam.         114 TGIPSQHQHQQQQHQQQAQLQHHLARHPPIPPGAPPPGGGGPGSLQQQQQQQQQQHHSIIV----------------------------- 
Drosophila-melanog.    134 SATGNLQQQQQQQQQQYQQHQQLLSQQQ------------LLSQQQQQYQQPQQQQQHFQQ----------------------------- 
 
                                                                            T164fsX5 
Homo-sapiens           126 -------------GVSQERNPGE-SSQPNVSDLSDKKESVSSVAQENAVKDFTSFSTHN---------------------------CSGP 
Pan-troglodytes        266 -------------GVSQERNPGE-SSQPNVSDLSDKKESVSSVAQENAVKDFTSFSTHN---------------------------CSGP 
Canis-lupus-fam.       245 -------------GESQESNPGKGSSQLNVSDLSDKRESVSSVAQENAVKDLISSSTQN---------------------------CSRS 
Rattus-norvegicus      154 -------------GESQEGNPGKSSSHPNVSGLSDDREPGTSTAQE--STDIDAFPTRN---------------------------YNGV 
Macaca-mulatta         126 -------------GVSQERNPGE-SSQPNVSDLSDKKESVSSVAQENAVKDFTSFSTHN---------------------------CSGP 
Mus-musculus           124 -------------EESQERNHGKSSRQPNVSGLSDNGEPVTSTTQE--SSGADAFPTRN---------------------------YNGV 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio             98 ------------------------NENPRIWDKSEAGMEN----------RLEVFPKHN---------------------------KAGD 
Monodelphis-domest.    238 ------LVQDSMPIPLFNNAPHTVTSKPNLNMYLEDLGSRVKSLKLNDSSLEPMKENLDSHQS---------------------SCYKGK 
Ornithorhynchus-anat.    1 ------------------------------------------------------------------------------------------ 
Bos-taurus              61 --------------RVVLSCAACPSSVPPHCAGTAGLLLS-------------------------------------------------V 
Xenopus-trop.           63 --------------KRCGVCVPCLRKEP--CGACYNCVNR-------------------------------------------------S 
Gallus-gal.            272 SKVCIETPFDLVPNSKESDSGSIDTSDPSSAVLLEELVPLAESHTEAESDLVLASEEHNSNSAPTVTSELNSQECLEDLSSFAESCLKGD 
Tetraodon-nig.         446 PFKGIKYMTKAGKFQVRTRCLACAHAAPDPCHAAPAVASLRVEYFEGSVRDGSAEPELAAELRSGIQGWSRERP--------GGPTHMGP 
Culex-pip.             153 -----------G-IIKADTMKDQ----PQQPMAPMAFYPTWQADPSQ--GWQNQFIQQIP--------------------------QNTP 
Aedes-aegypt.          141 -----------VGIIKAETMKDQ----PQQPMAPMAFYPTWQADPSQ--GWQNQFIQQIP--------------------------QNTP 
Apis-mellif.           467 -----------GAGFRPAAGFGN-----TVWHQGVAPVGAVAVETSAAPWPPQQFIQQIPAPNQLEELRYH-------------TQYSAA 
Nasonia-vitripen.       50 -----------GAGFRPATGFGN-----AVWHQGVSPVGAVTVEAAPAAWPPQQFIQQLPGPNQIEELRYH-------------TPYGAA 
Anopheles-gam.         175 -----------KSEPSVEVMKDQ----PQQPMAPMAFYPTWQADPSQ--GWQNQFIQQIP--------------------------QNTP 





Homo-sapiens           175 ENPELQILNEQEGKSANYHDKNIVLLKN-KA-----------VLMPNGATVSASSVEHTHGELLEKTLSQYYPDCVSIAVQK-TT----- 
Pan-troglodytes        315 ENPELQILNEQEGKSANYHDKNIVLLKN-KA-----------VLMPNGATVSASSMEHTHGELLEKTLSQYYPDCVSIAVQK-TT----- 
Canis-lupus-fam.       295 EKPELQIPNEQKEKNANYRDKNFTLLLTNKA-----------VLMPNGATVSASSMENTHGELLEKTLSQYYPDCVSVAVQK-TT----- 
Rattus-norvegicus      202 ENTEIPEEQEGG------NDRNALLLKN-KA-----------VLMPNGATVSAPSVEDTHGEFLEK--TQCYPDCVSMAVQNNTT----- 
Macaca-mulatta         175 ENPELQILNEQEGKSANYRDKNIVLLKN-KA-----------VLMPNGATVSASSMEHTHGELLEKTLSQYYPDCVSIAVQK-TT----- 
Mus-musculus           172 EIQVLNE-QEGE------KGRSVTLLKN-KI-----------VLMPNGATVSAHSEENTRGELLEK--TQCYPDCVSIAVQS-TA----- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            127 LTHAKINCN--------FTNGDLFSLSRNKQ-----------VQMPNGATTSPPSVKGTTGDLLEKTLSQYYPEHVSIAPQTNSS----- 
Monodelphis-domest.    301 PELDFQNIMVPSGSIFPTSFANYLLAGSDQQE-------------PIHGSLDQP-----VTQSTASDPLGGHGANQTLTLDSGQ------ 
Ornithorhynchus-anat.    1 ------------------------------------------------------------------------------------------ 
Bos-taurus              88 LCLVSGAFHRCDQ----------YETQKGSE---------QHSDVHTGSELSPVDGPVPG-QMDSGPVYHGDS---RQLSASGAP----- 
Xenopus-trop.           88 TSHQICKMRKCEQ----------LKKKRVVP----------MKGVENCSESILVDGPKTD-QMEAGPVNHVQEGRLKQECDSTLP----- 
Gallus-gal.            362 GDLESENVHLGSHSNSEAATGSNSLLHFESVSSLVESNMKLVDFVPVHKELDSCSDLSRTVENTESDSKNIFTASESVSDTSLTNIEVED 
Tetraodon-nig.         528 LTYCVPAVHRHPQPMRPTPHRQCHRRPPGPP---------TDTLQETVQKVISVDGPRSGGQMEIGSHDRLQEGALSLKLANGVNN---- 
Culex-pip.             199 AITPLNSLEFQPQGYAAYQPNGYVQTAGIGFD----------PNYGRT-YAAPPTVQRYEFQTNQ---IT----PINQVSLQSVS----- 
Aedes-aegypt.          188 AITPLNSLEFQPQGYAAYQPNSYVQTAGIGFD----------PNYGRT-YAAPPTVQRYEFQTNQ---IT----PINQVSLQSVS----- 
Apis-mellif.           528 APYHPQPVAYQQQTFITTDQSAFQRAGATGQY----------TITGQPSPLPPVAPQTVPSTTQR--PLNGQFMDPAATATQSVGYE--- 
Nasonia-vitripen.      111 APYHPQTVTYQQQTFITADQSAFQRAGTTGQY----------AITGQPSPLAPVAAQAPQAATPQRHPLNGQFIDPAGTAAQPVAYD--- 
Anopheles-gam.         222 AITPLNSLEFQPQGYAAYQPNGYVQTAGIGFD----------PNYGRT-YAAPPAVQRYDFQANQ---IA----PINQVSLQSVS----- 
Drosophila-melanog.    236 AITSLNSLDFQTQSY-AYPSNGYVQSG-LGFD----------PNYGRSPYAAP--VQRYDFQSQQ---LSTAPSAINQVGLQSVAG---- 
 
 
Homo-sapiens           247 --SHINAINSQATNELSCEITHPSHTSGQINSAQTSNSELPPKPAAVVSEACDADDADNASKLAAMLNTCSFQKPEQLQQQKSVFEICPS 
Pan-troglodytes        387 --SHINAINSQATNELSCEITHPSHTSGQINSAQTSNSELPPKPAAVVTEACDADDADNASKPAAMLNTCSFQKPEQLQQQKSVFEICPS 
Canis-lupus-fam.       368 --SHKHAINSQATNELSCEITHPSHTSGQINLPQTSNSELRPEPVAVVTEACDADKAS---KTAAMIGTCPFQKPE---KQKLLFDRCPS 
Rattus-norvegicus      267 --PHVNALSGQAAIELPREITQPSLTSAQINFSQTSSAQLPPEPAAMVTKACDLDSAS---KPAGVLGTCAFQKAEHQQ--KSVLGIGPS 
Macaca-mulatta         247 --SHINAINSQAT----NEITHPSHTSGQINSAQTSNSELPPKPAAVVTEACDADDADNASKPAAMLDTCPFQKPEQLQQQKSVFEICPS 
Mus-musculus           235 --SHVNTPSSQAAIELSHEIPQPSLTSAQINFSQTSSLQLPPEPAAMVTKACDADNAS---KPAIVPGTCPFQKAEHQQ--KSALDIGPS 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            193 ------------------------------------------------------------------------------------------ 
Monodelphis-domest.    367 ---------------IASSFPNFEKSLVAFTKDILAQEMHKPQDTSLLSELPSNNHSFKIVPE--------SGLKKESNSLSEDPKLASS 
Ornithorhynchus-anat.    1 ------------------------------------------------------------------------------------------ 
Bos-taurus             150 --------------------VNGAREPAGPSLLGTG-------SPWQ------ADQKPDWD-----TAPGPAHTAR----LEDAHDLVAF 
Xenopus-trop.          152 --------------------SKGCEDLANQLLMEANSWLSNTAAPQD------PCNKLNWD-----KPTIPNHAANNNSNLEDAKNLVAF 
Gallus-gal.            452 IEQLVKCIDAETLILNSGYVPALSSDIEKRAVDNISSESSREFSEGFVSELPSSTEISVLALEKAINADLPADLRLQQNDYSSQLESVGI 
Tetraodon-nig.         605 -------------------YPGGDETSVEAEQQRAGSVPPRPWVSGQGKVSDTQQQQPCWNGSHGANPVQPAHHAA----MEDAHNLVAF 
Culex-pip.             266 --------------FAPTVTYAGQVSTGPATVVSHNP----HAADQFNLQLA-------------------KQTSGNDMPGYPRVNSVPP 
Aedes-aegypt.          255 --------------FAPTVTYAGQVSTGPAVVSHN-------PHDQFNLQLN-------------------KQTSGNDMPGYPRVNSVPP 
Apis-mellif.           603 ------RQDYVNGYQQQDVTMAPPPSTTPTSRSSSVHMDNQQQQQASQQPQSQPQQPPTDTQVKGFATITASNVSGNEMPGYP-LQPGPQ 
Nasonia-vitripen.      188 ------RQEYVNGYQQQDITMAPPASTTPNSRSSSVHMEAQQPSNQQTVVQ------PGDTQVKGFATIAANNVSGNEMPGYP-LQPGPQ 
Anopheles-gam.         289 --------------FAPTVTYAGQVSTGPATIVSGHAGTTTNPHDQFNLQLGG-------SKQQQQSTAAASAASGNDMPGYPRVNSVPP 
Drosophila-melanog.    305 --------------FAP--SYAGQVSAAPVPPSQQQQ---QQQQQQQQQHLG---------------ADLNKTMSGNDTPGYPRVSSVPP 
 
                                                                                                  E368X         Q383X 
Homo-sapiens           335 PAEN-NIQGTTKLASGEEFCSGSSSNLQAPGG----------------------------------------SSERYLKQNEMNGAYFKQ 
Pan-troglodytes        475 PAEN-NIQGTTKLASGEEFCSGSSSNLQAPGG----------------------------------------SSERYLKQNEMNGAYFKQ 
Canis-lupus-fam.       450 RAENSNIQGTTKLVSGEEFCSGSSSNLQAPGG----------------------------------------SSERYLKQNETNGAYFRQ 
Rattus-norvegicus      350 SCAENINIQGNTKPFAEEYYAGSDSDLQTSLG----------------------------------------SSEQCIKQKETNGAYFRQ 
Macaca-mulatta         331 PAEN-NIQGTTKLASGEEFCSGSSSNLQAPGG----------------------------------------SSERYLKQNEMNGAYFKQ 
Mus-musculus           318 -RAENKTIQGSMELFAEEYYPSSDRNLQASHG----------------------------------------SSEQYSKQKETNGAYFRQ 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            193 ------------------------------------------------------------------------------------------ 
Monodelphis-domest.    434 DLGQLDGQSSQISETNVISVSMAFSNTASYSY----------------------------------------PFSYTTLLPTLEKKKRKR 
Ornithorhynchus-anat.    1 ------------------------------------------------------------------------------------------ 
Bos-taurus             198 SAVAEAVSSYGALST--------RLYETFNRE----------------------------------------MSREAGDNSRGPRPGPES 
Xenopus-trop.          211 SAVAEAMSTYGMPASGTPSSVSLQLYEKFNYE----------------------------------------TNRDNSGHLEGNAP---- 
Gallus-gal.            542 SLNLVQDNVSNSTQTVEASGPSSLTNPAGG-Y----------------------------------------PPAYSSVLPMLEKKKRRR 
Tetraodon-nig.         672 SAIAGSLPPSSSSPCLVQPN-TAQLYERFSQE----------------------------------------MGSD-GAQARLSAGTSEG 
Culex-pip.             319 RSLNCNGYSGQQEYGGQTTTQASSTNATNVTN-----------------------------------------ANGTSTSTGATTAP--- 
Aedes-aegypt.          305 RSLNCNGYSGQ-DYGGQTTTQASSA-TTNVTN-----------------------------------------ANGTSTSTGANSGTGSS 
Apis-mellif.           686 SLHNSNGYPGYVEMGQQQVQSQWQPQQVAQQQHQQQHLQRQH-----------------------------SVPDGGQRHLWSDTSTKMN 
Nasonia-vitripen.      265 SLHSSNGYPGYVELGQQQHQAQNQWQQVS---------------------------------------------DANRQHICSSNSNSSN 
Anopheles-gam.         358 RSLNCNGYSGQQDYGGLQTSTTTTTATTAASANGSSSSSSSSSVAPTTGTSSASPSAATVATAPNTGNGGGSSSNNSSTNNNNNGSTGSS 
Drosophila-melanog.    361 RSLNCNGYSGDYSGSPATNSNSNNNSSSNTSN---------------------------------------TNNSNASNNNATTVVSGGT 
 
 
Homo-sapiens           384 SSVFTKDSFSATTTPPPP--SQLLLSPPP------------------------------------------------------------- 
Pan-troglodytes        524 SSVFTKDSFSATTTPPPP--SQLLLSPPP------------------------------------------------------------- 
Canis-lupus-fam.       500 SSVFTKDSFSAPTTPPP---SQLLLSPPT------------------------------------------------------------- 
Rattus-norvegicus      400 SSVFPEDSISATTMTPPS-------PSPL------------------------------------------------------------- 
Macaca-mulatta         380 SSVFTKDSFSATTTPPPPPPSQLLLSPPP------------------------------------------------------------- 
Mus-musculus           367 SSKFPKDSISPTTVTPPS-------QSLL------------------------------------------------------------- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            193 -------------------------QVDQ------------------------------------------------------------- 
Monodelphis-domest.    484 CGVCEPCQKKENCGECVYCKNRKYSHHVC------------------------------------------------------------- 
Ornithorhynchus-anat.    1 ----------------------LLRLSGP------------------------------------------------------------- 
Bos-taurus             240 CSASSEDLDTLQTALALARHGMKPPNCNC------------------------------------------------------------- 
Xenopus-trop.          257 --SCPEDLNTLKAALALAKHGVKPPNCNC------------------------------------------------------------- 
Gallus-gal.            591 CGVCEPCLRKTNCEECSCCRKRKTSHRIC------------------------------------------------------------- 
Tetraodon-nig.         720 GGQPPEDLQTLQTALNQAKHGHKPPNCDC------------------------------------------------------------- 
Culex-pip.             365 --MHPPAQVPQSPNRQTQQQQQPPRPNSN------------------------------------------------------------- 
Aedes-aegypt.          352 SSMHPPAQVPQSPNRQTQQ--QPPRPNSN------------------------------------------------------------- 
Apis-mellif.           747 NSMNWSDGTLQQQQQQHQQQQKPPSQQQQQQQQQQQSMQANSMKGQESQQSMQMQGQQELPRPASHMSWENGSVKETPHTPQSWTDNTDN 
Nasonia-vitripen.      310 SIINSSSSTNNSSKISQK------------------------------------------------------------------------ 
Anopheles-gam.         448 SSMHPPQGVPQSPNR------QPPRPNSNNQQ---------------------------------------------------------- 
Drosophila-melanog.    412 TTPAPPPTVVAQPAS------SPMQPPNQ------------------------------------------------------------- 
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                                                    Q417X 
Homo-sapiens           411 ---------------------PLPQVPQLPSEGKSTLNGGVLEEHH-------------HYPNQSNTTLLREVKIEGKP-EAPPSQSPNP 
Pan-troglodytes        551 ---------------------PLPQVPQLPSEGKSTLNGGVLEEHH-------------HYPNQSNTTLLREVKIEGKP-EAPPSQSPNP 
Canis-lupus-fam.       526 ---------------------PLPQVSQLPSEGKSTLNDGVLEEHH-------------HYPNQSNTALLREVKIEGQC-EAQPSPSPNP 
Rattus-norvegicus      422 ---------------------APRPVLQLPSEGKGTLNDVALEEHH-------------RYPNQSDLTLSREGKTEHQPKKTTSSQSLNT 
Macaca-mulatta         409 ---------------------PLSQVPQLPSKGKSTLNGGVLEEHH-------------HYPNQSNTTLLREVKTEGKP-EAPPSQSPNP 
Mus-musculus           389 ---------------------APRLVLQPPLEGKGALNDVALEEHH-------------DYPNRSNRTLLREGKIDHQP-KTSSSQSLNP 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            197 ---------------------VTSNLPDQATSSPSFTSGFPIS------------------PQISASETLVKAPPEVQN-----SNGYNP 
Monodelphis-domest.    513 ---------------------KMRKCEELKKKP-MVIVPLEVIKEN-------------KRPQREKKPKVFKIHLDNKLVNGPRSESMEN 
Ornithorhynchus-anat.    8 ---------------------PTQQQPQQQQPRPLTTNP-QSNPIN-------------SFPGPVPNNLYMRLPN---P-VSPYSSSPHP 
Bos-taurus             269 ---------------------DGPECPDYLEWLEGKIKSVVVEGG--------------EERPRLPGTLPSGDAGLPAPVTGPLLNSEVP 
Xenopus-trop.          284 ---------------------DGPECPDYLEWLENKIKSTVKGSQ--------------ESPFPNLGQVSKELVQKQYPKEQVLNLENKN 
Gallus-gal.            620 ---------------------KKRKCEELKKPPPPITLPFEVLIEN-------------KRPHLTIKDLVLKANLENKPVNGRRPELMEC 
Tetraodon-nig.         749 ---------------------DGPDCPDYLEWLKKKIKLASGEIQGACKG--------VDTPQQLQPHLQQPHWQNHPQQYPQVNGGHRP 
Culex-pip.             392 ------------------QQLYAQQSPNPYNGNNNNT--ALQQSPNHNNNNNNGGANSNVYAQQTHTGMHTPSPMQTPDNHASPNHMNGS 
Aedes-aegypt.          379 ------------------QQLYAQQSPNPYSSNGNNS--NLQQSPNHNNG-ANTANNNNVYAQQTHSGMHTPSPMQTPDNHQSPSHMNGG 
Apis-mellif.           837 SQQQQTQGNWSRQSPKLRDAQNPRLTPSSQQQQHQHQGWLQHSPKLSDHQQNPSHQNARMTPSGQHNWQQSSPEMQQ--NSSQQNPRLTP 
Nasonia-vitripen.      328 ---------------------NPRMTPGPQQ----------------------------------HSWPQSSPEIQAQPNSAQQNPRLTP 
Anopheles-gam.         474 ------------------QQLYAQQSPNPYNGSAGGSGGSLQQSPSHNGNNTPAGGYG-----SGQSGMHTPSPMQQGTAATDNQHQQSP 
Drosophila-melanog.    435 ---------------------AVPQSPTRSNMLQQQQ--QQHQSPTGN-------------------GLQPYVAPQQQQQQQQQQHLSSP 
 
                                                                 R506X                                       R544X 
Homo-sapiens           466 STHVCSPSPMLSERPQNNCVNRNDIQTAGTMTVPLCSEKTRPMSEHLKHNPPIFG------SSGELQDNCQQLMRNKEQEILKGRDKEQT 
Pan-troglodytes        606 STHVCSPSPMLSERPQNNCVNRNDIQTAGTMTVPLCSEKTRPMSEHLKHNPPIFG------RSGELQDNCQQLMRNKEQEILKGRDKEQT 
Canis-lupus-fam.       581 STHIPNHSLMLPERPQNNCVNKNDIQTPGMMTVPACSEKVRQISEHLKHNPTILG------SSGDPQDHCQQLMGHREQDILKGRDKEQT 
Rattus-norvegicus      478 SVHTPNPPLMLPEQHQNDCV-------------PPCSEKTRKVSDYRMYYLPNHG------HGGDLQENSQYLMGHGEHEILKDANKGQT 
Macaca-mulatta         464 STHVCSPSPMLSERPQNNCVNRNDIQTAGTMTVPLCSEKTRPMSEHLKHNTPIFG------SIGQQQDNCQQLMRNKEQEILKGRDKEQT 
Mus-musculus           444 SVHTPNPPLMLPEQHQNDCG-------------SPSPEKSRKMSEYLMYYLPNHG------HSGGLQEHSQYLMGHREQEIPKDANGKQT 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            243 ELAVNGYSSFAAEQ---------------------------KKPAYSLSDLPELS------Q---------------------------- 
Monodelphis-domest.    568 SKCGNDEKQRLKLNQN-ILENVQTTEEDTMTGIEVEKWSENKKSPLTIHVKGDISGPVTETENLKNSEDNEKKTPLSDLIEPPKLFAQTV 
Ornithorhynchus-anat.   59 SDPYRGSSPMNLYPPSS-----------------------QPTASYLNSSNPMNP------YPG-------------------------- 
Bos-taurus             324 QMPPLEGLPLSQSALSIAKE----------KNISLQTAIAIEALTQLSSALPQP------SHATSQASCP-------------------- 
Xenopus-trop.          339 STCPSGNLPFSQNALSLAKE----------KNISLQTAIAIEALTQLSSALPQT------NNECPNAPSQPLINPHDQLTHFPSAKGNQL 
Gallus-gal.            676 SICGHGEKYRVKTNQTQPFENAQSKEKERMTGLEAEKWAHNEKPSFGVHVNGDTHGTVTGHEHLRNAEESERAVSPSQLAEPKKSFAQTI 
Tetraodon-nig.         810 PSYPQQHQGSHPKQASCSKSPIPCSPQPRRKTSVIQAAIAIEALTQLSDTRAQAP-----GSPGPGPYNSNFHQQHRTQPLPPRPPSGSG 
Culex-pip.             462 GQQQQGQDWGWNQQQQQQQQQS---ADLFNQSDRVNLNSRIKTMIMNKGD-PKD---------IGQQQQQQHMG-HLGGQGPASQQQQ-- 
Aedes-aegypt.          448 QQQSQGDWVGWNQQQQQQ---S---PDMFNQSDRVNLNSRLKTMIMNKND-PKDG-------VGGLQPTGQHMS-HLGVQAQGPAQQQ-- 
Apis-mellif.           925 SGQQMSQPGAQSQQQQQQQQLTPSNQMSWPDTPTSQPNWSPNSIKSDSSQQPQQQ-------WPDSQPSPRRTPGHQPGSWQPQPQPAQE 
Nasonia-vitripen.      363 SNQQWQP----QTKLEQNSRLTPSNQMSWPDTPTSQPNWSPSSMKSDGSQQPQQQ-------WPDSQPSPRRTPSHQSAAWQNQ---NTQ 
Anopheles-gam.         541 SHMQG--DWGWTQQQQQQQQQSQSGTDLFNQSDRVNLNSRLKTMIMSKGD-QKDA-------LLAGGQSSHLVGSHLGLQQQQQQQQTGT 
Drosophila-melanog.    483 PMQ----DWNWQQQQQQQQSLG---GEGYAQGERLHLNTRIKSMIMRKSD-PKDP-------PPDLQQQPQQVQ----------QQQQ-- 
 
                             P555fsX10         Q574fsX5                           N608fsX30 
Homo-sapiens           550 RDLVPPTQHYLKPGWIELKAPRFHQAESHLKRNEASLPSILQYQPNLSNQMTSKQYTGNSNMPGGLP-------RQAYTQKTTQLEHKSQ 
Pan-troglodytes        690 RDLVPPTQHYLKPGWIELKAPHFHQAESHLKRNEASLPSILQYQPNLSNQMTSKQYTGNSNMPGGLP-------RQAYTQKTTQLEHKSQ 
Canis-lupus-fam.       665 RGLVLPAQPYLKPGWIELKPPHFHQAESHPKCHEASLRSVLQYQSNPSNQMTSKQYTGNSSLPGGLP-------GQAYIQKIMQPEHRPQ 
Rattus-norvegicus      549 QG-----SVLAAPGWIELKASHFHKALHQTECKATSLHSGLRYQTSPTNQIGSIQSTGSVNMTGEFQ-------RPPYIQKTAQPEHKSQ 
Macaca-mulatta         548 RDLVPPTQHYLKPGWIELKAPHFHQAESHLKRNEASLPSVLQYQSNLSNQMTSKQYTGNSNMLGGLP-------RQAYTQKTTQLEHKSQ 
Mus-musculus           515 QG-----SVQAAPGWIELKAPNLHEALHQTKRKDISLHSVLHSQTGPVNQMSSKQSTGNVNMPGGFQ-------RLPYLQKTAQPEQKAQ 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            272 -------------------------------------------KDSESNVPSQTVVNGSSQIQEDRE-------ALPNDSECVNMFSKS- 
Monodelphis-domest.    657 KNGIKNVYYSPADADVSLKKVKFETNANLIDHDTESNPNPSLGNTTSSDNRAGALVPGIYHAHLKKEDNSLVIQKTDSTCHSTQYPTDTF 
Ornithorhynchus-anat.   94 -------------------------------------------PLNQSNQYPSYQCNGN------VP-------VETCPPYLGSFPSQPQ 
Bos-taurus             378 --LPEALSPPAPFRSPQSYLG---APSWPVVPPEEHP-SFAPDGPAFPAATPRTEFP-----EAWGTDT----PP---ATPQ-------- 
Xenopus-trop.          413 PMLPVARNELFQNQQSQLYTG---KNALPVPQSPRQT-SWEQNKKSSYQEGQYIPEN-----LSHSSSV----LPSDASTPQKPEFLQQW 
Gallus-gal.            766 KNGIKTLHYSSPEAVASLKKASVEERT-----DLTSNSHAQWMKATNLNDIVSTLTTSVSCVHPDKQGN-LFMKEENCTCSIFQDSHKSV 
Tetraodon-nig.         895 SVLPPPGSRSSSSRSQSVPPGPHSSHQAPVSSELHRPQSQGQPPHVTPLASSTSPFPGQGKHPGFSPNS----QHWQRGSGKGSEPTKLH 
Culex-pip.             536 --TGHFLSYSHHLRDSLTPT---AGV-----QSPAPN---SAMMGAGSVGGSNSASNNDGTIGDGGG---------GLINSISNIVDPNW 
Aedes-aegypt.          521 --TGHFLSYSHHLRDSLTPTSLAAGG-----SNPASGQSPAPMMGGGTGSGSNSTSN-DGTIGDGGG----------LINSISNIVDPNW 
Apis-mellif.          1008 SKMENQISWSPNSVIENQPTWGQQTTKQD-MQNSGERVLWQQQAATDTGKPNGFPDNQDAQESNVFAQSNRVNLNSRLKSMILNKQQQQQ 
Nasonia-vitripen.      439 DKMDNQMSWSPK--SENQTNWNQQNTN-------------------------------------------------RLKSMILNKQQQQQ 
Anopheles-gam.         621 QSTGHFLSYSHHLRDSLTPTHHLGGGPGSAQSASSAGPGLMPGGSGSSNSSSSTAANDGTTIGDGGGSGGGGGGGGGLINSIGNMVDQSW 
Drosophila-melanog.    546 --TGHFLSYSHHLRPEAALSANGPS------SATPTHPLPNLQQQQQQVQQVQQVQQQQQQQQAVGG--------QVAAEPIGGGGDHIW 
 
                                                                                          H682fsX10 
Homo-sapiens           633 MYQVEMN------------------QGQSQGTVDQHLQFQKPSHQVHFSKTDHLPKAHVQSLCGTRFHFQQRADSQTEKLMSP------- 
Pan-troglodytes        773 MYQVEMN------------------QGQSQGTVDQHLQFQKPSHQVHFSKTDHLPKAHVQSLCGTRFHFQQRADSQTEKLMSP------- 
Canis-lupus-fam.       748 RYHGEMN------------------QGQSQGTVDQQLQFQKPSLQVHFSKTDPSSKAHMQSLCAHRFYFEQRPDSQTEKLIPP------- 
Rattus-norvegicus      627 MYQVEMN------------------QGPSPGMGDQHLQFQKTSYQECISRTDLPPEAHG-----PQYHFHQR--------VDP------- 
Macaca-mulatta         631 MYQAEMN------------------QGQSQGAVDQHLQFQKPSHQVHFSKTNHLPKAYVQSLCGTRFHFQQRADSQTEKLMSP------- 
Mus-musculus           593 MYQVQVN------------------QGPSPGMGDQHLQFQKALYQECIPRTDPSSEAHPQAPSVPQYHFQQR--------VNP------- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            311 ------N------------------QNLSHG-----------------------------------------------SYTLP------- 
Monodelphis-domest.    747 LNHN-IS------------------AQENQSHIVTWEKRFDQGEVPESKPNRELAQDNSLVQPSLLTLMRDRRLTLEQVVAIE------- 
Ornithorhynchus-anat.  128 PMDLYRY------------------QSQDP----------------------------------------------LSKLSLP------- 
Bos-taurus             442 -SSWPMP-------------------RPSPDPMAELEQLLGSAS-DYIQSVFKRPE------------------ALP----TK------- 
Xenopus-trop.          490 VQNADLL-------------------KSPSDPMTGLKQLLGNTD-EYIKSVFKGPE------------------ALPNKKNVK------- 
Gallus-gal.            850 LQTSSVL------------------DLQESTCCPPLVKDEVHGEDGFKVPNTETQHENPSLQPTFLSLIKNRNLTVEQVVAIE------- 
Tetraodon-nig.         981 QSGYNVA------------------PHASPNPMSELKQLLGDTTGKFSGAPFKLPVTQQPRLCQNGSLQSQDNPALAGMKQEP------- 
Culex-pip.             604 KQTS-------------------------KSPGIG-IESNSGGANRAEHEQQQ----------------QHHHHHGAMMGATN------- 
Aedes-aegypt.          593 KQSS-------------------------KSPGLGGIESNGANRAEHEHHTLL----------------SDLHHGSKHQGFEQKQQLIDK 
Apis-mellif.          1097 QQQQQQ-----------------QQLQHQHQQLQQQQQSQQQQSQHQIGHQEQ----------------QQQHHTMHHQMQS-------- 
Nasonia-vitripen.      478 QQQIQN---------------------------------------------QM----------------PQDHHQAHHQMPP-------- 
Anopheles-gam.         711 KHQQGAGSNSNGSGTNNSSSTSVAAAAGMKSPSLTDHHQQQQQHHQHHHHHHHSHHQLQQQQQHDHLLAGDLHHGAKHSVFEQKQQLIDK 





Homo-sapiens           698 --------------------------VLKQHLNQQASETEPFSNSHLLQHKPHKQAAQTQPSQSSHLPQNQQQQQ--------------- 
Pan-troglodytes        838 --------------------------VLKQHLNQQASETEPFSNSHLLQHKPHKQAAQTQPSQNSHLPQNQQQQQ--------------- 
Canis-lupus-fam.       813 --------------------------TLKQHLIQQASETEPFSNSHLLQHKPHKQAAQTQTQPS-------------------------- 
Rattus-norvegicus      679 --------------------------STD---KQQATEAELFSS--FLQHTPHKQAAQTQASQNSNFPQVCQQQH--------------- 
Macaca-mulatta         696 --------------------------VLKQHLNQQASETEPFSNSHLLQHKPHKQAAQTQPSQNSHLPQNQQQQQ--------------- 
Mus-musculus           650 --------------------------SSDKHLSQQATETQRLSG--FLQHTPQTQASQTPASQNSNFPQICQQQQQ-------------- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            323 --------------------------PVTAGSPSQTSQTG--------QYNPQIKVPQK------------------------------- 
Monodelphis-domest.    811 --------------------------ALTQLSEAPSENSSPSKSDKNEETTNLTTNLLHSCK-AILCSVGSSAGKD-------------- 
Ornithorhynchus-anat.  147 --------------------------PIHTLYQQRFGNSQSFGPKYLNYGNPNMQVDAFS------------------------------ 
Bos-taurus             482 --------------------------PKVKVEVPSSSPSPVLQR----EAPTPSSEPDTHQKAQTALQQHLHHKR--------------- 
Xenopus-trop.          535 --------------------------PKHTIKSIKKESTEFLKMSPDQQLSQLLQTNEFHRNTQAALQQHLHHKR--------------- 
Gallus-gal.            915 --------------------------ALTQLSEVPLGTSSPAKADNTECTEERTSNLLHSYKRDISSSFTSSTLKE-------------- 
Tetraodon-nig.        1046 --------------------------DDHHAASFGMANCQQQQQSYAGIALPPGQTSISHS-TQAALQQHLHYKR--------------- 
Culex-pip.             645 -----------------------------HHSSNSSSSSSGGGGNLGGYPSHLDTKLDDKSPLNRFRHDNLN------------------ 
Aedes-aegypt.          642 NNTDPGGGGLHHDTGGG--------HDIKHKLHSSKSSSSSSSSSKSKSSSHKNSDKHSKSKNNHHLDMNQP------------------ 
Apis-mellif.          1146 -----------------------------QHVNSNNGSNGEYHTEERIRDTHDNADKLQEKQTDQYLSQSN------------------- 
Nasonia-vitripen.      499 -----------------------------QHTNNGDGSSGDMSADNRLRESHEDSDKLQEKRNEQYMNQSG------------------- 
Anopheles-gam.         801 NNTDPGGGGGIGSPTGVGSELKGKMGKSGGSSSSSSAAGSPSAGSPSSKAKGKGGDKHGKSKHGGHHHQQQQQHQQHHLDHLGLVDGKSS 
Drosophila-melanog.    667 --------------------------VVPPQQHPPVAAAQPKKSRSRSKASRAAAAAAAAAEAAAEIDRDRN------------------ 
 
 
Homo-sapiens           747 ------------------------------KLQIKNKEEILQTFPHPQSNNDQQREGSFFGQTKVEECFHGENQYSKSSEFETHNVQMGL 
Pan-troglodytes        887 ------------------------------KLQIKNKEEILQTFPHPQSNNDQQREGSFFGQTKVEECFHGENQYSKSSEFETHNVQMGL 
Canis-lupus-fam.       851 -----------------------------------------------QSNNDQQREGSFFSQIKVEECFRGENQYLKSSEFQTHNTQMGL 
Rattus-norvegicus      723 ------------------------------QLQRKNKEQMPQTFSHLHGTNHEQSQGQCFGTIKAEESFCGENQYSKPSNFQTHS-AQGG 
Macaca-mulatta         745 ------------------------------KLQMKNKEEVLQTFPHPQSNNDQQREGSFFGQIKVEECFHGENQYSKSSEFQTHNVQMRL 
Mus-musculus           698 -----------------------------QQLQRKNKEQMPQTFSHLQGSNDKQREGSCFGQIKVEESFCVGNQYSKSSNFQTHNNTQGG 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            348 ------------------------------------------------------------------------------------------ 
Monodelphis-domest.    860 -----------------------------FQDPNLKIDSVVLPPCPSLEKKTSRKPVLYNGQNNSKYPSTLMTNHNTSKTHASSRVTKSG 
Ornithorhynchus-anat.  181 ------------------------------------------------------------------------------------------ 
Bos-taurus             527 ------------------------------SLFLEQAHDASRPPPSELPAPG----WWAPPS--SPAPRPSDRPPKEKKKKPLTPAGGPL 
Xenopus-trop.          584 ------------------------------NLFVDPNAMEACTQEQ----QN----WWVPSSQQAPVSKTTEKPVKERKKRRQSPS---- 
Gallus-gal.            965 -----------------------------IKDTYLEKEEQLLTHCAHSQKQLPNKPVLYNGQSSISELRDKPPNLASEMYKLQLSSRDTK 
Tetraodon-nig.        1094 ------------------------------TLFSNHSPGFGASGPRATLACQNLKKWWPQGETEGLPHLTIKQEPKKKKSNQGSPVMKSM 
Culex-pip.             688 --SGFN------------------------------------PHLPHQQSSAGAFHHPAGGG---------------------------- 
Aedes-aegypt.          706 --IDSNKSSSNLNSYSSSSFMNDQHSSSSSSPSPYPNLNQTYPAINHSSSSSNQSSLGLGGYPSHPLDNKLDDKTPLNRSATTTSTADSI 
Apis-mellif.          1188 ------------------------------MISMAQSNESLTGNFLLHSHHPRVDSLPDGGGLWEWS----------------------- 
Nasonia-vitripen.      541 ------------------------------LMSMNQTNESMTGNFLLHSHHPRANSLPEGGGLWEWS----------------------- 
Anopheles-gam.         891 SSYSSSNFMMHHDQQLQLQQQQQQHQGYSNMNQTYPGSGSTTPNGSHQTSSGSLLGYSPAGGASSMMVDSKLVDDKSPLNRFRHDSLSSG 
Drosophila-melanog.    713 --------------------------------STDPGGGGLKPLSAHYPPHPHAAGGPPPGQD--------------------------- 
 
                                                        S826fsX14         S842X  Q847fsX24     
Homo-sapiens           807 EEVQNINRRNSPYSQ--------------TMKSSACKIQVSCSNNTHLVSENKEQTTHPELFAGNKTQNLHHMQYFPNNVIPKQDLLHRC 
Pan-troglodytes        947 EEVQNINRRNSPYSQ--------------TMKSSACKIQVSCSNNTHLVSENKEQTTHPELFAGNKTQNLHHMQYFPNNVIPKQDLLHRC 
Canis-lupus-fam.       894 EQGQNMNSRNPPYGQ--------------VLKSNAGKLQIACSNNTHLVPENKEQIINSELFAGNKTQNLHHMQYFPNNVTPKQDVLHRC 
Rattus-norvegicus      782 LEQVQNVNRSFPYAK--------------IETPNSSKVQTLCSNYTHPASESREQNLHLDLFIGNRTPNQQNTQCFPNNVTPSQDVAHRC 
Macaca-mulatta         805 EEVQNMNSRNSPYSQ--------------TVKSSACKIQVSCSNNTHLVSENKEQTIHPELFAGNKTQNLHHMQYFPNNVIPKQDLLHRC 
Mus-musculus           759 LEQVQNINKNFPYSK--------------ILTPNSSNLQILPSNDTHPACE-REQALHP---VGSKTSNLQNMQYFPNNVTPNQ-DVHRC 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            348 ---------------------------------------------------------------KTTDENLHGNRDFS------------L 
Monodelphis-domest.    921 LITEPSSNSSRNHSN--------------KEIVLQGRITVGRCAKTSHGLHTSSKLAFCRQLQESTGKRFDSKNNLSYKNTPHSQIEEDV 
Ornithorhynchus-anat.  181 --------------------------------------------------------------SCTIRPNVHHIGSFPP------------ 
Bos-taurus             581 GADRAGP-GIKPGVR--------------KPVHIKKSRPREAQPLFPPLRQIILEG-----LRPPASEDVQA----HPPAPVPTSQGSVV 
Xenopus-trop.          632 -QKQVEP-KPKP-QR--------------KQVQIKKPKVKEGSAVFMPVSQISLDT-----FRRVEKEENQG----KEMDAENSLPNNVQ 
Gallus-gal.           1026 TLSELRSNAKSFSGL--------------NTKKNYDPVTLSRCCNVQHTSNNLDTLGQLDQKPTCNDSSLEAG-SLIKEGGIHSQDEEDV 
Tetraodon-nig.        1154 SGMLAGPPQPKP-----------------KQIIIKKTKQKASMPTFLPHSQISIQKPALLMDRAPALTSLQPGSLPSQHLLGNSSQAAAA 
Culex-pip.             712 ----AASGSTASS------------------YNLMSVKK-----EPGLLDDGQ-PAPKFDG-YEKNYQNFIRYGDYN--DSSQPPQSQPP 
Aedes-aegypt.          794 HTFHISSLRTAST------------------AVLSTIRKPPPAEEPGLLDDGQ-P-IKSDG-YEKNYQNFIRYGEYN--DSSQPPQSQLP 
Apis-mellif.          1225 -----GGGNNALSN-----------------GTVLPDNGMTVIESFMKFGSEDKTVLEKHQQHEQQQQQQQQQSSLYHQQSEHEHRQLWK 
Nasonia-vitripen.      578 -----EGGTTAGMN-----------------NNAMTNSGMSSIDSLMHFTSQHKQTDKRPDIESNNVQNQINRN------------QWVA 
Anopheles-gam.         981 FNPHLQAGGTGTSGAFHHPGGSSAGQSAGSGYNLMSVKK-----EPGLMDDGQTALPKFDGGYEKNYQNFIRYGDYC--DNTQSPGAQAS 
Drosophila-melanog.    744 -------------------------------YHSQYIKT-----EPGLLGPPQ--PNKMEG-YERNYQNFIQYADFCQNDGQGQPVQQHH 
 
 
Homo-sapiens           883 FQEQEQKSQQASV-----LQGYKNRNQDMSGQQAAQLAQQRYLIHN-------HANVFPVPDQGGSHTQTPPQKDTQKHAALRWHLLQKQ 
Pan-troglodytes       1023 FQEQEQKSQQASV-----LQGYKNRNQDMSGQQAAQLAQQRYLIHN-------HANVFPVPDQGGSHTQTPPQKDIQKHAALRWHLLQKQ 
Canis-lupus-fam.       970 FQEQEQKPQQASV-----LQGYRSRNQDMSGQQATQLPQQRYLMQN-------QPNTFPVSDQGGSHSQTPPQKDIQKHAALRWHLLQKQ 
Rattus-norvegicus      858 FQEQEQKPHQASS-----LQGLKGRSRDEFSVPPAEATQARYLVHI-------QAKALPVPKQGGSHTQISPQKDTQKHAALRRLLLQKQ 
Macaca-mulatta         881 FQEQEQKSQQASV-----LQGYKSRNQDMSGQQAAQLAQQRYLIHN-------QANVFPVPDKGGSHTQTPPQKDIQKHAALRWHLLHKQ 
Mus-musculus           830 FQEQAQKPQQASS-----LQGLKDRSQGESPAPPAEAAQQRYLVHN-------EAKALPVPEQGGSQTQTPPQKDTQKHAALRWLLLQKQ 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            363 LQQQTHEPQAVES-----KLIPQIP--------------VRTLTKA-------EFHESFAQIQRESLSSNGAQMDVQRHAALRMHLLQRQ 
Monodelphis-domest.    997 AAQLTQLASIIES-----NNAKREEKEGTKT-LSSLESHDAQQKYNQEQSSFQEKLPVPVQNNRGSLLAKQKPSSHKKGKSASWKQRLKK 
Ornithorhynchus-anat.  197 YPAHEADGHFVEA-----ASRLPSSNP-----------------SN-------PSLEYPSIHKNGDHLPS-------------------- 
Bos-taurus             647 PLPPEPSLALFAP-----SPSG--DSLLAPTQEMRS----------------------------PSPVAALQPGSTG------------- 
Xenopus-trop.          696 TELLESQSLQLTG-----SQANPDDRKTVNTQEMCNENQSNIGKANNFALCVNRANSFVAKDQCPTPSTHDTSSSSGQGDSANQHTNVSD 
Gallus-gal.           1101 ATQLTQLAALIES-----NRANPAQKNDIKTSLLNLISHERQAKHN--QDLLQRKESVFFRHNCSSLLLKQKQSTNKKGNAVPWKPRHKK 
Tetraodon-nig.        1227 AGLPAPAQSQVSI-----SNSPTTSCIFPPASANTPTLVGPLPSPAVTGNAQSEGAGGQSSSNTSTTTTSLTSTSSSSTSNSQ------- 
Culex-pip.             771 QHGSSSLPGATKS----EYNSYYSPYGSYPGY--QN--YPNYHNQN----------FN--STSSTLSSTPETSIP-------LPAITTPV 
Aedes-aegypt.          861 QHGSSSLSGTTKS----EYNSYYSPYGTYPGY--QN--YPNYHNQN----------FNSPSGSSALPPTPEVTTP-------LPAITTPV 
Apis-mellif.          1293 EENKSHDNQCTDD------KSFQRRLCIDQQIHERTFEPCSNSEKNETKNDVTFPETPRVALMNENDTVNYPESSEKVASTELENNTNCD 
Nasonia-vitripen.      634 SADDNRENQSIDD------KSFQQRLCIDSNANEKSSLHSGQESK--------------------------------AAFDSNLAEVQYD 
Anopheles-gam.        1064 LQAGGGAGGASVKSASTDYNSYYSPYGSYSSYSTQS--YPNYHNQQSSAAAASGFGSGTGSNSNSNSSLPPAQTPEGNALLSLPAISTPV 
Drosophila-melanog.    795 GHGQQDYAGYHHN------SAYYGAGASSFQQNFQQNFVPGYQHSTYG---------ARGKPPANQPHQIHGHGQSLMELDRKPDTNSII 
83
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                           E961X                         T996fsX12         
Homo-sapiens           961 EQQQTQQPQTESCHSQMHRPIKVEPGCKPHACMHTAPP---ENKTWKKVTKQENPPASCDNVQQKSIIETMEQHLKQFHAKSLFDHKALT 
Pan-troglodytes       1101 EQQQTQQPQTESCHSQMHRPIKVEPGCKPHACMHTAPP---ENKTWKKVTKQENPPASCDNVQQKSIIETMEQHLKQFQAKSLFDHKALT 
Canis-lupus-fam.      1048 EQQQTQHPQTESCHNQMHRPIKVEPGSKPHTCMRLMSAQP-ENKTWKKTTKQEIPPPSCDNVQQRSILETMEQHLKQFQVKSLFDHKALT 
Rattus-norvegicus      936 EQQQIQQSQSESGHHQMPRPIKIEPGSKLSSCKHPTSG---PQENMPKRIKQESPLLSCDGGRTESIIETMERHLKQFQLKALCDYKILT 
Macaca-mulatta         959 EQQQTQQPQSESCHSQMHRPVKVEPGSMPHACMHTAPP---ENKTWKKVTKQENPPPSCDNVQQKSIIETMEQHLKQFQAKSLFDHKALT 
Mus-musculus           908 EQQQTQQSQP--GHNQMLRPIKTEPVSKPSSYRYPLSP---PQENMSSRIKQEISSPSRDNGQPKSIIETMEQHLKQFQLKSLCDYKALT 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            427 ERQSPNNIRQMMPAIKSENCSGFEISAQPMEVQRQHED---HTKVLKAVVKQEHPPSSCDENQQRSILATMEQQLKQYQLSPVFEKKSLV 
Monodelphis-domest.   1081 MPPAKNNLQNDQSERERLAWQYGKFHDLWVGSKLRRLGYISSREFHATMIEQNPLLTKVPKPLTQSTLSSPHK-KVFLPLTQIKFHRHLP 
Ornithorhynchus-anat.  238 SHLTHDYPQVPGTFSTLPHPLHLQN----------------------------------------------------------------- 
Bos-taurus             689 -----PLPPADDKLEELIRQFEAEFGDSFG-----LPG----PPSVPIQDPENQ-PTCLPAPE--------------------------- 
Xenopus-trop.          781 VPGQNDLSCLDDKLEDLIRQFEAEFGEDFS-----LPG-----SAVPSQNGEGP-PKQTPSGDPQFKLPFPSQLLPPENSTKPATHSNPA 
Gallus-gal.           1184 KPQEARYQQINRNQLELLSCQHSELQDIWISSKLHKLGQAMPQDSRIALAEKKSPRTKVQKALNQNALTLQEKPRLFLPQTQIKFHR-LS 
Tetraodon-nig.        1305 ---LPSLVNVDPKYEELIRQFEAEFGDSHPPQSKPLGA----KDSAPGKGGVCPNPTPPPKPDRDDQMEVSQEESGILCERAPVEAQNDG 
Culex-pip.             834 AHQTNFEQQIPAHTYPIPK---NSNLPQPD---VPIKLEAEDNSYLNAGSATPID---PLLNEPPP-SKSAPLAPEITPEPELPLPAAQT 
Aedes-aegypt.          926 AHQTNFEQQIPAHTYPIPK---NSGIPQPD---VPIKLEAEDNSYLTNTSVPPMSESSPVNNLPAA-IPNSAPSTQAAPEPEAP-PPTQP 
Apis-mellif.          1377 SSQSIKQENVGEYGCSSSDCVPSSTATSRSDDCASKAIKSEPDQKSQEGNNYKFR--GDGGPAKVSPGVGSWCCRRGGTEQPTPEHLREG 
Nasonia-vitripen.      686 SSQKIKQEFS----------CPVSVGAVSNEEQFSRDIKLENESRDQEESNYKFR--GDGGPAKMSPGVGSWCCRRGGTEQPTPEHLREG 
Anopheles-gam.        1152 THQTNFEQQIPAHTYPIPK---NNSLLPASDQGVSIKLEADDSAYGGSMGNSSATLGSEPGSDPGIGNQSSGSGTGALAEIDVGSQPVAT 
Drosophila-melanog.    870 PLPTNYEKDIPAYPIPPHRYALGHGAPPHLSHHGMLEPKIEDMGMLGHGGGYAY-----LGSEGKPLNNGFSCCRQGGTRPPTAEHLKDG 
 
 
Homo-sapiens          1048 LKSQKQVK---------------------------------------------------------------------------------- 
Pan-troglodytes       1188 LKSQKQVK---------------------------------------------------------------------------------- 
Canis-lupus-fam.      1137 LKSQKQVK---------------------------------------------------------------------------------- 
Rattus-norvegicus     1023 LNSQRQGD---------------------------------------------------------------------------------- 
Macaca-mulatta        1046 LKSQKQVK---------------------------------------------------------------------------------- 
Mus-musculus           993 LKSQK--H---------------------------------------------------------------------------------- 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            514 IKSPNKVK---------------------------------------------------------------------------------- 
Monodelphis-domest.   1170 ESAQEKMKEKLF---------------------------------------DALSLFQLCSKSPLSRPSSNVQVFTENGHNSQVQQSVNV 
Ornithorhynchus-anat.  263 -KGNEMMA---------------------------------------------------------------------------------- 
Bos-taurus             737 ------------------------------------------------------------------------------------------ 
Xenopus-trop.          860 LSNNPV------------------------------------------------------------------------------------ 
Gallus-gal.           1273 EVPQEKKKDRLFGYEVVNEQIKTAGSSDPPGIVPVKNDIAPCNQYSDLLSHNPLSVSQLKTASLLTRPSENTQMFTEKCN-SQVQQAVNV 
Tetraodon-nig.        1388 ILQVAPPCTE-------------------------------------------------------------------------------- 
Culex-pip.             914 TP---------------------------------------------------------------------------------------- 
Aedes-aegypt.         1008 TP---------------------------------------------------------------------------------------- 
Apis-mellif.          1465 CCQG-------------------------------------------------------------------------------------- 
Nasonia-vitripen.      764 CCQG-------------------------------------------------------------------------------------- 
Anopheles-gam.        1239 TVGGTTTTTTTT------------------------------------------------------------------------------ 
Drosophila-melanog.    955 TCLG-------------------------------------------------------------------------------------- 
 
 
Homo-sapiens          1056 --------------------------------------------------VEMSGPVTVLTRQTTAAELDSHTPALEQQTT-SSEKTPTK 
Pan-troglodytes       1196 --------------------------------------------------VEMSGPVTVLTRQTTAAELDSHTPALEQQTT-SSEKTPTK 
Canis-lupus-fam.      1145 --------------------------------------------------VEMSGPVTVLTRQTTAAELDSHTQALEQQATPSSEKTPTK 
Rattus-norvegicus     1031 --------------------------------------------------VETATNARSAGSE-------NHTPAAEPQAS-LSEKTPTK 
Macaca-mulatta        1054 --------------------------------------------------VEMSGPVTVLTRQTTAAELDSHTPALEQQAT-SSEKTPTK 
Mus-musculus           999 --------------------------------------------------VKVPTDIQAAESE-------NHARAAEPQA--------TK 
Equus-caballus           1 ------------------------------------------------------------------------------------------ 
Danio-rerio            522 --------------------------------------------------VEMAGAVTVISTN---------AEGNAKEQCKQQHFTPPK 
Monodelphis-domest.   1221 N------QSLNQNSQKDGATADDDQTQFQQDVEEPPRSQRLQSLPSPCCDTQVPGTIKTLRNENAACPGGRTASGLGVVTSHGATSDLGS 
Ornithorhynchus-anat.  270 --------------------------------------------------HAANGLSKVLPGRP-------------------HEGLPAQ 
Bos-taurus             737 ----------------------------------------------SPFATRS---PKQIKIESSGAVTVLSTTCFHSEEG-GQEATPTK 
Xenopus-trop.          866 -------------------------------------SREVSNNLDSLFSSKS---PKQIKIESSGAITVVSTTCFYSEENQHLDGTPTK 
Gallus-gal.           1362 GQTHPLPQTFSQSNLRAGETCGEDKAYVQQGAVDQRVDPKSQMLPVSCSAGQVPGTVEALRNMECAGEVTILTSRSLGTDHPQSTGDSGC 
Tetraodon-nig.        1398 -------------------------------------KQQPPGPLESLFSTPGSPLPKRMKIEASGDVAVLSTTCFSEED------TPTK 
Culex-pip.             916 -------------------------------------------------TPTTGKSKKSDKKDKANKEAAGGE----VEIKTEGGTTSG- 
Aedes-aegypt.         1010 -------------------------------------------------TPTTGKSKKSEKKEKANKDSPSGD----SETKPEGGSSKS- 
Apis-mellif.          1469 ----------------------------------------------------------LQTRDEILADGTDKS-----DVKNEGPQS--- 
Nasonia-vitripen.      768 ----------------------------------------------------------LQTRDEFSEDSPQKS-----EVKNEDSAG--- 
Anopheles-gam.        1251 -------------------------------------------TTTNTTTGTKSKSKKGEKKDKAAKDNSHGAGGDGADGKAEGGATTGG 
Drosophila-melanog.    959 ----------------------------------------------------LGIQPKEELIDEDELIDTHGN-----GLKPIGGVGKAK 
 
                                                                                                        Q1170fsX55 
Homo-sapiens          1095 RTAAS--VLNNFIESPSKLLDTPIKNLLDTPVK-TQYDFPSCRCVEQ---IIEKDEGPFYTHLGAGPNVAAIREIMEERFGQKGKAIRIE 
Pan-troglodytes       1235 RTAAS--VLNNFIESPSKLLDTPIKNLLDTPVK-TQYDFPSCRCVEQ---IIEKDEGPFYTHLGAGPNVAAIREIMEERFGQKGKAIRIE 
Canis-lupus-fam.      1185 RTAGS--VLNNFLESPSKLLDTPIKNLLDTPVK-TQYDFPSCRCVEQ---IIEKDEGPFYTHLGAGPNVAAIREIMEERFGQKGKAIRIE 
Rattus-norvegicus     1063 RTADS--VLTDVSESPSDSDTPVEDISCEACKN-AEKD-----------------EGPYYTHLGAGPNVAAIRTIMEERFGEKGKAIRIE 
Macaca-mulatta        1093 RTAGS--VLNNFIESPSKLLDTPIKNLLDTPVK-TQYDFPSCRCVGK---CQKCTET--------------------------------- 
Mus-musculus          1024 STDCS--VLDDVSESDTPGEQ-SQNGKCEGCN--PDKD-----------------EAPYYTHLGAGPDVAAIRTLMEERYGEKGKAIRIE 
Equus-caballus           1 --------------------------------------------------------------------------MQMCRFGQKGKAIRIE 
Danio-rerio            553 KIEPG---LQSFLESPMKLLNTPIKNLMDTPLK-TQYEIPSCHCVEQ---ISERDEGPYYTHLGSASNVAGIRKIMEERSGMTGSAIRIE 
Monodelphis-domest.   1305 SPGKN--TLSCFLESPMTFLDTPTKNLLDTPTKKGPSELPSCSCVEQ---IIEKDEGPYYTHLGTGPSVAAVREIMEARYGEKGRAIRIE 
Ornithorhynchus-anat.  291 AQGGL--PKPSDIPHQDRPLLAPVPEDNDD------------------------------------------------------------ 
Bos-taurus             777 AENPLTPTLSGFLESPLKYLDTPTKSLLDTPAKRAQAEFPTCDCVEQ---IVEKDEGPYYTHLGSGPTVASIRELMEERYGEKGKAIRIE 
Xenopus-trop.          916 SDLPFNPTLSGFLDSPLKYLTSPTKSLIDTPAKKAQAEFPTCDCVEQ---INEKDEGPYYTHLGSGPTVASIRELMEERFGQKGDAIRIE 
Gallus-gal.           1452 SPAKN--TLSSFLESPMKFLDTPTKNLIDTPTKKGQSELPTCDCVEQ---IIEKDEGPYYTHLGTGPSVAAVREIMENRYGAKGSAVRIE 
Tetraodon-nig.        1445 DSLPSSPSLRGFLESPLRYLDTPTKTLFNTPSKDLQAEFPTCTCVEQ---ILEKDEGPYYNHLGAGPTVAAVRDLMERRTGLKGDAIRLE 
Culex-pip.             952 ---GKSKKKEPKASKKEQEAAAAKQAEDEKLEKAHKPEAPDCDCFNSTDNKAPSEPGSYYTHLGSASTLEELRRETEARVGLTGKQLRIE 
Aedes-aegypt.         1046 -----SKKKESKGSKKEQEAAAIKQAEDEKLEKAHKPEAPDCDCFTSSDTKAPSEPGSYYTHLGAASSLEELRRETETRVGLSGKQLRIE 
Apis-mellif.          1493 ------------PRNGGAPSTTKLQDHLEKLKNNVRSEVPDCNCFP--ADKCPPEPGSYYTHLGAAASLPDLRNDLERRTGLKGNAIRFE 
Nasonia-vitripen.      792 -----------GKASNGSTTGTKLQEHLEKLKNNVRTEVPDCDCFS--ADKCPPEPGSYYSHLGAAASLPDLRNDLERRTGLKGHAIRFE 
Anopheles-gam.        1298 STTSKSKSKKESKSVKKEPIDPAQKADDDKLEKSHKPEAPDCDCFSSGTDKAPSEPGSYYTHLGCAATLEDLRRETELRVGLTGKQLRIE 















                                                           R1214W  T1220fsX6                               
                                                              R1216X                 L1240fsX2             R1261L   
Homo-sapiens          1179 RVIYTGKEGKSSQGCPIAKWVVRRSSSEEKLLCLVRERAGHTCEAAVIVILILVWEGIPLSLADKLYSELTETLRKYGTLTNRRCALNEE 
Pan-troglodytes       1319 RVIYTGKEGKSSQGCPIAKWVVRRSSSEEKLLCLVRERAGHTCEAAVIVILILVWEGIPLSLADKLYSELTETLRKYGTLTSRRCALNEE 
Canis-lupus-fam.      1269 RVIYTGKEGKSSQGCPIAKWVVRRSCSEEKLLCLVRERAGHTCEAAVIVILILVWEGIPLSLADKLYSELTETLRKYGTLTNRRCALNEE 
Rattus-norvegicus     1133 RVIYTGKEGKSSQGCPIAKWVYRRSSTEEKLLCLVRVRAKHTCDTAVIVIVILLWDGIPKPLASELYSELTEILSNRGICTNRRCAQNEN 
Macaca-mulatta        1144 ------------------------------------------------------------------------------------------ 
Mus-musculus          1092 KVIYTGKEGKSSQGCPIAKWVYRRSSEEEKLLCLVRVRPNHTCETAVMVIAIMLWDGIPKLLASELYSELTDILGKCGICTNRRCSQNET 
Equus-caballus          17 RVVYTGKEGKSSQGCPIAKWVVRRSCSEEKLLCLVRERAGHTCEAAVIVILILVWEGIPLSLADRLYSELTETLRKYGALTNRRCAHNEE 
Danio-rerio            636 KVLYTGKEGKSGLGCPIAKWVIRRANEDEKILVLVRERAGHSCETSCVVVVILIWEGIPTSLADRLYMELSDTLTKHGALTNRRCALNEE 
Monodelphis-domest.   1390 VVVYTGKEGKSSQGCPIAKWVIRRSSDEEKLLCLVRQRAGHHCQTAVIVILILAWEGIPHLLADTLYQELTQSLNKYGCPTTRRCALNED 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus             864 KVIYTGKEGKSSRGCPIAKWVIRRHTLEEKLLCLVRHRAGHHCQNAVIVILILAWEGIPRSLGDTLYQELTDTLRKYGNPTSRRCGLNDD 
Xenopus-trop.         1003 KVIYTGKEGKSSRGCPIAKWVIRRQSEDEKLMCLVRQRAGHHCENAVIIILIMAWEGIPRSLGDSLYNDITETITKYGNPTSRRCGLNDD 
Gallus-gal.           1537 VVVYTGKEGKSSQGCPIAKWVIRRSSDEEKLLCLVRQRAGHHCQTAVIVILILAWEGIPHLLADTLYKELTQSLRKYGCPTSRRCALNED 
Tetraodon-nig.        1532 KVVYTGREGKSSQGCPIAKWVIRRGSETEKLLCLVRERAGHHCPNAVIIIVILAWEGVPRAMADMLYRDLSDSLTKYGNPTNRRCGFNDD 
Culex-pip.            1039 KVVYTGKEGKSSQGCPIAKWVIRRVDQEEKLLFVVKRRQGHRCKASFIVICIVVWDGIPTQEADSVYRMLAVKLNKYGLPTVRRCATNEN 
Aedes-aegypt.         1131 KVVYTGKEGKSSQGCPIAKWVIRRVDPEEKLLFIVKRRQGHRCKAAFIVICIVVWDGIPTQEADSVYRMLSVKLNKYGLPTVRRCATNEN 
Apis-mellif.          1569 KVIYTGKEGKTTQGCPMAKWILRRSGLEEKILTIVKHRQGHKCPTAWIVVAMVAWEGVPTHEADRIYSLLSHKLNRFGLPTTRRCGTNEP 
Nasonia-vitripen.      869 KVVYTGKEGKTTQGCPMAKWVIRRSGIEEKILTIVKHRQGHKCATAWIVVAMVAWEGVPNHEADRIYSLLSHKLNRFGLPTTRRCGTNEP 
Anopheles-gam.        1388 KVVYTGKEGKSSQGCPIAKWVIRRVDPEEKLLFVVKRRQGHRCKASFIVICIVVWDGIPTHEADSVYRMLAVKLNKFGLPTVRRCATNEN 
Drosophila-melanog.   1077 KIVYTGKEGKTSQGCPVAKWVIRRADLEEKILVVVKKRPGHRCIAAYIVVCMVAWDGMPRLEADNAYKNLIPKLNKYGLPTTRRCATNEN 
                            C1271fsX28         W1291R        
                            C1271X       F1285del  
Homo-sapiens          1269 RTCACQGLDPETCGASFSFGCSWSMYYNGCKFARSKIPRKFKLLGDDPKEEEKLESHLQNLSTLMAPTYKKLAPDAYNNQIEYEHRAPEC 
Pan-troglodytes       1409 RTCACQGLDPETCGASFSFGCSWSMYYNGCKFARSKIPRKFKLLGDDPKEEEKLESHLQNLSTLMAPTYKKLAPDAYNNQIEYEHRAPEC 
Canis-lupus-fam.      1359 RTCACQGLDPETCGASFSFGCSWSMYYNGCKFARSKIPRKFKLLGDDPKEEEKLESHLQNLSTLMAPTYKKLAPDAYNNQIEYEHRAPEC 
Rattus-norvegicus     1223 RNCCCQGENPETCGASFSYGCSWSMYYNGCKFARSKNPRKFRLHGDEPKEEEKLGSHLQNLATVIAPIYKKLAPDAYRNQVEFEHRAIEC 
Macaca-mulatta        1144 -----HGVYPELANLSSDMGFSFFF----------------------------------------------------------------- 
Mus-musculus          1182 RNCCCQGENPETCGASFSFGCSWSMYYNGCKFARSKKPRKFRLHGAEPKEEERLGSHLQNLATVIAPIYKKLAPDAYNNQVEFEHQAPDC 
Equus-caballus         107 RTCACQGLDPDTCGASFSFGCSWSMYYNGCKFARSKIPRKFKLLVDDPKEEEKLESHLQNLSTLMAPTYKKLAPDAYNNQIEYEHRAPEC 
Danio-rerio            726 RTCACQGLEADACGASFSFGCSWSMYYNGCKFARSKVPRKFKLLADDPKEEEKIEQNLQGLATYIAPVYKKMAPDAYSNQVEHENRAPDC 
Monodelphis-domest.   1480 RTCACQGMDPETCGASFSFGCSWSMYFNGCKFARSKNPRRFRLIADDPKEEEILESNLQSLATDVAPVYKKLAPDAFRNQVENEPLGPDC 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus             954 RTCACQGKDPNTCGASFSFGCSWSMYFNGCKYARSKTPRKFRLAGDNPKEEEVLRKSFQDLATEVAPLYKRLAPQAYQNQVTNEEIAIDC 
Xenopus-trop.         1093 RTCACQGKDPNTCGASFSFGCSWSMYFNGCKYARSKTPRKFRLIGENPKEEDGLKDNFQNLATKVAPVYKMLAPQAYQNQVNNEDIAIDC 
Gallus-gal.           1627 RTCACQGLDPETCGASFSFGCSWSMYFNGCKFARSKNPRKFRLLTDDPKQEELLEHNLQTLATDVAPVYKKLAPEAFQNQVENEHMGPDC 
Tetraodon-nig.        1622 RTCACQGKDPEKSGASFSFGCSWSMYFNGCKYARSKMPRKFRLQGDRPEEEDKVRDRFQALATHVAPLYKQLAPQAYSNQCQTESKAPDC 
Culex-pip.            1129 RTCACQGLDPETCGVSYSFGCSWSMYYNGCKYARSKTVRKFRLSVKN--EEAEIEERMNVLATMLSPLYVTVAPQAFQNQVQYEREAPDC 
Aedes-aegypt.         1221 RTCACQGLDPETCGVSYSFGCSWSMYYNGCKYARSKTVRKFRLSVKN--EEAEIEERMNILATMLSPLYVTVAPQAFQNQVQYEREAPDC 
Apis-mellif.          1659 RTCACQGLDPETCGASFSFGCSWSMYYNGCKYARSKTVRKFRLSVRS--EEQEVEERMHVLATLLSPLYLSLAPEAFNNQTQFEREASEC 
Nasonia-vitripen.      959 RTCACQGLDPDTCGASFSFGCSWSMYYNGCKYARSKTVRKFRLSVRS--EEQEVEERMHVLATLLSPLYLSLAPEAFNNQTQFEREASEC 
Anopheles-gam.        1478 RTCACQGLDPELCGVSYSFGCSWSMYYNGCKYARSKTVRKFRLSVKN--EEAEIEERMNVLATMLSPLYVTVAPQAFQNQVQYEREAPDC 
Drosophila-melanog.   1167 RTCACQGLDPESSGASYSFGCSWSMYYNGCKYARSKTVRKFRLSVKS--EEAAIEDHMNLIATLLAPVFKQVCPRSYDNQTKYEHEASDC 
                                                                 L1398R 
                                                               C1396W                   S1424fsX23 
Homo-sapiens          1359 RLGLKEGRPFSGVTACLDFCAHAHRDLHNMQNGSTLVCTLTREDNREFGGKPEDEQLHVLPLYKVSDVDEFGSVEAQEEKKRSGAIQVLS 
Pan-troglodytes       1499 RLGLKEGRPFSGVTACLDFCAHAHRDLHNMQNGSTLVCTLTREDNREFGGKPEDEQLHVLPLYKVSDVDEFGSVEAQEEKKRSGAIQVLS 
Canis-lupus-fam.      1449 RLGLKEGRPFSGVTACLDFCAHAHRDLHNMQNGSTLVCTLTREDNREIGGKPEDEQLHVLPLYKVSDVDEFGSVEAQEKKKQNGAIQVLS 
Rattus-norvegicus     1313 RLGLKEGRPFSGVTACLDFSAHAHRDQQNMANGSTVVVTLTREDNREVGGQPEDEQLHVLPLYTIATEDEFGSTEGQEEKILQGSIQVLH 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1272 CLGLKEGRPFSGVTACLDFSAHSHRDQQNMPNGSTVVVTLNREDNREVGAKPEDEQFHVLPMYIIAPEDEFGSTEGQEKKIRMGSIEVLQ 
Equus-caballus         197 RLGLKEGRPFSGVTACLDFCAHAHRDLHNMQNGSTLVCTLTREDNREIGGKPEDEQLHVLPLYKVSDVDEFGSVEAQEEKKRNGAIQVLS 
Danio-rerio            816 RLGLKEGRPFSGVTACLDFCAHAHRDLHNMQGGSTVVCTLTREDNREIGKIPEDEQLHVLPLYKPSSTDEFGSAEAQLEKTKTGAIQVLS 
Monodelphis-domest.   1570 RLGRKDGRPFSGVTACIDFCAHAHKDTHNMNNGSTVVCTLTKEDNRSVGVVPKDEQLHVLPLYKISQTDEFGTKEGLEAKIKTGAIQVLT 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1044 RLGLKEGRPFSGVTACMDFCAHAHKDQHNLYNGCTVVCTLTKEDNRCVGKIPEDEQLHVLPLYKMASTDEFGSEENQNAKVGSGAIQVLT 
Xenopus-trop.         1183 RLGLKEGRPFSGVTACMDFCAHAHKDQHNLYNGCTVVCTLTKEDNRMIGRVAEDEQLHVLPLYKVSTTDEFGSEEGQLEKIKKGGIHVLS 
Gallus-gal.           1717 RLGSKDGRPFSGVTACIDFCAHAHKDTHNMHNGSTVVCTLTKEDNRRVGVIPSDEQLHVLPLYKISQTDEFGTEEGLEAKIKAGAIQVLT 
Tetraodon-nig.        1712 RLGLKEGRPFSGVTACMDFCAHAHKDQHNLYNGCTVVCTLTKEDNREVQKIPDDEQLHVLPLYKVSPTDEFGREEGQRLKMKTGAIQVLQ 
Culex-pip.            1217 RLGLKPGKPFSGVTCCLDFCAHTHRDLHNMQDGCTVQVTLLKPLPPGVK--PDDEQLHILPLYTMDTTDEFDSEEGQKKKAETGAVQVLE 
Aedes-aegypt.         1309 RLGLKPGKPFSGVTCCLDFCAHTHRDLHNMQDGCTVQVTLLKPLPPGVK--ADDEQLHILPLYTMDTTDEFDSEEGQKKKAETGAVQVLE 
Apis-mellif.          1747 RLGFKPGRPFSGVTACIDFCAHSHRDLHNMNNGCTVVVTMTK--HRTLSK-PEDEQLHVLPLYIMDTTDEYGSKEGQDEKVRAGAVEVLT 
Nasonia-vitripen.     1047 RLGFKPGRPFSGVTACIDFCAHAHRDLHNMNNGCTVVVSLTK--HRSFSK-PDDEQLHVLPLYIMDDSDEFGSKEGQEAKIKSGAIEVLT 
Anopheles-gam.        1566 RLGLKPGKPFSGVTCCLDFCAHTHRDLHNMQDGCTVQVTLLKPLPPGVK--PDDEQLHVLPLYTMDTTDEFDSEEGQKKKHETGAVQVLE 
Drosophila-melanog.   1255 RLGLEPGKPFSGVTACLDFCAHSHRDLHNMQDGCTVHVALLKPGNRDTRL-PDDEQFHVLPLYTMDGTDEFESVEGQRDKHRTGAVQMLD 
 
 
Homo-sapiens          1449 SFRRKVRMLAEPVKTCRQRKLEAKKAAAEKLSSL--------------------------------------------------ENSSNK 
Pan-troglodytes       1589 SFRRKVRMLAEPVKTCRQRKLEAKKAAAEKLSSL--------------------------------------------------ENSSNK 
Canis-lupus-fam.      1539 SFRRKVRMLAEPVKTCRQRKLEAKKAAAEKLSSL--------------------------------------------------ENNTNK 
Rattus-norvegicus     1403 SFRRRRVRRLVDPPKNCRQKK-----LEAKKARK--------------------------------------------------LSSLEN 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1362 SFRRRRVIRIGELPKSCKKKAEPKKAKTKKAARK--------------------------------------------------RSSLEN 
Equus-caballus         287 SFRRKVRMLPEPVKTCRQRKLEAKKAAAEKLSSL--------------------------------------------------ESSANK 
Danio-rerio            906 SFRRQVRMLPEPAKSCRQRKLDAKRANKPNNNTP--------------------------------------------------NSKTDN 
Monodelphis-domest.   1660 AFPREVRMLAEPVKATKKKKVDIRRVQTEKPGQV--------------------------------------------------PKKHPP 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1134 AFPREVRRLPEPAKSCRQRQLEARKAAAEKKK----------------------------------------------------VQKEKL 
Xenopus-trop.         1273 SFPREVRKLSEPAKSCRQRQLEAKKAAAEKKK----------------------------------------------------LQKEKL 
Gallus-gal.           1807 AFPREVRMLAEPLRATKKKKPDTRRTLSEKQQLV--------------------------------------------------DKKYST 
Tetraodon-nig.        1802 AFRREVRKLPEPAKSCRQRRLEAKKASSEKKKNK--------------------------------------------------MMQQTR 
Culex-pip.            1305 KFTTEVRVRSTPLQPCRRHGKKRGNGKDEKNKDGN-------------------------------------------------SSNNED 
Aedes-aegypt.         1397 KFATEVRVRSTPLQPCRRHGKKRGNGKDEKSKD---------------------------------------------------DSNNEE 
Apis-mellif.          1834 KYPCEVRVRSVPLQPCRRHGKKRKEDEPDTISSKKDSSKNVNEKITESGRQIPGHQELIRPQMRDTQLSLEMASMFEGMDAQLQSSQVSS 
Nasonia-vitripen.     1134 KYPCEVRVRSVPLQPCRRHGKKRKEDEPDVASNKKD-TKSPAEKFVDTNR-PQMYQDPSRPPLRDSQLSLEMTSMLEGMDAQLQSSQVSS 
Anopheles-gam.        1654 KFQTEVRVRSTPLQPCRRHGKKRGNGKDEKLG----------------------------------------------------KDGSDG 
















                           K1493fsX77 
Homo-sapiens          1489 NEKEKSAPSRT-----------------------KQTENASQAKQLAELLRLSGPVMQQSQQPQPLQKQPPQPQQQQRPQQQQPHHP--- 
Pan-troglodytes       1629 NEKEKSAPSRT-----------------------KQTENASQAKQLAELLRLSGPVMQQSQQPQPLQKQPPQPQQQQRPQQQQPHHP--- 
Canis-lupus-fam.      1579 NEKEKSASSRT-----------------------KQTENASQAKQLAELLRLSGPVMQQSQQPPPPPLQKQPPQPQKQPPQQQQQQQQQQ 
Rattus-norvegicus     1438 CSNKNEKEKSS-----------------------SRTRPMENASPMIQMTAQLRLSGSVIQQPQSLQRHLQQVQRPPQPQPPQPQ----- 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1402 CSSRTEKGKSS-----------------------SHTKLMENASHMKQMTAQPQLSGPVIRQPPTLQRHLQQGQRPQQPQPPQPQPQTTP 
Equus-caballus         327 NEKEKPALPRT-----------------------KQTENGSQTKQLAELLRLSGPVMQQPQQPQQPPPHSQPQQLQKQPPQPQPPQP--- 
Danio-rerio            946 TQQAKQKQTAY-----------------------ENPTVTGRGNMRTNLDSGHLPQAHAGHQPQ------QQFPQQTHPNPSYASPP--- 
Monodelphis-domest.   1700 PVKLKNGPLEA-----------------------PNRAPQPLGNRTEALQPEIKSEPPDSHFNLHSVANTTS---YSWIKSIHHPLK--- 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1172 STPEKIKQEALELAGITTDPGLSLKGGLSQQSLKPSLKVEPQSPFSSFKYSGNTVVESYSVLGSCRPSDPYSVNSVYSYHSHYAQPGLAA 
Xenopus-trop.         1311 VSPDKTKQEPSDKKTCQQNP------GVPQQQTKPCIKVEPSNHYNNFKYNGNGVVESYSVLGSCRPSDPYSMNSVYSYHSFYAQPNLPS 
Gallus-gal.           1847 PIKLKTEAPEN-----------------------LSNTLHCLGNKADALKPGIKTETSDHLCAMKHTSNTTKNCSLLKQYTASPPFK--- 
Tetraodon-nig.        1842 ETPDKSVVKAEICLTAS-----------------PQAQVNQGGVKQEVKANIKKEHERYPAQAAD------MFNNICPHPSFYARGGLPP 
Culex-pip.            1346 SVPETPPPPPPP---------------------TKKESKSKSKKGSSNSGATNTTTNSNGSNSNGSNSNQNS-----QSSTGSGSPRAQT 
Aedes-aegypt.         1436 SVPETPPPPPPP---------------------TKKESKSKSKKGSSNS----------SNNSNSGNGSNSS-----QSSSGSGSPKGQS 
Apis-mellif.          1924 TVLDSPVSMYPQG--------------------WGYQNEQQWSRNGWLDQRKNNWLNPWREYS-FGGLDRDAKVDPDSTSLDDIRPRSTV 
Nasonia-vitripen.     1222 TVLDSPVSMYQS---------------------WNYQTEQQWSRPGWLDQRKSNWMNPWTEYGPFGGLDREVKVDPDSTSLDDSRPRSAV 
Anopheles-gam.        1692 AAPDTPPPPPPP---------------------TKKESKSKSKKSSAASTASSGASTANSVASPGPGGSGSTGAGGGSGGSGSGSPRAHT 
Drosophila-melanog.   1381 AVGDANSQSSSS---------------------NGAQSQTQANNQQS-SPPALGTAHIKKENGNGVNANGAS-----SKSKGKGKSNQSN 
 
 
Homo-sapiens          1553 ----------------------------------------------------------------QTESVNSYSASGSTNPYMRRPN-PVS 
Pan-troglodytes       1693 ----------------------------------------------------------------QTESVNSYSASGSTNPYMRRPN-PVS 
Canis-lupus-fam.      1646 QQHHPMTNNS------------------------------------------------------QSESVNSYSSSGSANLYMRRPNPVIQ 
Rattus-norvegicus     1500 -------HIL------------------------------------------------------PSNSQPVGSHSSGSTNVYMRQPAPLS 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1469 QPQPQPQHIM------------------------------------------------------PGNSQSVGSHCSGSTSVYTRQPTPHS 
Equus-caballus         391 ------------------------------------------------------------------------------------------ 
Danio-rerio           1004 ----------------------------------------------------------------------------------------FT 
Monodelphis-domest.   1761 ------------------------------------------------------------------------------------------ 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1262 VNGFHSKYAL------------------------------------------------------PAFSYYGFPSSNPVFPSQFLGAG--- 
Xenopus-trop.         1395 VNGFHSKYAL------------------------------------------------------PPFGFYGFPN-NPVVPNQFMNYGTSD 
Gallus-gal.           1911 ------------------------------------------------------------------------------------------ 
Tetraodon-nig.        1909 AWPALCNLPA------------------------------------------------------MHNGYYNYPPNALFARKLRTYEGRSA 
Culex-pip.            1410 PGNNSTKSS----------------------------GSAGSGSGGGGS-------------------VPNVPNKAGNGQ-VPAVVPNNG 
Aedes-aegypt.         1490 SNSNSSKAS----------------------------G---ETSANGNN-------------------SATNATKATTPQ-GPATG-NNG 
Apis-mellif.          1993 SQDEHRPGSRNLPNSTMDSPRNYYSHSPRAHPISPRSTHTGTPGDIGYSMSPRGCPPT---LQDQKNASPRSSGYPDTG--YSHPLPTSR 
Nasonia-vitripen.     1291 SQEDYRPASR--QNSNSESPRANYTQSSRGHPISPRASLPSTPVESIYSTPPRTCPSTPHEPHDQRLISPRSSGYGSAPSEFSLSSPSPR 
Anopheles-gam.        1761 PGSQKSTGS----------------------------GKGGSGSNGGSSNAALDLVTGVLTEKHSSPLHGQGAGGAGGAL-VAAGGGNGG 
Drosophila-melanog.   1444 NSSASTPGS----------------------------APPSTPSPRCQTP------------------VTNNPSPAGSAFSTPPVHGSNA 
 
 
Homo-sapiens          1578 PYPNSSHTSDIYGSTSPMNFYSTSSQAAGSYLNSSNPMNPYPGLLNQ------------------NTQYPSYQCNGNLSVDNCSPYLGSY 
Pan-troglodytes       1718 PYPNSSHTSDIYGSTSPMNFYSTSSQAAGSYLNSSNPMNPYSGLLNQ------------------NTQYPSYQCNGNLSVDNCSPYLGSY 
Canis-lupus-fam.      1682 AYPSSSHTSDIYGGASPMNLYSTSSQATGSYLNSSNPMNPYTGLLNQ------------------NNQYPAYQCNGNVSVDNCSPYLGSY 
Rattus-norvegicus     1529 PYPSSSHAADMYGDANHVNFHPTSSHAAGLYLSPSNSMNPYPGLFNQ------------------NNQYAASQCNGSMSADSGPPFLGPY 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1505 PYPSSAHTSDIYGDTNHVNFYPTSSHASGSYLNPSNYMNPYLGLLNQ------------------NNQYAPFPYNGSVPVDNGSPFLGSY 
Equus-caballus         391 ----------------------------------QRPQQPLQPLHHP------------------LTTNPQYQCNGNVSMDTCSLYLGSY 
Danio-rerio           1006 RFPNASKPSTPHPQTPSVDPYASPLHAPNSYINASNAPSPYSRSLAP------------------SPLYNGYQCNGGIPMDNYHPYHSSN 
Monodelphis-domest.   1761 ----------------------------------GTNLPLNSPLTPV------------------SGLATTS-FQNDSEISYGFSDQGSV 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1295 AWGHGGG-SSSFEKKPDLHALHNSLSPAYGGAEFAELPGQAVPTDTH------------------HPASHHQQPAYPGPKEYLLPKAPQI 
Xenopus-trop.         1430 ARNSGWM-NNCFEKKPELQSLADGMNQSYG----SELSEQSFRRSSE------------------VPHHYSLQNPS-SQKSVNVPHRTTP 
Gallus-gal.           1911 ----------------------------------VDSLHPYSSLAHK------------------PGITAVTNIQQDFSVPYGYFECSSK 
Tetraodon-nig.        1945 AFLKAEVKSEEVEKKPDVQGLQARL-------------AEAFPGGYS------------------QPANFSQSRPS---------LASSE 
Culex-pip.            1452 S--TSAFTAPNNINSPNNNGGT------STLVDMASMIDNFTDAQLQ------------------SNQISSTVLDSPYSYDYNTGQYIDN 
Aedes-aegypt.         1528 S--NSAFTPPNAITSPNN-GGN------STLVDMASMIDNFTDAQLQ------------------SNQISSTVLDSPYSYDYNTGQYIDN 
Apis-mellif.          2078 SYPNMYMDTRQSSASPKTNCINFPAHLD--QRSALNRTNHHQLHNINNARNVGGNCDQSKLPYPKPGQNSSQQKYPTTQNYLEVQKSQIE 
Nasonia-vitripen.     1379 NYQNS-LDGRQNSISPRAAYQNSSYNLESPQRNTPSRNNQHTSTPIG-------SEAARRNQSPSMNQLRSPSLNSSDSYSSNISSPRYP 
Anopheles-gam.        1822 TGGSSAFTAPNTINSPNSLANNGANNTNSTLIDMASMIDNFTDAQLQ------------------SNQISSTVLDSPYSYDYNTGQYIDN 
Drosophila-melanog.   1488 N--PQSNGGQGTGNQPGQLMSS-----NSSLMNMATMIDTFTDAQLQ------------------SNQISSTVLDSPYSYDYQTASYIDS 
 
 
Homo-sapiens          1650 SPQSQPMDLYRYPSQDPLSKLSLPPI--------------------------HTLYQPRFGNSQSFTSKYLGYGNQNMQGDGFSS-CTIR 
Pan-troglodytes       1790 SPQSQPMDLYRYPSQDPLSKLSLPPI--------------------------HTLYQPRFGNSQSFTSKYLGYGNQNMQGDGFSS-CAIR 
Canis-lupus-fam.      1754 SPQSQPMDLYRYPNQDPLSKLNLPPI--------------------------HTLYQPRFGNSQSFSSKYLGYGNQNIQGDAFSS-CTIK 
Rattus-norvegicus     1601 SPQSQSRGLHRYPNQDHLSNLNLPPI--------------------------HTLYPQRS-DSPFKYLNYGNQNNVQRDRDAFTN-CPLK 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1577 SPQAQSRDLHRYPNQDHLTNQNLPPI--------------------------HTLHQQTFGDSPSKYLSYGNQN---MQRDAFTTNSTLK 
Equus-caballus         429 SSQSQPMDLYRYPNQDPLSKLNLPPI--------------------------HTLYQPRLGSSQSFTSKYLGNGNQSVQGGAFSN-CTIR 
Danio-rerio           1078 LKHPDMFHPQRNP----------------------------------------LYSEQQYNAPQHYGVNYPPHYGEAMATNGYGN-CNMR 
Monodelphis-domest.   1798 PPWTVVSTKYSGAN---------------------------------------------------------------------------- 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1366 HPVSRDPSPFAQSSNCYNRSIKQEP---------------------------VDPLVHTESVTREPGKMGKTPLPEASQNGGPSHLWGQY 
Xenopus-trop.         1496 APVETTP---YSNLPCYNKVIKKEPG--------------------------SDPLVDSFQRAN----SVHSHSPGVNHSLQASDLPISY 
Gallus-gal.           1949 QPHVTPYINCKNFD---------------------------------------------------------------------------- 
Tetraodon-nig.        1995 ASNRGTP------------VIKQEPL--------------------------DVPVYEGSTPGR-----ATPHTPGTTPQPAP---WSAH 
Culex-pip.            1516 RQYYNNWPTDYYGNRTDPS--KMLGRNEE---------------------IPDTTTRPGSNSS-----NSAFSPSIPDPTKTPTPIHMDD 
Aedes-aegypt.         1591 RQYYNNWPTDYYGNRTDPN--KMLGRNEE---------------------IPDTTTRPGSNSS-----NSAFSPSIPDPTKTPTPIHLDD 
Apis-mellif.          2166 QPFVNRIQGHYHPPHHVQSSRNLPYQGPHETNM-----DMFSGLSVSSCMSNTSHKEFGTTNSDLLLHTSSHLPSSNPPNGTQNLGSIDQ 
Nasonia-vitripen.     1461 VDHNQRFPGSMAQNIAEMQDSKSTPKAPISQIP-----QQSESNSRLAEYANQGYAMPGPMNSDYLLQNPLHMPSLPHQTYDQQNENSVN 
Anopheles-gam.        1894 RQYYNNWPTDYYGNRGDPSKLAGLGRNEE---------------------IPDTTTRPGSNSS-----NSAFSPSIPDPTKTPTPIHMDD 





Homo-sapiens          1713 PNV--------------------------------------------------------------------------------------- 
Pan-troglodytes       1853 PNV--------------------------------------------------------------------------------------- 
Canis-lupus-fam.      1817 TNV--------------------------------------------------------------------------------------- 
Rattus-norvegicus     1663 PNV--------------------------------------------------------------------------------------- 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1638 PNV--------------------------------------------------------------------------------------- 
Equus-caballus         492 ANT--------------------------------------------------------------------------------------- 
Danio-rerio           1127 PGI--------------------------------------------------------------------------------------- 
Monodelphis-domest.   1812 ------------------------------------------------------------------------------------------ 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1429 SGG--------------------------------------------------------------------------------------- 
Xenopus-trop.         1553 KAN--------------------------------------------------------------------------------------- 
Gallus-gal.           1963 ------------------------------------------------------------------------------------------ 
Tetraodon-nig.        2039 RVN--------------------------------------------------------------------------------------- 
Culex-pip.            1578 -YS---------------------ATKLSQ-------------------------------------------------------QQSQN 
Aedes-aegypt.         1653 -YS---------------------TTKLNQ-------------------------------------------------------QQSQN 
Apis-mellif.          2251 RKY---------------------RMYKSHEQKTPGINQMSPAPSDQVGGWNMLGSWYPDQNKPYDQQQVYNDQVNSERNHQQSIDHQKT 
Nasonia-vitripen.     1546 SAE---------------------QKRTLNNSRGP-SNLNYPSGLTEQSNWSSLSSWGNETAKKSAQSPSHTTHQG--LPSKLEYGNTSK 
Anopheles-gam.        1958 -YG---------------------STKLGQGQVHHHHHQLQQQ-----------QQQQQQQHQQQHQQHQQQHQQQQQHQQQQSQQQTQN 
Drosophila-melanog.   1640 GYGPGNYQTLVSNPASNLTNPGGVTTEVQQQHQQAQQQSALTGGVGPGGLPVVGGAPGDLKGRLVSEENPDSTTLVNHHHHHHNLTESKL 
 
 
Homo-sapiens          1716 --------------------HHVGKLPPYPTHEMDGHFMGATSRLPPNLSNPNMDYKNGEHHSPSHIIHN-------------------- 
Pan-troglodytes       1856 --------------------HHVGKLPPYPTHEMDGHFMGATSRLPPNLSNPNMDYKNGEHHSPSHIIHN-------------------- 
Canis-lupus-fam.      1820 --------------------HHVGTFPPYSTHEMDGHFMGATSRLPTNLSNSNIDYKNGEHPPSSHIIHN-------------------- 
Rattus-norvegicus     1666 --------------------HHLPTFSSYATPKMDGHFMGAASRLP--YSHPNMEYKSSDHHLPPHMIHG-------------------- 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1641 --------------------HHLATFSPYPTPKMDSHFMGAASRSP--YSHPHTDYKTSEHHLPSHTIYS-------------------- 
Equus-caballus         495 --------------------HHAGTFPPYSTPEMDGHCMGAAARLPPNLSNPSIDYTNDEHNPSSHIIHN-------------------- 
Danio-rerio           1130 --------------------HSMGHYPGFDSNMSTNAFARPPS------AHLHLDYAAAGNAYPKPHISQ-------------------- 
Monodelphis-domest.   1812 --------------------TVAKECPGLLLNAKPASVPGVASPMTDP--QIHADLPTGPVEHLVSNMAT-------------------- 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1432 --------------------PSMSPKRTNGVGGSWGVFPPVESPAVIPDKLGSFGGSCLTPSHFPDGQHQ-------------------- 
Xenopus-trop.         1556 --------------------GALSSSGRTNAESPCSMFMPNDKNGLE--KKDYFGVHSNAPGLKDKQWPP-------------------- 
Gallus-gal.           1963 --------------------VSVKDYTGILLNDKMNGVPPILPEVTAPGPPAHKDPLPSILEHQPDKQNC-------------------- 
Tetraodon-nig.        2042 --------------------G--------SCDSPLNLRAGPDGPAVN-------------PEQFHQQHSP-------------------- 
Culex-pip.            1591 TYHTLQQ-------------PEQGFVKPKPPDYNPGYGY---HPNTAMSYGYHPP------YTPYDPYQ--NYNYG-------------- 
Aedes-aegypt.         1666 TYHTLQQ-------------PEQGFVKPKPPDYNPGYGY---HPNTPMGYGYHSP------YTPYDPYQ--NYNYG-------------- 
Apis-mellif.          2320 FNWNDRVPHPDQSKPPCWETPSDPSPFRVPKGRPPSRTAAGQNPNADS-AYQNSSN--RTFLKPQEPIRNGIYADSPSNNAIQNNGTMHQ 
Nasonia-vitripen.     1612 TSWDERQSHSDAIKPAWDAPPEPPSPFRVPKGRPPSRTTPNHNPQPESGNSQSSVS--KTFLKPQEPIKN-------------------S 
Anopheles-gam.        2015 TYHTLQQ-------------PEQGFVKPKPPDYNPAAGYGYHHPNTPMGYGYHHHHHPPYHHTPYDPYQ--NYNYG-------------- 
Drosophila-melanog.   1730 TALTAMQPMTNLAPLTTSHHPQEGFVKPKPPPSDYTAQYTAQYPNNYQMYPPPPPP-PHSAYSAYDAYQNMNYNYGY-----------HQ 
 
 
Homo-sapiens          1766 -------YSAAPGMFNSSLHALHLQNKENDMLSHTANGLSKMLPALNHD----------------------------------------- 
Pan-troglodytes       1906 -------YSAAPGMFNSSLHALHLQNKENDMLSHTANGLSKMLPALNHD----------------------------------------- 
Canis-lupus-fam.      1870 -------YGAAPGMFNSSLHALHLQNKENDMLSHTANGLSKMLPGLNHD----------------------------------------- 
Rattus-norvegicus     1714 -------YPTAASGSVSSSSHAFHNKENDNMVSHTANGLSRVLPGFNHD----------------------------------------- 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1689 -------YTAAASG--SSSSHAFHNKEND----NIANGLSRVLPGFNHD----------------------------------------- 
Equus-caballus         545 -------YSAAPSLFNTSLHALHLQNQENHMLAHTALGLSKMLPALNHD----------------------------------------- 
Danio-rerio           1174 -------NPHMFSPNLNTLSMQSHKDLG--ISMHEANGISQGFPPLGKE----------------------------------------- 
Monodelphis-domest.   1860 -------FPPPSLLSPVPQIPSLDDSTPAKSDYEHKTGPSEVAALAPSL----------------------------------------- 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1482 -------WGLFPGEGQQPAPQPAGRLRGKPWSPCKFGSNASALAGPGLT-EKPWGVGAGDFSSALKGGPGFQDKLWSPLKGEEGRIPTPG 
Xenopus-trop.         1604 -------YGTDVSVRQHDSLDSQS--PGKVWSSCKLSDSSAALPSSASTQDKNWNGRQVSLNQGMKESALFQEKLWNSVAASDRCSATPS 
Gallus-gal.           2013 -------QPQSDSSPSSQMISSCDLSVPLSSPAKDAVGNEADCSHRCPV----------------------------------------- 
Tetraodon-nig.        2071 -------Y-------------------PPQWASYPAPN--AAMPPAAAS-------------------PSLQGRLFPDALQQ-------- 
Culex-pip.            1643 -------YPPQSYHPT------YHNMYP-----------ATQTQLAGTG----------PAPPPPPTAVIPAPPPPSNWN---------- 
Aedes-aegypt.         1718 -------YPPQSYHPT------YHNMYS-----------ATQTQLPGTG----------PAPPPPPTAVIPAPPPPSNWN---------- 
Apis-mellif.          2407 NNQIRRSEWTEDKTRENFHD-PRQNMANPNSNCFPWAEEMKQVQDFHGMPGLGHPHASFPQYGLYPTYPVFDKPYSNSWDG--------- 
Nasonia-vitripen.     1681 PIQQRKPEWPQDRLREGFQESTRQEVPNQNPGLSWAEAEMKQVQDFHTMTGLGHP--SFPQYG-YPSYPVFDKPYPNTWDG--------- 
Anopheles-gam.        2076 -------YPPQSYHHH------HHTTYHNMYPAAAAAAAAAQTQLPGTG----------PAPPPPPTAVIPAPPPPSNWN---------- 
Drosophila-melanog.   1808 AYSPYGMYPQQTPPPTPPPPSPNWNMYGHHQTGSVNSGYGSANPAAGAGSLISSHGSVASAGVGLQKAMVPVPGPLHHQQQQVLQQQQQQ 
 
                                                                                     L1819fsX 
Homo-sapiens          1808 --------------------------------------------------RTACVQGGLHKLSDANGQEKQPLALVQGVASG-------- 
Pan-troglodytes       1948 --------------------------------------------------RTACVQGGLHKLSDANGQEKQPLAPVQGVASS-------- 
Canis-lupus-fam.      1912 --------------------------------------------------RTASVQEGLHKLQDAGNQEKQPSAAED------------- 
Rattus-norvegicus     1756 --------------------------------------------------RTASAQGPLYSLPDYSQEKQPGVSGQDG---A-------- 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1725 --------------------------------------------------RTASAQELLYSLTGSSQEKQPEVSGQDA---A-------- 
Equus-caballus         587 --------------------------------------------------RTASVQEGLHKLPDDSSQEKQPSAAEDN------------ 
Danio-rerio           1214 --------------------------------------------------CFNFNQPSSLKLPNENAHN-PAVNPTQLPQVS-------- 
Monodelphis-domest.   1902 --------------------------------------------------ANATKQELELAAPLSSATEQTPSDELTESADS-------- 
Ornithorhynchus-anat.  319 ------------------------------------------------------------------------------------------ 
Bos-taurus            1564 -----------------------ASQLDKAWQSFGMPLGPSEKLFGALKSEEKLWDPFSLEEGTAEGPPNKGTVKEEKGAGG-------- 
Xenopus-trop.         1685 D---------------RSSITPCSELQDKNWGSFPNPTVNSLKTD----SSQNHWDPYSLDDNMDDGQSK--SVKEE------------- 
Gallus-gal.           2055 --------------------------------------------------EKGSSHREQMCD--FDCTDEKQNSALGQPTDS-------- 
Tetraodon-nig.        2106 -------------------------------------------------SDQACWNPSQGDSDAASTKG-----LEE------------- 
Culex-pip.            1689 ----------------------------LYPPHP-----HHQSHIAPTTASQLHAS---HLGS---KQQDLTPVMQQAVQPP-----APP 
Aedes-aegypt.         1764 ----------------------------LYPPHP-----HHQTHIPPSTPSQLHTPHQPHLNP---KQHDIPPAMQQAPQPP-----APP 
Apis-mellif.          2487 ---------------YNYHQPYPHPQTSEYPPQLYQQPKRETCFPSPQYPYQGVP-PYQSLNPGWARWDTP---RWDIYGPPSYFPVLPE 
Nasonia-vitripen.     1759 ---------------YNYNPAYHPQAAEYPAAQFYQQPKRDSCFPPAQYPFQNVPAPYQGLNPGWARWEAPGCPRWDLYGPPSYFPVLPE 
Anopheles-gam.        2133 ----------------------------LYPPHLGTAPSTAQLHVAAAAAGALGKQSELGGAVGAGMMSQSAVVPQAPAAPP-----SAP 
Drosophila-melanog.   1898 QQQQQQQQQQQQQQQQQQVQQLQQEAPQTILPDLSNGQTNSDTVATPTPTGDSSSNDAGPGNPGAGNQAPASGAGAATTAPP-----IAS 
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                                                                   I1873T   H1881Q                  K1911-L1916del  
                                           S1848X                     C1875R              R1896S            G1913D 
Homo-sapiens          1840 ----------AEDNDEVWSDSEQSFLDPDIGGVAVAPTHGSILIECAKRELHATTPLKNPNRNHPTRISLVFYQHKSMNEPKHGLALWEA 
Pan-troglodytes       1980 ----------AEDNDEVWSDSEQSFLDPDIGGVAVAPTHGSILIECAKRELHATTPLKNPNRNHPTRISLVFYQHKSMNEPKHGLALWEA 
Canis-lupus-fam.      1939 -------------NDEVWSDSEQSFLDPDIGGVAVAPTHGSILIECAKRELHATTPLKNPNRNHPTRISLVFYQHKSMNEPKHGLALWEA 
Rattus-norvegicus     1785 ----------SVEDIEVWSDSEHNFQDPSIGGVAIAPTHGSILIECAKCEVHATTKVNKPNRKKPARISLVFYQHKNLNEPKHSLAVWEA 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1754 ----------AVQEIEYWSDSEHNFQDPCIGGVAIAPTHGSILIECAKCEVHATTKVNDPDRNHPTRISLVLYRHKNLFLPKHCLALWEA 
Equus-caballus         615 --------------DEVWSDSEQSFLDPDIGGVAVAPTHGSILIECAKRELHATTPLKNPNRNHPTRISLVFYQHKSMNEPKHGLALWEA 
Danio-rerio           1245 ----------EKKEEDVWSDSEHNFLDPEIGGVAVAPSHGSIIIECAKRELHATTPVKKPDRNHPTRISLVFYQHKNLNEAKHGLSLWEA 
Monodelphis-domest.   1934 ----------EERSEEMWSDSEHNFLDDNIGGVAVAPSHGSVLIECARRELHATTPIRKPNRNHPTRISLVFYQHKNLNEPRHGWAVWEA 
Ornithorhynchus-anat.  319 ----------------IWSDSEHSFLDPDIGGVAVAPTHGSILIECAKRELHATTPLKNPNRNHPTRISLVFYQHKSMNEPKHGLALWEA 
Bos-taurus            1623 ----------AEEEEELWSDSEHNFLDENIGGVAVAPAHGSILIECARRELHATTPLKKPNRCHPTRISLVFYQHKNLNQPNHGLALWEA 
Xenopus-trop.         1741 ------------DDEEIWSDSEHNFLDENIGGVAVAPGHGSILIECARRELHATTPLKKPNRCHPTRISLVFYQHKNLNQPNHGLALWEA 
Gallus-gal.           2085 ----------EEKAEEMWSDSEHNFLDDDIGGVAVAPSHGSILIECARRELHATTPIKKPNRNHPTRISLVFYQHKNLNEPKHGLAMWEA 
Tetraodon-nig.        2129 ------------DKEEVWSDSEHNFLDPNIGGVAVAPAHGSILIECARRELHATTPLKKPDRSHPTRISLVFYQHKNLNQPMHGLGLWEA 
Culex-pip.            1735 PPPK-----ETLGEVTESNENTDCFEDPQMGGVAIALPHGSVVIECAKLEMHSTTAVKKPNRLNPTRMTLIFYQHRNLNRPKHGIAEWAE 
Aedes-aegypt.         1813 PPPK-----ETLGEVTETNENVDCFEDPQMGGVAIALPHGSVVIECAKLEMHSTTALKKPNRLNPTRMTLIFYQHRNLNRPKHGIAEWAE 
Apis-mellif.          2558 PPPK----AEPLGEVADYSDNEECFKDSQMGGVAIALSHGSVLFECAKHEMHATTALKKPNRLNPTRISLVFYQHRNLNRARHGWDEWEE 
Nasonia-vitripen.     1834 PAPK----AEPLGEVADYSDNEECFKDSQMGGVAIALGHGSVLFECAKHEMHATTALKRPNRLNPTRISLVFYQHRNLNRPRHGWDEWEE 
Anopheles-gam.        2190 LPPK-----ETLGEVTETNENLDCFEDPQMGGVAIALPHGSVIIECAKLEMHSTTAVKKPNRLNPTRMTLIFYQHRNLNRPKHGIAEWAE 
Drosophila-melanog.   1983 PGSTNSTKIEPIGEVAEINENIEAFQDPQMGGVAIALNHGSVLIECAKHEMHATTAVRRPDRHHPTRMTLIFYQHRNLNRCRHGIDEWEE 
 
 
Homo-sapiens          1920 KM---AEKAREK-------------------EEECEKYGPDYVPQKSHGK---------------------------------------- 
Pan-troglodytes       2060 KM---AEKAREK-------------------EEECEKYGPDYVPQKSHGK---------------------------------------- 
Canis-lupus-fam.      2016 KM---AEKAREK-------------------EEECEKYGPDYVPQKTHGK---------------------------------------- 
Rattus-norvegicus     1865 KM---AGKARKE-------------------EEECEKYGSDHVSQKNHGK---------------------------------------- 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1834 KM---AEKARKE-------------------EE-CGKNGSDHVSQKNHGK---------------------------------------- 
Equus-caballus         691 KM---AEKAREK-------------------EEECEKYGPDYVPQKTHGK---------------------------------------- 
Danio-rerio           1325 KM---AEKAREK-------------------EEDAEKHGAENTSSKSGGK---------------------------------------- 
Monodelphis-domest.   2014 KM---AERAREK-------------------EREAERLATEN----ANNQ---------------------------------------- 
Ornithorhynchus-anat.  393 KM---AEKGREK-------------------EEECEKYGPDYVPQKTHGK---------------------------------------- 
Bos-taurus            1703 KMKQLAERARAR-------------------QEEAARLGLGHQEAKLYGK---------------------------------------- 
Xenopus-trop.         1819 KMKQLAERARAR-------------------EEEAAKLGI-KQEVKSLGK---------------------------------------- 
Gallus-gal.           2165 KM---AERAKEK-------------------EKEAERLGTENTELNSSSR---------------------------------------- 
Tetraodon-nig.        2207 KMKLLAERALQR-------------------QQEAALLGLSQEDIKALGK---------------------------------------- 
Culex-pip.            1820 KMRLKKLGLAVN-------------------DPIDDKDMLLD---DIKAE---------------------------------------- 
Aedes-aegypt.         1898 KMRLKKLGLATN-------------------DPIDDKDMLLMQEDDIKSE---------------------------------------- 
Apis-mellif.          2644 KMRLRKLGVTTTNTTTTTNSST-------NSQPLSTPSTPTSPASATISE---------------------------------------- 
Nasonia-vitripen.     1920 KMRLRKLGVSATSAGGTATS-------------QAAPSTSSSPGAATASE---------------------------------------- 
Anopheles-gam.        2275 KMRLKKLGIPTN-------------------DPLDDKDMLLED--DIKAE---------------------------------------- 
Drosophila-melanog.   2073 KMRVKKINTDLDNKAKEERERLIKKAAGEDMDELDEDALMQDEPVPIKKESSANGQQLKNGASGSKKKKSSDSKKSQANEQSKNEKVALH 
 
                                                                    P1962L 
Homo-sapiens          1948 ------------------------------KVKREPAEPHETSEP--TYLRFIKSLAERTMSVTTDSTVTTSPYAFTRVTGPYNRYI--- 
Pan-troglodytes       2088 ------------------------------KVKREPAEPHETSGP--TYLRFIKSLAERTMSVTTDSTVTTSPYAFTRVTGPYNRYI--- 
Canis-lupus-fam.      2044 ------------------------------KVKREPTEPHEPSEP--TYLRFIKSLAERTMSVTTDSTVTTSPYAFTRVTGPYNRYI--- 
Rattus-norvegicus     1893 ------------------------------RVKREPTGPQETPKP--SYLRFIHSLAENTVSMTTDSTVTTRPYAFTQVTGPYNTYV--- 
Macaca-mulatta             ------------------------------------------------------------------------------------------ 
Mus-musculus          1861 ------------------------------QEKREPTGPQE---P--SYLRFIQSLAENTGSVTTDSTVTTSPYAFTQVTGPYNTFV--- 
Equus-caballus         719 ------------------------------KVKREPSEPHESSEP--TYLRFIKSLTERTMSVTTDSTVTTSPYAFTRVTGPYNRYI--- 
Danio-rerio           1353 ------------------------------KAKREHSEHSEPSEP--PYKQFLLMLTERSMSCTTNTYVSTSPYAFTKVTGPYNNFM--- 
Monodelphis-domest.   2038 ------------------------------KTKQPTESPEIFCEE----NELNQIPSRKALTVTHDNVITVSSYALTQVAGPYNHWV--- 
Ornithorhynchus-anat.  421 ------------------------------KAKREPVEPHEPSEP--TYLRFIKALAQRTMSVTTTSTVTTSPYAFTRVTGPYNRYI--- 
Bos-taurus            1734 ------------------------------KRKWGGAVVPESQ----HKEKKGMVPTRQALAMPTDSAVTVSSYAYTKVTGPYSRWI--- 
Xenopus-trop.         1849 ------------------------------KRKWGGAATTETP----PVEKKDYTPTRQAATILTDSATTSFSYAYTKVTGPYSRFI--- 
Gallus-gal.           2193 ------------------------------KTKQTSENREIFYED----NEFNQIPSRRALTVTKDNVITVSSYALTRVAGPYNHWA--- 
Tetraodon-nig.        2238 ------------------------------KRKWGAAAAGASPGPGQSKDKREGPVTRLAPTAHTTSVVTASPYAFTRLTGPYSHFV--- 
Culex-pip.            1848 ------------------------------PLDELHHMRHIG-------DEHDMMDVEYSGV---------------------------- 
Aedes-aegypt.         1929 ------------------------------PLDDLHHMRHMG-------DEHDMMDVEYSGV---------------------------- 
Apis-mellif.          2687 ------------------------------KSTPLPYIPSVPS------SQFMMRSPTYTTMTWTTLFPMHPCMITGPYQEGGAIG---- 
Nasonia-vitripen.     1957 ------------------------------APLALPHVPNVPS------SQFMMRSPTYTTMTWTTLFPMHPCMITGPYQEGGAIG---- 
Anopheles-gam.        2304 ------------------------------PLDELHHMRHIG-------DEHDMMDVEYPGV---------------------------- 
Drosophila-melanog.   2163 APTLTTTSWTTLFPTHPCVVSGKYPEGNSSPTSSTNNAPNGGGCP--AQQQQHLPPPPGSGLIHPPPGTPTGTAAPPPLPTPHQQLPQQQ 
 
 
Homo-sapiens               -- 
Pan-troglodytes            -- 
Canis-lupus-fam.           -- 
Rattus-norvegicus          -- 
Macaca-mulatta             -- 
Mus-musculus               -- 
Equus-caballus             -- 
Danio-rerio                -- 
Monodelphis-domest.        -- 
Ornithorhynchus-anat.      -- 
Bos-taurus                 -- 
Xenopus-trop.              -- 
Gallus-gal.                -- 
Tetraodon-nig.             -- 
Culex-pip.                 -- 
Aedes-aegypt.              -- 
Apis-mellif.               -- 
Nasonia-vitripen.          -- 
Anopheles-gam.             -- 
Drosophila-melanog.   2251 QT 
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Supplementary Figure 4: Alignment of TET2 with homologues TET1 and TET3
Alignment of the TET2 protein with its two known homologues. Positions of nonsense and frameshift mutations are indicated 
in red. Missense mutations and in-frame deletions are indicated in green.
Supplementary Figure 5: Confirmation of TET2 splice-variants 
Top left: agarose gel showing PCR products designed to cover the isoform-specific boundaries. The location of the primers is shown 
in the table (top right) and figure (bottom). The results of sequencing of the PCR products are shown in the table.




exons present in 
sequenced PCR product
1 1A/3A 336 1A + 3A
482 1A + 2 + 3A
2 1B/3A 293 1B + 3A
439 1B + 2 + 3A
3 3A/3B 97 3A + 3B
4 3A/4 226 3A + 4
317 3A + 3C + 4
5 3A/4 302 3A + 4
393 3A + 3C + 4
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Supplementary Figure 6: Copy number aberrations in patient 44 before and after progression to AML
(a) SNP-array based analysis of chromosome 4 of patient 44 shows a microdeletion at 4q24 that is present both in the neoplastic 
MDS cells and in the leukemic blasts at the time AML was diagnosed. The microdeletion is absent in the T-cells.
(b and c) SNP-array based analysis of chromosomes 7 (b) and 11 (c) shows that the leukemic blasts of patient 44 show ad-
ditional chromosomal aberrations, consisting of a 7q deletion and a (subclonal) 11q duplication, when compared to the MDS 






Supplementary Figure 7: Determination of allelic burden using Genescan analysis 
Results of Genescan analysis of 4 patients with a deletion in the TET2 gene of >1 basepairs. The blue peaks correspond with the 
wild type allele, the white peaks with the mutated allele. (a) Patient (UPN 101) with a 18 bp deletion in TET2. (b) UPN 
103 showing a 2 bp deletion. This patient had a second mutation of TET2. (c) UPN 87 with 4 bp deletion. (d) UPN46 with 
a 3bp deletion. This patient carried a missense mutation of TET2 as well.
Supplementary Figure 8: Determination of allelic burden using pyrosequencing 
Representative examples of pyrosequencing. (a) pyrosequencing of TET2 in UPN75 shows a G>T conversion (c.1102G>T) 
that is not present in the reference sample (b). (c) analysis of DNA from patient 74 shows a homozygous deletion of a cytosine 
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Supplementary Figure 9: TET2 mutation detection in bone marrow subpopulations
Sequence analysis of TET2 was performed using DNA from T-cells, the mononuclear bone marrow cells and three hematopoietic 
subfractions of seven patients (Supplementary Table 6a). Sequence analysis of DNA from patient 77 is shown. The insertion of 
a thymine (c.3718_3719insT) is detected in all cell fractions, except T-cells.  
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Supplementary Table 1: Genomic copy number changes detected by 250k SNP-array analysis
* The column ‘Reference’ indicates which reference was used to exclude normal copy number variations. 1 = SNP-array analysis 
of individually hybridized DNA from 1015 healthy controls, 2= SNP-array analysis of DNA from pool of 10 healthy indivi-
duals hybridized simultaneously with SNP-arrays of respective MDS patients, 3= T-cells of the respective MDS patient. In ad-
dition, we compared our data with the data published in ‘the database of genomic variants’ as indicated in the methods section.
UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
1 RAEB RAEB1 int-1 46,XX 8 q22.1 0,07 Loss 96462846 96529372 0 1,2



















3 RAEBt RAEB2 high 47,XY,5,add(6)(p24),del(7)(q22),+8, add(12)
(p13),+mar[2]/46,XY,-5, add(6)(p24), del(7)(q22),+8, 
add(12)(p13),  -13,der(20)t(13;20)(q14;q12),+mar[8]
8 p23.3-q24.3 146,08 Gain 180568 146263538 >50 1,2
3 p13-14.1 5,31 Loss 66376379 71682261 12
3 q21.1 1,59 Loss 123309207 124896432 15
5 p15.2-p15.1 1,98 Loss 13802952 15782509 6
5 p11-q11.2 1,40 Loss 49596616 50994294 2 EMB, ISL1
5 q14.3-q21.2 14,27 Loss 89576224 103846899 31
5 q23.2-q31.3 15,15 Loss 126273797 141421684 >50
5 q32-q34 16,84 Loss 144698251 161541603 >50
6 p25-p24.3 11,03 Loss 119769 11151025 >50
7 q21.13-q36.3 68,74 Loss 90060987 158798338 >50
12 p13.31-p12.3 9,34 Loss 8007288 17344362 >50
13 q12.3-q14.12 13,70 Loss 30646541 44347142 >50
13 q14.3-q21.1 2,04 Loss 52477690 54520177 1 OLFM4
20 p12.3-q11.22 20,71 Loss 7407565 28119554 >50
20 q11.23-q13.12 9,13 Loss 34401989 43528383 >50
20 q13.31-q13.32 0,61 Loss 54917455 55528558 5 BMP7, SPO11, RAE1, 
RBM38, CTCFL
4 RAEB RAEB1 int-1 46,XY no aberrations 1,2
5 RAEB-t AML high 46,XY, inv (7)(q22;q36)[9]/46,XY [11]  4 q21.23 0,29 Gain 84408893 84701659 6 1,2
7 q11.23 2,09 Gain 71680977 73771865 31
22 q12.3 0,17 Gain 31045559 31212808 3 RFPL3, C22orf28, 
FBXO7
6 RAEB-t AML int-2 46,XX 8 q21.3 0,16 Loss 93074623 93233515 1 RUNX1T1 1,2,3
7 RAEB-t RAEB2 int-2 46~48, XY, -4, del(5)(q13q33), der(7) add (7)(p22)
add(7)(q31), ?10(p11), tas(1;4;15)(p11;p11), -15, ?16, 
-21, +mar1, +mar2, +mar3, +mar4 
6 q24.1 0,81 Gain 140758746 141571579 0 1,2
15 q22.31-qter 37,62 Gain 62570778 100192115 >50
16 complex pattern
21 q21.1 0,49 Gain 22328428 22814209 0
21 q21.2-3 6,31 Gain 23364758 29679365 20
21 q21.3 0,33 Gain 29743331 30073388 1 GRIK1
21 q22.13-qter 10,10 Gain 36796361 46894358 >50
4 q13.1-q35.2 128,82 Loss 62352873 191167888 >50
5 q14.3-q34 69,84 Loss 90859194 160694752 >50
6 q24.1 0,44 Loss 142254945 142699855 2 NMBR,  GPR126
7 q31.1-q36.3 48,95 Loss 109843714 158798338 >50
10 p12.1-q11.22 5,30 Loss 27103830 32408595 22
10 q25.2-q25.3 2,11 Loss 114358392 116466398 12
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*  SNP-array analysis confirmed that well-known cytogenetic aberrations, such as loss of chromosome 7 and the co-occurrence 
of multiple cytogenetic defects correlated with a more aggressive phenotype. In this cohort, the newly defined copy number 
abnormalities did not significantly correlate with the established MDS subtypes.
UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
1 RAEB RAEB1 int-1 46,XX 8 q22.1 0,07 Loss 96462846 96529372 0 1,2



















3 RAEBt RAEB2 high 47,XY,5,add(6)(p24),del(7)(q22),+8, add(12)
(p13),+mar[2]/46,XY,-5, add(6)(p24), del(7)(q22),+8, 
add(12)(p13),  -13,der(20)t(13;20)(q14;q12),+mar[8]
8 p23.3-q24.3 146,08 Gain 180568 146263538 >50 1,2
3 p13-14.1 5,31 Loss 66376379 71682261 12
3 q21.1 1,59 Loss 123309207 124896432 15
5 p15.2-p15.1 1,98 Loss 13802952 15782509 6
5 p11-q11.2 1,40 Loss 49596616 50994294 2 EMB, ISL1
5 q14.3-q21.2 14,27 Loss 89576224 103846899 31
5 q23.2-q31.3 15,15 Loss 126273797 141421684 >50
5 q32-q34 16,84 Loss 144698251 161541603 >50
6 p25-p24.3 11,03 Loss 119769 11151025 >50
7 q21.13-q36.3 68,74 Loss 90060987 158798338 >50
12 p13.31-p12.3 9,34 Loss 8007288 17344362 >50
13 q12.3-q14.12 13,70 Loss 30646541 44347142 >50
13 q14.3-q21.1 2,04 Loss 52477690 54520177 1 OLFM4
20 p12.3-q11.22 20,71 Loss 7407565 28119554 >50
20 q11.23-q13.12 9,13 Loss 34401989 43528383 >50
20 q13.31-q13.32 0,61 Loss 54917455 55528558 5 BMP7, SPO11, RAE1, 
RBM38, CTCFL
4 RAEB RAEB1 int-1 46,XY no aberrations 1,2
5 RAEB-t AML high 46,XY, inv (7)(q22;q36)[9]/46,XY [11]  4 q21.23 0,29 Gain 84408893 84701659 6 1,2
7 q11.23 2,09 Gain 71680977 73771865 31
22 q12.3 0,17 Gain 31045559 31212808 3 RFPL3, C22orf28, 
FBXO7
6 RAEB-t AML int-2 46,XX 8 q21.3 0,16 Loss 93074623 93233515 1 RUNX1T1 1,2,3
7 RAEB-t RAEB2 int-2 46~48, XY, -4, del(5)(q13q33), der(7) add (7)(p22)
add(7)(q31), ?10(p11), tas(1;4;15)(p11;p11), -15, ?16, 
-21, +mar1, +mar2, +mar3, +mar4 
6 q24.1 0,81 Gain 140758746 141571579 0 1,2
15 q22.31-qter 37,62 Gain 62570778 100192115 >50
16 complex pattern
21 q21.1 0,49 Gain 22328428 22814209 0
21 q21.2-3 6,31 Gain 23364758 29679365 20
21 q21.3 0,33 Gain 29743331 30073388 1 GRIK1
21 q22.13-qter 10,10 Gain 36796361 46894358 >50
4 q13.1-q35.2 128,82 Loss 62352873 191167888 >50
5 q14.3-q34 69,84 Loss 90859194 160694752 >50
6 q24.1 0,44 Loss 142254945 142699855 2 NMBR,  GPR126
7 q31.1-q36.3 48,95 Loss 109843714 158798338 >50
10 p12.1-q11.22 5,30 Loss 27103830 32408595 22
10 q25.2-q25.3 2,11 Loss 114358392 116466398 12
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UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
8 RARS RARS int-1 46,XY 1 p35.1 0,03 Loss 34043642 34076730 1 CSMD2 1,2
3 p14.2 0,10 Loss 61813257 61917627 1 PTPRG
9 RA RCMD low 46,XX no abberations 1,2
10 RAEBt RAEB2 int-2 46,XX no abberations 1,2
11 RARS RCMD-
RS
int-1 47,XX, +8 [6], 46,XX [4] 6 p25.2 0,04 Gain 2942543 2978804 1 NQO2 1,2
8 p23.3-q24.3 146,08 Gain 180568 146263538 >50
3 q26.2 0,06 Loss 170273620 170330795 1 EVI1
12 RA RA int-1 46,XY, -20, +mar 4 q12 0,22 Gain 56465465 56683501 2 EXOC1, CEP135 1,2,3
20 p11.1-q11.21 4,39 Gain 26027655 30419769 23
20 q13.2-qter 12,17 Gain 50205838 62376958 >50
20 p13-p11.1 25,92 Loss 17408 25938002 >50
20 q11.21-q13.2 19,72 Loss 30455952 50173696 >50
13 RAEB RAEB2 high 47,XY, +11 [5] / 46,XY [15] 1 p31.3 0,07 Gain 62192315 62261604 1 INADL 1,2
13 q32.3 0,18 Gain 99477577 99659263 1 PCCA
12 p12.3 0,08 Loss 16899069 16975264 0
14 RA RCMD int-1 46,XX, t(1;21)(q21;q22) no abberations 1,2
15 RAEBt AML high 46,XX no abberations 1,2
16 RARS RCMD-
RS
int-1 46,XY del (20)(q12) [6]/45X, -Y, del(20)(q12) [3]/ 
46XY [1]
20 q11.22-23 0,81 Gain 33421667 34236327 13 1,2
20 q11.23-q13.2 14,78 Loss 35391249 50173696 >50
21 q22.13-q22.2 0,48 Loss 38511815 38987776 2 KCNJ15, ERG
17 RAEB RAEB1 int-1 46,XY no abberations 1,2
18 RAEB-t RAEB2 int-2 46,XX 1 q31.2 0,20 Loss 189824778 190021009 0 1,2
19 RARS RCDM-
RS
low 46,XY, possibly abberation 13 [in 4/32] en -Y [in 
3/32]
X q27.1 0,42 Gain 139482978 139903522 1 CDR1 1,2
20 RAEB RAEB1 int-1 46,XY 1 p35.3 0,22 Gain 29023832 29244086 0 1,2,3
6 q15 0,13 Gain 90428707 90555860 0
6 q16.1 0,48 Gain 96718690 97201861 3 FUT9, KIAA0776, 
FHL5
21 RA RCMD int-1 46, XY 9 q22.1 0,45 Gain 89747998 90202303 2 CCRK, SPIN1 1,2
9 q22.31 0,58 Gain 93612061 94193550 7
2 q35 0,07 Loss 217399487 217467761 1 TNP1
3 p24.3 0,04 Loss 17003231 17045586 1 PLCL2
22 RAEBt AML high 47XY, +8 [5], 46XY [15] no abberations 1,2
23 RA RCMD int-1 46,XX/46X, Xq- 11 q12.2 0,10 Gain 60123089 60222990 1 C11orf64 1,2
X pter-p11.1 57,80 Gain 142664 58075602 >50
17 q25.1-q25.3 1,91 Loss 71568536 73478189 22
17 q25.2 0,22 Loss 72010995 72229750 6
X q11.2-q28 91,75 Loss 62794454 154500683 >50
24 RA 5q- low 46,XX,del(5)(q13q33) 7 q36.1-2 0,34 Gain 151950636 152292559 2 XRCC2, ACTR3B 1,2
5 q14.3-q33.3 72,52 Loss 83559251 156083322 >50
25 RAEB RAEB2 int-2 46,XX no abberations 1,2
26 RA/RAEB RA/
RAEB1
Int-2 46,XX,del(7)(q22),del(20)(q11)[17]/46,XX [3] 7 q21.3-36.2 59,06 Loss 94297190 153359077 >50 1,2
20 q11.21-q13.2 18,41 Loss 31058802 49469644 >50
21 q22.12 0,15 Loss 35234754 35386104 1 RUNX1 
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UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
8 RARS RARS int-1 46,XY 1 p35.1 0,03 Loss 34043642 34076730 1 CSMD2 1,2
3 p14.2 0,10 Loss 61813257 61917627 1 PTPRG
9 RA RCMD low 46,XX no abberations 1,2
10 RAEBt RAEB2 int-2 46,XX no abberations 1,2
11 RARS RCMD-
RS
int-1 47,XX, +8 [6], 46,XX [4] 6 p25.2 0,04 Gain 2942543 2978804 1 NQO2 1,2
8 p23.3-q24.3 146,08 Gain 180568 146263538 >50
3 q26.2 0,06 Loss 170273620 170330795 1 EVI1
12 RA RA int-1 46,XY, -20, +mar 4 q12 0,22 Gain 56465465 56683501 2 EXOC1, CEP135 1,2,3
20 p11.1-q11.21 4,39 Gain 26027655 30419769 23
20 q13.2-qter 12,17 Gain 50205838 62376958 >50
20 p13-p11.1 25,92 Loss 17408 25938002 >50
20 q11.21-q13.2 19,72 Loss 30455952 50173696 >50
13 RAEB RAEB2 high 47,XY, +11 [5] / 46,XY [15] 1 p31.3 0,07 Gain 62192315 62261604 1 INADL 1,2
13 q32.3 0,18 Gain 99477577 99659263 1 PCCA
12 p12.3 0,08 Loss 16899069 16975264 0
14 RA RCMD int-1 46,XX, t(1;21)(q21;q22) no abberations 1,2
15 RAEBt AML high 46,XX no abberations 1,2
16 RARS RCMD-
RS
int-1 46,XY del (20)(q12) [6]/45X, -Y, del(20)(q12) [3]/ 
46XY [1]
20 q11.22-23 0,81 Gain 33421667 34236327 13 1,2
20 q11.23-q13.2 14,78 Loss 35391249 50173696 >50
21 q22.13-q22.2 0,48 Loss 38511815 38987776 2 KCNJ15, ERG
17 RAEB RAEB1 int-1 46,XY no abberations 1,2
18 RAEB-t RAEB2 int-2 46,XX 1 q31.2 0,20 Loss 189824778 190021009 0 1,2
19 RARS RCDM-
RS
low 46,XY, possibly abberation 13 [in 4/32] en -Y [in 
3/32]
X q27.1 0,42 Gain 139482978 139903522 1 CDR1 1,2
20 RAEB RAEB1 int-1 46,XY 1 p35.3 0,22 Gain 29023832 29244086 0 1,2,3
6 q15 0,13 Gain 90428707 90555860 0
6 q16.1 0,48 Gain 96718690 97201861 3 FUT9, KIAA0776, 
FHL5
21 RA RCMD int-1 46, XY 9 q22.1 0,45 Gain 89747998 90202303 2 CCRK, SPIN1 1,2
9 q22.31 0,58 Gain 93612061 94193550 7
2 q35 0,07 Loss 217399487 217467761 1 TNP1
3 p24.3 0,04 Loss 17003231 17045586 1 PLCL2
22 RAEBt AML high 47XY, +8 [5], 46XY [15] no abberations 1,2
23 RA RCMD int-1 46,XX/46X, Xq- 11 q12.2 0,10 Gain 60123089 60222990 1 C11orf64 1,2
X pter-p11.1 57,80 Gain 142664 58075602 >50
17 q25.1-q25.3 1,91 Loss 71568536 73478189 22
17 q25.2 0,22 Loss 72010995 72229750 6
X q11.2-q28 91,75 Loss 62794454 154500683 >50
24 RA 5q- low 46,XX,del(5)(q13q33) 7 q36.1-2 0,34 Gain 151950636 152292559 2 XRCC2, ACTR3B 1,2
5 q14.3-q33.3 72,52 Loss 83559251 156083322 >50
25 RAEB RAEB2 int-2 46,XX no abberations 1,2
26 RA/RAEB RA/
RAEB1
Int-2 46,XX,del(7)(q22),del(20)(q11)[17]/46,XX [3] 7 q21.3-36.2 59,06 Loss 94297190 153359077 >50 1,2
20 q11.21-q13.2 18,41 Loss 31058802 49469644 >50
21 q22.12 0,15 Loss 35234754 35386104 1 RUNX1 
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UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
27 RARS RARS int-1 47,XY, +21 [7]/46XY [3] 9 p13.2 0,23 Gain 36489448 36717652 0 1,2
21 q22.11 0,24 Gain 34027879 34268175 2 ITSN1, ATP50
8 q22.1 0,12 Loss 93733795 93858178 0
15 q22.2 0,13 Loss 57997597 58122959 1 FOXB1
20 p11.23 0,05 Loss 19928024 19979632 3 RIN2, NAT5, 
CRNKL1
28 RAEB RAEB1 int-2 46,XX, +1, der ((1;7)(q10;p10) 1 q12-q44 103,85 Gain 142756696 247110269 >50 1,2
7 q11.21-q36.3 97,06 Loss 61740813 158798338 >50
29 RAEB RAEB2 int-2 46,XY 9 p24.3 1,14 Gain 1344499 2483292 1 SMARCA2 1,2
30 RAEB RAEB2 int-2 46,XY 6 p22.3 0,05 Loss 15515724 15564163 1 JARID2 1,2
13 q21.31 0,03 Loss 63497560 63530806 0
31 RARS RARS low 46,XY no abberations 1,2
32 RAEB RAEB2 high 47,XY, +8 [7],/47XY, +21 [8]/46XY [5] 3 p14.3 0,58 Gain 57434952 58015066 6 1,2
8 p23.2-q24.21 122,78 Gain 6047363 128823871 >50
21 q21.1-q22.3 37,01 Gain 9887804 46894358 >50
1 q41 0,00 Loss 213927087 213928502 1 USH2A
13 q32.3 0,02 Loss 99949768 99973880 1 PCCA
X q26.2-q26.3 1,30 Loss 133304184 134603832 12
33 RAEBt RAEB2 int-1 46XY, ?(17q) [7]/46XY [3] no abberations 1,2,3
34 RAEB-t RAEB2/
AML
int-2 46,XX 1 q21.3 0,58 Gain 151880407 152463750 12 1,2
2 p16.2 0,29 Gain 53968471 54257611 2 PSME4, ACYP2
7 p22.1 1,06 Gain 5662651 6720219 17
12 q24.31 2,17 Gain 119533318 121719778 31
22 q12.2 0,59 Gain 28135407 28723544 10
22 q12.2-3 1,90 Gain 29316172 31212808 27
2 p16.3 0,17 Loss 52128333 52295286 0
10 q11.23 0,01 Loss 49581707 49590614 1 WDFY4
18 q22.1 0,05 Loss 63985304 64034323 0
35 RA RCMD int-1 47,XY, +21, del(20)(q11) 14 q21.3 0,18 Gain 49624023 49807419 3 c14orf138, SOS2, 
L2HGDH
1,2
10 q21.3 0,14 Loss 68064862 68201848 1 CTNNA3
20 q11.21-q13.2 18,82 Loss 31204465 50029445 >50
36 RARS RCMD-
RS
low 46,XY no abberations 1,2
37 RAEBt AML int-2 46,XY no abberations 1,2
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UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
27 RARS RARS int-1 47,XY, +21 [7]/46XY [3] 9 p13.2 0,23 Gain 36489448 36717652 0 1,2
21 q22.11 0,24 Gain 34027879 34268175 2 ITSN1, ATP50
8 q22.1 0,12 Loss 93733795 93858178 0
15 q22.2 0,13 Loss 57997597 58122959 1 FOXB1
20 p11.23 0,05 Loss 19928024 19979632 3 RIN2, NAT5, 
CRNKL1
28 RAEB RAEB1 int-2 46,XX, +1, der ((1;7)(q10;p10) 1 q12-q44 103,85 Gain 142756696 247110269 >50 1,2
7 q11.21-q36.3 97,06 Loss 61740813 158798338 >50
29 RAEB RAEB2 int-2 46,XY 9 p24.3 1,14 Gain 1344499 2483292 1 SMARCA2 1,2
30 RAEB RAEB2 int-2 46,XY 6 p22.3 0,05 Loss 15515724 15564163 1 JARID2 1,2
13 q21.31 0,03 Loss 63497560 63530806 0
31 RARS RARS low 46,XY no abberations 1,2
32 RAEB RAEB2 high 47,XY, +8 [7],/47XY, +21 [8]/46XY [5] 3 p14.3 0,58 Gain 57434952 58015066 6 1,2
8 p23.2-q24.21 122,78 Gain 6047363 128823871 >50
21 q21.1-q22.3 37,01 Gain 9887804 46894358 >50
1 q41 0,00 Loss 213927087 213928502 1 USH2A
13 q32.3 0,02 Loss 99949768 99973880 1 PCCA
X q26.2-q26.3 1,30 Loss 133304184 134603832 12
33 RAEBt RAEB2 int-1 46XY, ?(17q) [7]/46XY [3] no abberations 1,2,3
34 RAEB-t RAEB2/
AML
int-2 46,XX 1 q21.3 0,58 Gain 151880407 152463750 12 1,2
2 p16.2 0,29 Gain 53968471 54257611 2 PSME4, ACYP2
7 p22.1 1,06 Gain 5662651 6720219 17
12 q24.31 2,17 Gain 119533318 121719778 31
22 q12.2 0,59 Gain 28135407 28723544 10
22 q12.2-3 1,90 Gain 29316172 31212808 27
2 p16.3 0,17 Loss 52128333 52295286 0
10 q11.23 0,01 Loss 49581707 49590614 1 WDFY4
18 q22.1 0,05 Loss 63985304 64034323 0
35 RA RCMD int-1 47,XY, +21, del(20)(q11) 14 q21.3 0,18 Gain 49624023 49807419 3 c14orf138, SOS2, 
L2HGDH
1,2
10 q21.3 0,14 Loss 68064862 68201848 1 CTNNA3
20 q11.21-q13.2 18,82 Loss 31204465 50029445 >50
36 RARS RCMD-
RS
low 46,XY no abberations 1,2
37 RAEBt AML int-2 46,XY no abberations 1,2
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UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
38 RAEB RAEB1 int-2 46,XX, ?del(12)(q23q24), del(20)(q11) [7]/46,XX, 
idem, del(5)(q15) [2]/ 46,XX [2]
2 p23.3 1,13 Gain 24121646 25249516 9 1,2
4 p15.33 0,26 Loss 14553996 14815436 1 CPEB2
6 p22.3 0,02 Loss 15515724 15532723 1 JARID2
6 p21.1 0,13 Loss 45520635 45645653 1 RUNX2
11 p15.3 0,12 Loss 11346019 11463667 1 GALTNL4
12 p12.3 0,08 Loss 16899069 16975264 0
13 q21.33 0,06 Loss 69587308 69643614 1 ATXN8OS
X q13.1 0,17 Loss 68747848 68914019 1 EDA
39 RAEB-t RAEB2 int-1 46,XY 1 q21.3 0,38 Gain 152088568 152463750 8 1,2
8 q24.21 0,13 Gain 130597259 130723928 0
40 RAEB RAEB2 high 46,XY, t(3;16)(q26;q2?3) [2]/ 46,XY [8] 7 p22.2 0,20 Gain 4298964 4495687 0 1,2
10 p11.23 0,43 Gain 30473297 30902186 3 MTPAP, MAP3K8, 
LOC729668
12 q23.2 0,06 Loss 101321326 101380604 1 IGF1
41 RA RARS int-1 47,XY, +19 [8]/46,XY [2] 19 p13.3-q13.43 63,52 Gain 212033 63731511 >50 1,2
X p21.1 0,63 Gain 35722446 36348491 2 CXorf22, CXorf30
42 RAEB RAEB1 int-1 46,XY no abberations 1,2
43 RA RCMD int-2 46,XX, del (5)(q13q33) [1]/45,XX, del(5)(q13q33), 
-7 [5]
no abberations 1,2
44 RAEB RAEB2 int-2 46,XY 8 q12.1 0,18 Gain 56860110 57045025 2 TGS1, LYN 1,2
9 p24.1 0,66 Gain 6212553 6868215 5 IL33, GLDC, 
UHRF2, TP-
D52L3, JMJD2C
18 q21.1 0,43 Gain 46524501 46951934 4 MRO, ME2, 
ELAC1, SMAD4
4 q24.23 0,83 Loss 105908963 106740191 2 TET2, PPA2
7 p22.3-q36.3 158,46 Loss 141322 158798338 >50
45 RAEB RAEB1 int-2 46,XX,del(5)(q13;q33),t(X;16)(p11;q24),   inv (12)
(p12q23)
5 q15-q33.2 58,24 Loss 96824371 155068532 >50 1,2
11 q25 0,05 Loss 130408303 130457358 0
46 RA RCMD low 46,XX no abberations 1,2
47 RAEBt AML int-1 46,XY 9 q21.33 0,56 Gain 87662476 88225190 4 MAK10, GOLM1, 
ISCA1, ZCCHC6
1,2
11 q12.1 0,31 Gain 57350416 57662037 2 OR6Q1, OR9I1
21 q22.12 0,15 Loss 35156070 35308597 1 RUNX1
48 RAEB RAEB2 int-2 46,XY 3 p24.3 0,08 Loss 17081031 17157701 1 PLCL2 1,2
49 RARS RCMD-
RS
int-1 46,XX no abberations 1,2
50 RA RCMD low 46,XY 12 q23.2 0,04 Loss 101338462 101380604 1 IGF1 1,2
52 RAEB RAEB1 int-1 46,XY, del (9)(q22q32) 9 q21.2-q31.1 23,26 Loss 78591021 101851030 >50 1,2
13 q31.3 0,01 Loss 93195621 93202489 1 GPC6
53 RAEB RAEB1 int-2 42,X, -Y,-5,-7,-17,-18,+mar1[5]/ 
43,idem,+mar2[2]/46,XY[3]
13 q32.1 0,23 Gain 94686683 94921466 2 ABCC4, CLDN10 1,2,3
5 p15.31-15.2 3,27 Loss 8822738 12088080 8
5 q11.1-q35.3 131,03 Loss 49596616 180629495 >50
7 p22.3-q36.3 158,46 Loss 141322 158798338 >50
18 p11.32-q23 75,91 Loss 210071 76115554 >50
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UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
38 RAEB RAEB1 int-2 46,XX, ?del(12)(q23q24), del(20)(q11) [7]/46,XX, 
idem, del(5)(q15) [2]/ 46,XX [2]
2 p23.3 1,13 Gain 24121646 25249516 9 1,2
4 p15.33 0,26 Loss 14553996 14815436 1 CPEB2
6 p22.3 0,02 Loss 15515724 15532723 1 JARID2
6 p21.1 0,13 Loss 45520635 45645653 1 RUNX2
11 p15.3 0,12 Loss 11346019 11463667 1 GALTNL4
12 p12.3 0,08 Loss 16899069 16975264 0
13 q21.33 0,06 Loss 69587308 69643614 1 ATXN8OS
X q13.1 0,17 Loss 68747848 68914019 1 EDA
39 RAEB-t RAEB2 int-1 46,XY 1 q21.3 0,38 Gain 152088568 152463750 8 1,2
8 q24.21 0,13 Gain 130597259 130723928 0
40 RAEB RAEB2 high 46,XY, t(3;16)(q26;q2?3) [2]/ 46,XY [8] 7 p22.2 0,20 Gain 4298964 4495687 0 1,2
10 p11.23 0,43 Gain 30473297 30902186 3 MTPAP, MAP3K8, 
LOC729668
12 q23.2 0,06 Loss 101321326 101380604 1 IGF1
41 RA RARS int-1 47,XY, +19 [8]/46,XY [2] 19 p13.3-q13.43 63,52 Gain 212033 63731511 >50 1,2
X p21.1 0,63 Gain 35722446 36348491 2 CXorf22, CXorf30
42 RAEB RAEB1 int-1 46,XY no abberations 1,2
43 RA RCMD int-2 46,XX, del (5)(q13q33) [1]/45,XX, del(5)(q13q33), 
-7 [5]
no abberations 1,2
44 RAEB RAEB2 int-2 46,XY 8 q12.1 0,18 Gain 56860110 57045025 2 TGS1, LYN 1,2
9 p24.1 0,66 Gain 6212553 6868215 5 IL33, GLDC, 
UHRF2, TP-
D52L3, JMJD2C
18 q21.1 0,43 Gain 46524501 46951934 4 MRO, ME2, 
ELAC1, SMAD4
4 q24.23 0,83 Loss 105908963 106740191 2 TET2, PPA2
7 p22.3-q36.3 158,46 Loss 141322 158798338 >50
45 RAEB RAEB1 int-2 46,XX,del(5)(q13;q33),t(X;16)(p11;q24),   inv (12)
(p12q23)
5 q15-q33.2 58,24 Loss 96824371 155068532 >50 1,2
11 q25 0,05 Loss 130408303 130457358 0
46 RA RCMD low 46,XX no abberations 1,2
47 RAEBt AML int-1 46,XY 9 q21.33 0,56 Gain 87662476 88225190 4 MAK10, GOLM1, 
ISCA1, ZCCHC6
1,2
11 q12.1 0,31 Gain 57350416 57662037 2 OR6Q1, OR9I1
21 q22.12 0,15 Loss 35156070 35308597 1 RUNX1
48 RAEB RAEB2 int-2 46,XY 3 p24.3 0,08 Loss 17081031 17157701 1 PLCL2 1,2
49 RARS RCMD-
RS
int-1 46,XX no abberations 1,2
50 RA RCMD low 46,XY 12 q23.2 0,04 Loss 101338462 101380604 1 IGF1 1,2
52 RAEB RAEB1 int-1 46,XY, del (9)(q22q32) 9 q21.2-q31.1 23,26 Loss 78591021 101851030 >50 1,2
13 q31.3 0,01 Loss 93195621 93202489 1 GPC6
53 RAEB RAEB1 int-2 42,X, -Y,-5,-7,-17,-18,+mar1[5]/ 
43,idem,+mar2[2]/46,XY[3]
13 q32.1 0,23 Gain 94686683 94921466 2 ABCC4, CLDN10 1,2,3
5 p15.31-15.2 3,27 Loss 8822738 12088080 8
5 q11.1-q35.3 131,03 Loss 49596616 180629495 >50
7 p22.3-q36.3 158,46 Loss 141322 158798338 >50
18 p11.32-q23 75,91 Loss 210071 76115554 >50
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54 RAEB RAEB2 high 46,XX, t(6;9)(p23;q34) 18 q12.1 0,13 Loss 29450139 29578054 1 ASXL3 1,2
18 q22.1 0,03 Loss 64003187 64034323 0
55 RA RA int-1 46,XX, t(3;3)(q21;q26) [6]/ 46XX [4] 2 q24.3 0,11 Loss 166903186 167012202 1 SCN7A 1,2
56 RA RCMD int-1 46,XX 1 p21.1 0,10 Loss 105679389 105776622 0 1,2
57 RAEB RAEB2 Int-2 46,XY 12 q23.2 0,03 Loss 101321326 101351175 1 IGF1 1,2
58 RAEB RAEB2 high 46,XX, del (1)(q11), del(5)(q14q34), -7, -18, +mar1, 
+mar2 [10], 55,XX, idem, +del(5)(q14q34), +8, +9, 
+10, +11, +14, +15, +21, +22 [9]/ 46,XX [1]
1 q22-23.1 1,33 Gain 153918705 155250725 33 1,2
22 q12.2 0,26 Gain 28025929 28290335 8
1 p31.2 0,93 Loss 65709653 66640400 2 LEPR, PDE4B
1 p31.2-p22.2 21,38 Loss 67182626 88561025 >50
1 p22.1-22.3 2,82 Loss 93955123 96779720 10
1 p13.2-3 2,59 Loss 110106932 112699113 29
5 q21.3-q35.2 68,00 Loss 107276507 175279396 >50
7 p15.3 0,43 Loss 22010967 22445643 1 RAPGEF5
7 p12.3-q36.3 109,52 Loss 49280157 158798338 >50
18 q11.2-q23 55,77 Loss 20348828 76115554 >50
59 RAEB RAEB1 int-2 45,XX, -7 [9], 46XX [1] 1 q41 0,03 Loss 213927087 213954109 1 USH2A 1,2
7 p22.3-q36.3 158,46 Loss 141322 158798338 >50
60 RARS RCMD-
RS





12 q21.32 0,03 Loss 87344571 87370350 0
61 RARS RCMD-
RS
low 46,XY no abberations 1,2
62 RARS RCMD-
RS
low 46,XX 2 p22.3 0,81 Gain 32134203 32942048 4 SPAST, NLRC4, 
YIPF4, BIRC6
1,2
2 q23.3 0,20 Loss 154085999 154290496 0
63 RARS RCMD-
RS
low 46,XY 1 p35.1 0,01 Loss 34056481 34067461 1 CSMD2 1,2
9 q31.1 1,93 Loss 103835445 105762025 1 CYLC2
64 RAEB RAEB2 high 43~46,?Y,add (X)(q28),-5,-6,del(7)(q22?), 
-10,-11,-12,-17,+15,+21,+mar1-3[16]/46,XY[4]
5 p13.2-13.1 2,07 Loss 37334638 39400231 8 1,2,3
5 q12.1-q12.3 3,34 Loss 60882776 64218736 9
5 q12.3-q13.2 5,76 Loss 65200747 70959114 29
5 q13.3-q35.3 105,43 Loss 75197159 180629495 >50
6 p22.3 5,04 Loss 15481631 20522665 15
6 p22.3 1,28 Loss 22055196 23338700 0
7 q11.21-q36.3 97,06 Loss 61740813 158798338 >50
10 q11.21-11.22 7,17 Loss 42155347 49321754 40
12 p13.33-q14.1 61,06 Loss 50446 61106231  
12 q21.31-q23.1 18,24 Loss 81443995 99681334 >50
12 q23.3-q24.33 25,95 Loss 106454871 132287718 >50
17 p13.3-q11.1 22,01 Loss 18901 22029237 >50
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54 RAEB RAEB2 high 46,XX, t(6;9)(p23;q34) 18 q12.1 0,13 Loss 29450139 29578054 1 ASXL3 1,2
18 q22.1 0,03 Loss 64003187 64034323 0
55 RA RA int-1 46,XX, t(3;3)(q21;q26) [6]/ 46XX [4] 2 q24.3 0,11 Loss 166903186 167012202 1 SCN7A 1,2
56 RA RCMD int-1 46,XX 1 p21.1 0,10 Loss 105679389 105776622 0 1,2
57 RAEB RAEB2 Int-2 46,XY 12 q23.2 0,03 Loss 101321326 101351175 1 IGF1 1,2
58 RAEB RAEB2 high 46,XX, del (1)(q11), del(5)(q14q34), -7, -18, +mar1, 
+mar2 [10], 55,XX, idem, +del(5)(q14q34), +8, +9, 
+10, +11, +14, +15, +21, +22 [9]/ 46,XX [1]
1 q22-23.1 1,33 Gain 153918705 155250725 33 1,2
22 q12.2 0,26 Gain 28025929 28290335 8
1 p31.2 0,93 Loss 65709653 66640400 2 LEPR, PDE4B
1 p31.2-p22.2 21,38 Loss 67182626 88561025 >50
1 p22.1-22.3 2,82 Loss 93955123 96779720 10
1 p13.2-3 2,59 Loss 110106932 112699113 29
5 q21.3-q35.2 68,00 Loss 107276507 175279396 >50
7 p15.3 0,43 Loss 22010967 22445643 1 RAPGEF5
7 p12.3-q36.3 109,52 Loss 49280157 158798338 >50
18 q11.2-q23 55,77 Loss 20348828 76115554 >50
59 RAEB RAEB1 int-2 45,XX, -7 [9], 46XX [1] 1 q41 0,03 Loss 213927087 213954109 1 USH2A 1,2
7 p22.3-q36.3 158,46 Loss 141322 158798338 >50
60 RARS RCMD-
RS





12 q21.32 0,03 Loss 87344571 87370350 0
61 RARS RCMD-
RS
low 46,XY no abberations 1,2
62 RARS RCMD-
RS
low 46,XX 2 p22.3 0,81 Gain 32134203 32942048 4 SPAST, NLRC4, 
YIPF4, BIRC6
1,2
2 q23.3 0,20 Loss 154085999 154290496 0
63 RARS RCMD-
RS
low 46,XY 1 p35.1 0,01 Loss 34056481 34067461 1 CSMD2 1,2
9 q31.1 1,93 Loss 103835445 105762025 1 CYLC2
64 RAEB RAEB2 high 43~46,?Y,add (X)(q28),-5,-6,del(7)(q22?), 
-10,-11,-12,-17,+15,+21,+mar1-3[16]/46,XY[4]
5 p13.2-13.1 2,07 Loss 37334638 39400231 8 1,2,3
5 q12.1-q12.3 3,34 Loss 60882776 64218736 9
5 q12.3-q13.2 5,76 Loss 65200747 70959114 29
5 q13.3-q35.3 105,43 Loss 75197159 180629495 >50
6 p22.3 5,04 Loss 15481631 20522665 15
6 p22.3 1,28 Loss 22055196 23338700 0
7 q11.21-q36.3 97,06 Loss 61740813 158798338 >50
10 q11.21-11.22 7,17 Loss 42155347 49321754 40
12 p13.33-q14.1 61,06 Loss 50446 61106231  
12 q21.31-q23.1 18,24 Loss 81443995 99681334 >50
12 q23.3-q24.33 25,95 Loss 106454871 132287718 >50
17 p13.3-q11.1 22,01 Loss 18901 22029237 >50
104
Chapter 3
UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
65 RARS RARS low 46,XX 2 q13 0,43 Gain 112666184 113098605 4 ZC3H8, ZC3H6, 
TTL, POLR1B
1,2
9 q21.11 0,14 Gain 70861066 70996190 2 FXN, TJP2
11 q13.4 0,29 Gain 73188293 73477649 5 MRPL48, CH-
CHD8, UCP2, 
UCP3, C2CD3
11 q14.1-2 0,22 Gain 85272986 85497725 1 PICALM
20 q11.22-23 2,59 Gain 31511054 34103073 38
22 q13.1-2 0,96 Gain 38930433 39888178 10
1 q41 0,03 Loss 213927087 213959926 1 USH2A
16 q23.3 0,06 Loss 80717166 80780421 1 MPHOSPH6
18 q12.3 0,08 Loss 39201389 39276981 0
66 RA RCMD int-1 47,XY, +8 [5]/ 46,XY [5] 8 p23.2-1 0,14 Gain 6116508 6257591 1 MCPH1 1,2,3
5 q21.1 0,07 Loss 102105029 102170530 0
12 p13.2 0,17 Loss 11771243 11939631 1 ETV6
67 RARS RCMD-
RS
low 46,XY no abberations 1,2,3
68 RAEBt RAEB2 high 46-48 XY, -5,-7, t(12;12)(p13;q22), add (21)(q22), 
-22x2, +r1, +r2, +r2, +mar1, +mar2, +mar3, +mar3 
[cp9]/46,XY [1]




21 q22.13-2 2,53 Gain 36927512 39459104 13
21 q22.2 0,62 Gain 40566752 41185373 1 DSCAM
21 q22.2-3 0,89 Gain 41215523 42109613 10
21 q22.3 3,63 Gain 42159278 45789927 >50
22 complex pattern
5 p12-qter 131,03 Loss 49596616 180629495 >50
6 q21 2,24 Loss 106097724 108338935 10
6 q21 0,14 Loss 109064223 109206411 1 FOXO3
7 q11.22-q21.11 11,71 Loss 68428002 80136823 >50
7 q21.11-q21.12 2,11 Loss 84526794 86638287 4 SEMA3D, GRM3, 
KIAA1324L, 
DMTF
7 q21.12-q21.3 9,96 Loss 86981089 96941847 48
7 q22.1-q36.3 59,50 Loss 99298043 158798338 >50
12 p12.3 2,10 Loss 15551848 17655985 6
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65 RARS RARS low 46,XX 2 q13 0,43 Gain 112666184 113098605 4 ZC3H8, ZC3H6, 
TTL, POLR1B
1,2
9 q21.11 0,14 Gain 70861066 70996190 2 FXN, TJP2
11 q13.4 0,29 Gain 73188293 73477649 5 MRPL48, CH-
CHD8, UCP2, 
UCP3, C2CD3
11 q14.1-2 0,22 Gain 85272986 85497725 1 PICALM
20 q11.22-23 2,59 Gain 31511054 34103073 38
22 q13.1-2 0,96 Gain 38930433 39888178 10
1 q41 0,03 Loss 213927087 213959926 1 USH2A
16 q23.3 0,06 Loss 80717166 80780421 1 MPHOSPH6
18 q12.3 0,08 Loss 39201389 39276981 0
66 RA RCMD int-1 47,XY, +8 [5]/ 46,XY [5] 8 p23.2-1 0,14 Gain 6116508 6257591 1 MCPH1 1,2,3
5 q21.1 0,07 Loss 102105029 102170530 0
12 p13.2 0,17 Loss 11771243 11939631 1 ETV6
67 RARS RCMD-
RS
low 46,XY no abberations 1,2,3
68 RAEBt RAEB2 high 46-48 XY, -5,-7, t(12;12)(p13;q22), add (21)(q22), 
-22x2, +r1, +r2, +r2, +mar1, +mar2, +mar3, +mar3 
[cp9]/46,XY [1]




21 q22.13-2 2,53 Gain 36927512 39459104 13
21 q22.2 0,62 Gain 40566752 41185373 1 DSCAM
21 q22.2-3 0,89 Gain 41215523 42109613 10
21 q22.3 3,63 Gain 42159278 45789927 >50
22 complex pattern
5 p12-qter 131,03 Loss 49596616 180629495 >50
6 q21 2,24 Loss 106097724 108338935 10
6 q21 0,14 Loss 109064223 109206411 1 FOXO3
7 q11.22-q21.11 11,71 Loss 68428002 80136823 >50
7 q21.11-q21.12 2,11 Loss 84526794 86638287 4 SEMA3D, GRM3, 
KIAA1324L, 
DMTF
7 q21.12-q21.3 9,96 Loss 86981089 96941847 48
7 q22.1-q36.3 59,50 Loss 99298043 158798338 >50
12 p12.3 2,10 Loss 15551848 17655985 6
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69 RAEB RAEB1 int-2 58,XY, +1, +2, +8, +9, +10, +11, +13, +14, +20, +21, 
+21, add (22)(p13), +mar1 [10]
1 p36.33-q44 243,22 Gain 2095738 247110269 >50 1,2
2 p25.3-q37.3 242,69 Gain 24049 242650580 >50
8 p23.3-q24.3 146,08 Gain 180568 146263538 >50
9 pter-q31.1 103,17 Gain 30910 105160491 >50
9 q31.1-qter 34,63 Gain 105638843 140147760 >50
10 p15.3-q26.13 126,80 Gain 148946 126946025 >50
11 p15.5-q25 134,24 Gain 201447 134439182 >50
13 q11-q34 96,13 Gain 17960319 114092980 >50
14 q11.2-q32.33 86,85 Gain 19502641 106356482 >50
20 p13-q13.33 62,36 Gain 17408 62376958 >50
21 p11.2-q22.3 36,63 Gain 9887804 46522771 >50
22 q11.1-q13.33 35,02 Gain 14441016 49522492 >50
16 p13.2 0,10 Loss 6974942 7073249 1 A2BP1
71 RAEB RAEB 2 int-2 46,XY 7 p12.3 0,03 Loss 48496055 48527687 1 ABCA13 1,2
8 q24.22 0,07 Loss 131905912 131972316 1 ADCY8
10 p14 0,02 Loss 11132318 11152680 1 CUGBP2
10 q23.31 0,38 Loss 91579028 91962828 0
11 p14.1 0,04 Loss 30699318 30737507 0
72 RAEB RAEB 1 int-1 46,XY 1 p31.1 0,05 Loss 82832295 82881647 0 1,2
73 RAEB RAEB 1 int-1 47, XX, +8 [7]/46,XX [3] 8 p23.3-p12 35,94 Gain 180568 36115976 >50 1,2
8 p12-q24.3 110,07 Gain 36196622 146263538 >50
2 p16.3 0,12 Loss 50817046 50934328 1 NRXN1
74 RAEBt AML high 46,XY 15 q21.1 0,06 Loss 45864214 45920576 0 1,2
18 q12.1 0,05 Loss 29473233 29527498 1 ASXL3
75 RAEB RAEB1 int-1 46,XY no abberations 1,2
76 RAEB t AML high 45,XX, del(5), -7 7 p22.3-p22.2 1,32 Gain 1969259 3293525 10 1,2
8 p11.22-q24.3 106,64 Gain 39624983 146263538 >50
5 p13.2-p13.1 1,39 Loss 38183243 39568994 7
5 q15-q34 70,62 Loss 94248164 164864377 >50
7 p21.3 3,10 Loss 7501906 10605336 6
7 p21.2-q36.3 143,63 Loss 15171632 158798338 >50
8 p23.3-p22 16,28 Loss 1134406 17415901 >50
12 p13.2-p12.1 13,44 Loss 11892519 25336389 >50
12 p12.1-p11.1 8,69 Loss 25362747 34051454 30
16 q12.1-q22.1 16,41 Loss 50943957 67352875 >50
16 q22.2-q24.3 18,12 Loss 70572907 88690776 >50
20 p13-p11.23 18,63 Loss 17408 18645665 >50






low 46,XX no abberations 1,2
79 RARS RCMD-
RS
int-1 46,XY 7 p21.2-p21.1 0,47 Gain 14762273 15229190 1 DGKB 1,2
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69 RAEB RAEB1 int-2 58,XY, +1, +2, +8, +9, +10, +11, +13, +14, +20, +21, 
+21, add (22)(p13), +mar1 [10]
1 p36.33-q44 243,22 Gain 2095738 247110269 >50 1,2
2 p25.3-q37.3 242,69 Gain 24049 242650580 >50
8 p23.3-q24.3 146,08 Gain 180568 146263538 >50
9 pter-q31.1 103,17 Gain 30910 105160491 >50
9 q31.1-qter 34,63 Gain 105638843 140147760 >50
10 p15.3-q26.13 126,80 Gain 148946 126946025 >50
11 p15.5-q25 134,24 Gain 201447 134439182 >50
13 q11-q34 96,13 Gain 17960319 114092980 >50
14 q11.2-q32.33 86,85 Gain 19502641 106356482 >50
20 p13-q13.33 62,36 Gain 17408 62376958 >50
21 p11.2-q22.3 36,63 Gain 9887804 46522771 >50
22 q11.1-q13.33 35,02 Gain 14441016 49522492 >50
16 p13.2 0,10 Loss 6974942 7073249 1 A2BP1
71 RAEB RAEB 2 int-2 46,XY 7 p12.3 0,03 Loss 48496055 48527687 1 ABCA13 1,2
8 q24.22 0,07 Loss 131905912 131972316 1 ADCY8
10 p14 0,02 Loss 11132318 11152680 1 CUGBP2
10 q23.31 0,38 Loss 91579028 91962828 0
11 p14.1 0,04 Loss 30699318 30737507 0
72 RAEB RAEB 1 int-1 46,XY 1 p31.1 0,05 Loss 82832295 82881647 0 1,2
73 RAEB RAEB 1 int-1 47, XX, +8 [7]/46,XX [3] 8 p23.3-p12 35,94 Gain 180568 36115976 >50 1,2
8 p12-q24.3 110,07 Gain 36196622 146263538 >50
2 p16.3 0,12 Loss 50817046 50934328 1 NRXN1
74 RAEBt AML high 46,XY 15 q21.1 0,06 Loss 45864214 45920576 0 1,2
18 q12.1 0,05 Loss 29473233 29527498 1 ASXL3
75 RAEB RAEB1 int-1 46,XY no abberations 1,2
76 RAEB t AML high 45,XX, del(5), -7 7 p22.3-p22.2 1,32 Gain 1969259 3293525 10 1,2
8 p11.22-q24.3 106,64 Gain 39624983 146263538 >50
5 p13.2-p13.1 1,39 Loss 38183243 39568994 7
5 q15-q34 70,62 Loss 94248164 164864377 >50
7 p21.3 3,10 Loss 7501906 10605336 6
7 p21.2-q36.3 143,63 Loss 15171632 158798338 >50
8 p23.3-p22 16,28 Loss 1134406 17415901 >50
12 p13.2-p12.1 13,44 Loss 11892519 25336389 >50
12 p12.1-p11.1 8,69 Loss 25362747 34051454 30
16 q12.1-q22.1 16,41 Loss 50943957 67352875 >50
16 q22.2-q24.3 18,12 Loss 70572907 88690776 >50
20 p13-p11.23 18,63 Loss 17408 18645665 >50






low 46,XX no abberations 1,2
79 RARS RCMD-
RS
int-1 46,XY 7 p21.2-p21.1 0,47 Gain 14762273 15229190 1 DGKB 1,2
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80 RARS RARS int-1 47,XY, +8 [4]/46,XY [6] 8 p23.3-q24.3 146,05 Gain 180568 146225933 >50 1,2
11 p11.2-q14.1 32,55 Gain 44984291 77533005 >50
13 q14.3-q31.3 41,25 Loss 52538263 93786901 43
13 q33.1-q34 11,73 Loss 102330199 114063361 32
81 RA RCMD Int-1 46,XX 1 q25.2 0,02 Loss 178024667 178040788 0 1,2
83 RA MDS-U low 46,XY 11 q22.3 0,24 Gain 107129408 107368940 1 SLC35F2 1,2
84 RA RA low 46,XX no abberations 1,2
85 RA RA Int-1 46, XY 11 q22.3 0,05 Gain 107198330 107252235 1 SLC35F2 1,2
86 RA RA low 46,XY 20 p11.21 0,12 Loss 25277915 25399180 3 ABHD12, GINS1, 
NLP
1,2
87 RA RA low 46,XY 7 q36.1 0,13 Loss 148058806 148191991 2 CUL1, EZH2 1,2
14 q23.3 0,04 Loss 65268892 65309210 1 FUT8
88 RA RA low 46,XX 14 q32.32 0,34 Gain 102137865 102481588 4 RCOR1, TRAF3, 
AMN, CDC42BPB
1,2
89 RA RA low 46,XY 4 q32.3 0,47 Gain 167421392 167895140 1 SPOCK 1,2
10 p15.1 0,01 Loss 3826471 3840780 0
90 RA RA low 46,XY 3 p24.2 0,07 Loss 26613719 26679147 0 1,2
3 q26.1 0,17 Loss 165712710 165881821 0
91 RA RA low 46,XX no abberations 1,2
92 RA RCMD low 46, XY 18 q21.1 0,01 Loss 46365043 46378713 1 MAPK4 1,2
93 RA RCMD Int-1 46,XY 13 q34 0,91 Gain 110741933 111649459 1 ARHGEF7 1,2
14 q23.3 0,02 Loss 64257847 64281211 1 PLEKHG3
94 RA RCMD Int-1 46, XX 9 q33.3 2,21 Gain 125385926 127597542 15 1,2
96 RA RCMD low 46,XX no abberations 1,2
97 RA RCMD Int-1 46,XY 21 q22.11-12 1,83 Loss 34506950 36333250 9 1,2
98 RA RCMD low 46,XY 3 p24.2 0,07 Loss 26613719 26679147 0 1,2
18 q21.1 0,00 Loss 46365043 46365939 1 MAPK4
99 RA RCMD low 46,XY 15 q14 0,18 Gain 36987323 37167451 0 1,2
2 p12 0,02 Loss 77088727 77105708 1 LRRTM4
12 p13.32 0,03 Loss 3307020 3333041 0
18 q12.1 0,00 Loss 28553357 28554420 0
100 RA RCMD low 46, XY 4 p15.2 0,09 Gain 25116956 25203433 0 1,2
102 RA RCMD low 46, XY 14 q13.1-q13.2 1,29 Gain 34118096 35403781 9 1,2
103 RAEB RAEB1 int-1 46,XX no abberations 1,2
104 RAEBt AML high 43-48, XY, -5 [14], +4 [5], -4 [2], +18 [5], t(11;17) 
[11], t(21;21) [2] 
5 complex pattern 1,2
7 q22.1-q31.33 23,75 Gain 100719050 124467674 >50
8 p22-q24.3 127,47 Gain 18793861 146263538 >50
14 q13.1-q13.2 0,74 Gain 34118096 34857861 6
21 p11.2-q22.3 37,01 Gain 9887804 46894358 >50
6 p25.3-p24.1 12,58 Loss 119769 12701540 >50
7 q31.33-q36.3 34,32 Loss 124481081 158798338 >50
15 q14 3,85 Loss 32680396 36528251 8
15 q15.1 1,66 Loss 38336909 39998311 32
17 p13.3-q25.3 78,58 Loss 18901 78599918 >50
22 q11.21 1,11 Loss 18496182 19607471 13
105 RAEBt RAEB2 int-2 46, XY 14 q13.1-q13.2 0,98 Gain 34035039 35018769 8 1,2
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UPN FAB WHO IPSS Cytogenetics Chr Cytoband Size (Mb) Type start end Ref Seq genes 
(validated)
Genes Reference
80 RARS RARS int-1 47,XY, +8 [4]/46,XY [6] 8 p23.3-q24.3 146,05 Gain 180568 146225933 >50 1,2
11 p11.2-q14.1 32,55 Gain 44984291 77533005 >50
13 q14.3-q31.3 41,25 Loss 52538263 93786901 43
13 q33.1-q34 11,73 Loss 102330199 114063361 32
81 RA RCMD Int-1 46,XX 1 q25.2 0,02 Loss 178024667 178040788 0 1,2
83 RA MDS-U low 46,XY 11 q22.3 0,24 Gain 107129408 107368940 1 SLC35F2 1,2
84 RA RA low 46,XX no abberations 1,2
85 RA RA Int-1 46, XY 11 q22.3 0,05 Gain 107198330 107252235 1 SLC35F2 1,2
86 RA RA low 46,XY 20 p11.21 0,12 Loss 25277915 25399180 3 ABHD12, GINS1, 
NLP
1,2
87 RA RA low 46,XY 7 q36.1 0,13 Loss 148058806 148191991 2 CUL1, EZH2 1,2
14 q23.3 0,04 Loss 65268892 65309210 1 FUT8
88 RA RA low 46,XX 14 q32.32 0,34 Gain 102137865 102481588 4 RCOR1, TRAF3, 
AMN, CDC42BPB
1,2
89 RA RA low 46,XY 4 q32.3 0,47 Gain 167421392 167895140 1 SPOCK 1,2
10 p15.1 0,01 Loss 3826471 3840780 0
90 RA RA low 46,XY 3 p24.2 0,07 Loss 26613719 26679147 0 1,2
3 q26.1 0,17 Loss 165712710 165881821 0
91 RA RA low 46,XX no abberations 1,2
92 RA RCMD low 46, XY 18 q21.1 0,01 Loss 46365043 46378713 1 MAPK4 1,2
93 RA RCMD Int-1 46,XY 13 q34 0,91 Gain 110741933 111649459 1 ARHGEF7 1,2
14 q23.3 0,02 Loss 64257847 64281211 1 PLEKHG3
94 RA RCMD Int-1 46, XX 9 q33.3 2,21 Gain 125385926 127597542 15 1,2
96 RA RCMD low 46,XX no abberations 1,2
97 RA RCMD Int-1 46,XY 21 q22.11-12 1,83 Loss 34506950 36333250 9 1,2
98 RA RCMD low 46,XY 3 p24.2 0,07 Loss 26613719 26679147 0 1,2
18 q21.1 0,00 Loss 46365043 46365939 1 MAPK4
99 RA RCMD low 46,XY 15 q14 0,18 Gain 36987323 37167451 0 1,2
2 p12 0,02 Loss 77088727 77105708 1 LRRTM4
12 p13.32 0,03 Loss 3307020 3333041 0
18 q12.1 0,00 Loss 28553357 28554420 0
100 RA RCMD low 46, XY 4 p15.2 0,09 Gain 25116956 25203433 0 1,2
102 RA RCMD low 46, XY 14 q13.1-q13.2 1,29 Gain 34118096 35403781 9 1,2
103 RAEB RAEB1 int-1 46,XX no abberations 1,2
104 RAEBt AML high 43-48, XY, -5 [14], +4 [5], -4 [2], +18 [5], t(11;17) 
[11], t(21;21) [2] 
5 complex pattern 1,2
7 q22.1-q31.33 23,75 Gain 100719050 124467674 >50
8 p22-q24.3 127,47 Gain 18793861 146263538 >50
14 q13.1-q13.2 0,74 Gain 34118096 34857861 6
21 p11.2-q22.3 37,01 Gain 9887804 46894358 >50
6 p25.3-p24.1 12,58 Loss 119769 12701540 >50
7 q31.33-q36.3 34,32 Loss 124481081 158798338 >50
15 q14 3,85 Loss 32680396 36528251 8
15 q15.1 1,66 Loss 38336909 39998311 32
17 p13.3-q25.3 78,58 Loss 18901 78599918 >50
22 q11.21 1,11 Loss 18496182 19607471 13
105 RAEBt RAEB2 int-2 46, XY 14 q13.1-q13.2 0,98 Gain 34035039 35018769 8 1,2
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Supplementary Table 2: Regions of segmental telomeric uniparental disomy in 102 MDS patients 
*  The column ‘Reference’ indicates which reference was used to exclude normal copy number variations. 1 = SNP-array ana-
lysis of individually hybridized DNA from 1015 healthy controls, 2= SNP-array analysis of DNA from pool of 10 healthy 
individuals hybridized simultaneously with SNP-arrays of respective MDS patients, 3= T-cells of the respective MDS pa-
tient. In addition, we compared our data with the data published in ‘the database of genomic variants’ as indicated in the 
methods section.
** No statistically significant correlation was seen between the occurrence of UPD in specific regions and the clinical phenotype.
UPN FAB WHO IPSS Cytogenetics Chr. Cytoband Size 
(Mb)





33 RAEBt RAEB2 int-1 46,XY, ?(17q) 
[7]/46,XY [3]
6 p25.3-p21.2 36,58 273303 36849394 >50 1,2,3
52 RAEBt RAEB1 int-1 46,XY, del (9)
(q22q32)
4 q13.1-q35.2 125,22 64853829 190069644 >50 1,2









17 p13.3-p11.2 21,75 18901 21768021 >50 1,2
73 RAEB RAEB1 int-1 47,XX,+8[7]/
46,XX[3]
4 q12-q35.2 137,50 53370091 190870267 >50 1,2
74 RAEBt AML high 46,XY 4 q23-q35.2 89,79 100281453 190069644 >50 1,2
97 RA RCMD int-1 46,XY 7 q11.21-q36.3 95,88 61740813 157619927 >50 1,2
100 RA RCMD low 46,XY 4 q22.3-q35.2 94,02 97149541 191167888 >50 1,2
103 RAEB RAEB1 int-1 46,XX 7 q21.2-q36.3 66,63 92133353 158765589 >50 1,2
105 RAEBt RAEB2 int-2 46,XY 1 p36.33-p35.3 25,95 2095738 28045984 >50 1,2
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Supplementary Table 3: Identified SNPs in the coding sequence of TET2 in MDS patients and controls
Substitu-
tion


















in 2 cohorts 
(n=206)       %
c.A5284G rs2454206 ns p.I1762V 67 (66) 59 (57) 18 (67) 61
c.T5162G rs34402524 ns p.L1721W 18 (18) 24 (23) 5 (19) 20
c.G5103A rs62623390 ns p.M1701I 3 (2.9) 1 (0.96) 2 (7.4) 1.9
c.A5333G rs62621450 ns p.H1778R 4 (3.9) 5 (4.8) 1 (3.7) 4.4
c.G3513A s 1 (0.98) 2 (1.9) 0 (0) 1.5
c.C100T ns p.L34F 4 (3.9) 1 (0.96) 1 (3.7) 2.4
c.G1064A rs61744960 ns p.G355D 12 (12) 12 (12) 3 (11) 12
c.C1088T rs17253672 ns p.P363L 11 (11) 7(6.7) 2 (7.4) 8,7
c.C86G rs12498609 ns p.P29R 3 (2.9) 4 (3.8) 1 (3.7) 3.4
c.G652A rs6843131 ns p.V218M 4 (3.9) 4 (3.8) 1 (3.7) 3.9
c.T2599C ns p.Y867H 1 (0.98) 3 (2.9) 0 (0) 1.9
c.C5167T ns p.P1723S 1 (0.98) 3 (2.9) 0 (0) 1.9
c.A2771G rs34485921 ns p.H924R 0 (0) 1 (0.96) 0 (0) 0.5
c.G3117A rs3796927 s 0 (0) 2 (1.9) 0 (0) 1.0
c.G368A ns p.R123H 0 (0) 1 (0.96) 0 (0) 0.5
c.G1285A ns p.G429R 0 (0) 1 (0.96) 0 (0) 0.5
c.A2846G ns p.H949R 0 (0) 1 (0.96) 0 (0) 0.5
c.A3251C ns p.Q1084P 0 (0) 1 (0.96) 0 (0) 0.5
c.T4140C rs3733609 s 0 (0) 2 (0.96) 0 (0) 1.0




Supplementary Table 4: Characteristics of myelopoiesis in peripheral blood used for expression analysis in 
granulocytes
Patient FAB/WHO Peripheral blood microscopy of myelopoiesis
Quantitative 
(% of total peripheral blood cells)
Qualitative
1 RARS/RCMD-RS 2% metamyelocytes, 39% band 
granulocytes, 1% eosinophilic 
granulocytes
Hyper- and hypogranulation, Pelger-
Huet anomaly, abnormal nuclear 
chromatin
2 RA/5q- syndrome  1% promyelocytes, 9% myelocytes, 4% 
metamyelocytes, 8% band granulocytes, 
51% segmented granulocytes
Decreased myelopoiesis, 
hypogranulation, abnormal nuclear 
chromatin, vacuolization
3 RA/RA 2% band granulocytes, 51% segmented 
granulocytes, 8% basophilic granulocytes, 
9% eosinophilic granulocytes
Hypogranulation, abnormal nuclear 
chromatin, vacuolization
4 RA/RCMD 1% band granulocytes, 43% segmented 
granulocytes, 1% basophilic granulocytes
Hypogranulation, vacuolization
5 RA/RA 1% myelocytes, 1% metamyelocytes, 
2% band granulocytes, 72% segmented 
granulocytes, 2% eosinophilic 
granulocytes
Hypogranulation, Pelger-Huet 
anomaly, abnormal nuclear 
chromatin, vacuolization
6 RAEBt/AML 14% myeloblasts, 3% myelocytes, 3% 
metamyelocytes, 10% band granulocytes, 
11% segmented granulocytes, 1% 
basophilic granulocytes, 3% eosinophilic 
granulocytes
Hypogranulation, abnormal nuclear 
chromatin
7 RAEB/RAEB1 1% blasts, 1% promyelocytes, 2% 
myelocytes, 3% metamyelocytes, 10% 
band granulocytes, 54% segmented 




anomaly, abnormal nuclear chromatin
8 RAEB/RAEB1 not available not available
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Supplementary Table 5: Allelic burden of TET2 mutations in MDS
5a: Comparison of allelic burden of TET2 mutations using pyrosequencing and chromosomal abnormalities using 
SNP-array analysis in 5 MDS patients.
UPN* abnormality location % of affected cells**
11 missense mutation c.5643T>G 60
duplication Chr. 8 80
52 missense mutation c.2526C>A 80
deletion 9q21.2-q31.1 70
59 missense mutation c.1516A>T 66
deletion Chr. 7 74
73 missense mutation c.3871T>C 100
duplication Chr. 8 73




* All patients with TET2 mutations for which allelic burden was determined and which carried additional chromosomal ab-
normalities are included in this comparison. **Allelic burden of TET2 mutation were as described in Supplementary Table 5b. 
For calculation of the percentage of affected cells in large chromosomal abnormalities we used the log2 test-over-reference ratio’s 
of chromosome X in sex-mismatched reference selections as a representative of a copy number change in all cells. 
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5b: Allelic burden of TET2 mutations in MDS measured by pyrosequencing and genescan analysis
UPN WHO SNP-array









affected by TET2 
mutation (%)
9 RCMD     c.3812_3813insT  N/A 44 88
c.4571delC 49 N/A 98
11 RCMD-RS     c.5643T>G 30 N/A 60
36 RCMD-RS     c.2985_2986insA 28 N/A 56
44 RAEB2   4q24.23* c.1147C>T 49 N/A 49
46 RCMD     c.2881G>T 48 N/A 96
      c.5688G>T N/A N/A 43**
      c.3854_3856delTCT N/A 22 44
50 RCMD     c.1249C>T 30 N/A 60
52 RAEB1 4q   c.2526C>A  80 N/A 80
           (homozygous)
59 RAEB1     c.1516A>T 33 N/A 66
72 RAEB1     c.1630C>T 41 N/A 82
             
        c.5623T>C 46 N/A 92
73 RAEB1 4q12-q35.1   c.3871T>C 100 N/A 100
          (homozygous)
74 AML 4q23-q35.2   c.3508delC 100 N/A 100
            (homozygous)
75 RAEB1     c.1102G>T 53 N/A 100
        c.5543C>G 52 N/A 100
77 RAEB1     c.3718_3719insT N/A 50 100
             
        c.4193T>G 52 N/A 100
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UPN WHO SNP-array









affected by TET2 
mutation (%)
79 RCMD-RS     c.5738G>A 58 N/A 100
81 RCMD     c.1720delC 43 N/A 86
83 MDS-U     c.3658delA  46 N/A 92
        c.3813C>A N/A N/A 77**
87 RA     c.2540_2543delAGAC N/A 33 66
96 RCMD     c3640C>T 52 N/A 100
        c3646C>T 38 N/A 76
97 RCMD     c.4188C>G N/A N/A 75**
        c.5618T>C 55 N/A 100
98 RCMD     c.1665_1666insC N/A 50 100
100 RCMD 4q22.3-q35.2   c.2045_2046insA 74 N/A 74
              (homozygous)
101 RCMD     c.del5731_5748 N/A 50 100
102 RCMD     c.3782G>T 37 N/A 74
103 RAEB1     c.5455delT N/A 35 70
        c.489_490delAC N/A 11 22
104 AML     c.2477delG 57 N/A 100
N/A: not analyzed
*SNP-array analysis showed that this deletion was present in all cells
** In  three cases in which pyrosequencing was inconclusive, allele burden was determined by comparison of peak-height of 
the mutant and wild-type allele in the original sequencing reaction
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Supplementary Table 6: Expression of TET2 mutants in bone marrow subpopulations
6a: Expression of TET2 mutants in bone marrow subpopulations









7 c5885C>T present N/A present N/A
9 c.3812_3813insT present present present N/A
c.4571delC present present present N/A
36 c.2985_2986insA present present present N/A
72 c.1630C>T present present present absent
74 c.3508delC present present present N/A
75 c.1102G>T present present N/A absent
c.5543C>G present present N/A absent
77 c.4193T>G present present absent absent
c.3718_3719insT present present present absent
*  To analyze the presence of mutations in different hematopoietic cell populations at the mRNA level, sequence analysis was 
performed on cDNA of FACS-sorted CD13/33-positive, CD34-positive and CD71-positive cells of MDS patients (n=5). 
N/A: not analyzed
6b: Pyrosequencing of reverse-transcribed TET2 mRNA in bone marrow subpopulations
UPN Mutation Cell fraction Pyrosequencing*                                            
(reverse transcribed mRNA)
Mutant allele (%) Wild type allele (%)
9 c.4571delC CD34 49 51
CD13/33 45 55
CD71 45 55
36 c.2985_2986insA CD34 38 62
CD13/33 N/A N/A
CD71 45 55
72 c.1630C>T CD34 47 53
CD13/33 52 48
CD71 39 61
75 c.1102G>T CD34 52 48
CD13/33 52 48
CD71 N/A N/A
c.5543C>G CD34 61 39
CD13/33 42 58
CD71 N/A N/A
*  To determine the ratio between the expression of mutant and wild-type allele in different hematopoietic cell subpopulations, 
pyrosequencing was performed on cDNA of FACS-sorted CD13/33-positive, CD71-positive and CD34-positive cells of MDS 
patients (n=4). N/A: Not analyzed
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Flt3**   NPM1   TET2
Type of TET2 mutation
 
AML1 71 M0 46,XY wt wt wt    










AML3 24 unk 46,XY wt wt wt    








AML5 61 M2 46,XY wt muta-
tion
wt    
AML6 68 M1/
M0
N/A (failed) wt wt wt    
AML7 70 M4 46,XY  wt wt wt    










AML9 61 M2 47 XXY* wt muta-
tion
wt    
AML10 69 M2 46,XX wt muta-
tion
wt    
AML12 49 unk N/A muta-
tion
wt wt    




wt    
AML16 70 M5 46,XY wt muta-
tion






wt wt wt    
AML18 70 M7 46,XY,del(13)(q14q22)
[2]/46,XY,+1,der(1;7)
(q10;p10)[5]/46,XY[4] 
wt wt wt    
AML19 67 unk 46,XY,  abberation 
chr. 17





wt wt wt    




wt wt wt    
AML22 72 M1/ 
M2
46,XX wt wt muta-
tion
indel c.1239delC p.P413fsX13
AML24 41 M4 46,XY muta-
tion












Flt3**   NPM1   TET2




N/A wt wt muta-
tion
indel c.3353delA p.N1118fsX17
AML26 62 M5 46,XY muta-
tion
wt wt      
AML27 42 M5 46,XX wt muta-
tion
wt      
AML28 53 M3 46,XX, t(15,17)
(q22;q21)
N/A wt wt      




wt wt      
AML30 46 M3 46,XX, t(4;10;15;17) wt wt wt      




wt wt      




wt wt      
AML33 38 M3 46,XY, t(15;17)
(q22;q21)
wt wt wt      
AML35 32 M3 46,XY, t(1;17;15) muta-
tion
wt wt      
AML36 63 M3 t(15;17), der 3, der 8 muta-
tion
wt wt      







 wt = wildtype
*  Patient UPN AML9 showed this karyotypic abnormality in both bone marrow and germ-line cells.
**   Both Flt3 ITD and Flt3 TKD mutations were analyzed. Patients UPN AML12,14,24,26, 29, 31,32 and 36 showed 
a Flt3 ITD. Patient UPN35 had both a Flt3 ITD and Flt3 TKD mutation.
119
Acquired mutations in TET2 are common in myelodysplastic syndromes









Median age at diagnosis
(p = 0.45)

































































































Supplementary Table 9: Primers
Primers for TET2 sequencing
Primer (5’to 3’) Forward/ 
reverse
Location
tgtaaaacgacggccagtCAGTTTGCTATGTCTAGGTATTCCGA Forward Intron 2/3A
caggaaacagctatgaccAGAAGGTTCACTAACTGTGCGTTTT Reverse Exon 3A
tgtaaaacgacggccagtTTCAACTAGAGGGCAGCCTTG Forward Exon 3A
caggaaacagctatgaccTGTGCGTTTTATTCCTCCATTTT Reverse Exon 3A
tgtaaaacgacggccagtCAGAATAGTCGTGTGAGTCCTGAC Forward Exon 3A
caggaaacagctatgaccGCAATGGAAACACAATCTGGA Reverse Exon 3A
tgtaaaacgacggccagtGAACACACACATGGTGAACTCC Forward Exon 3A
caggaaacagctatgaccAATTGTGATGGTGGTGGTGG Reverse Exon 3A
tgtaaaacgacggccagtTCCAGGGAACCACAAAGCTAG Forward Exon 3A
caggaaacagctatgaccGCTTGAGGTGTTCTGACATTGG Reverse Exon 3A
tgtaaaacgacggccagtACATGTATGCAGCCCTTCTCC Forward Exon 3A
caggaaacagctatgaccGGGAATCTGCTCTTTGTTGAAA Reverse Exon 3A
tgtaaaacgacggccagtACCAACATCTCCAGTTCCAA Forward Exon 3A
caggaaacagctatgaccATGCACTTGATTTCATGGTCT Reverse Exon 3A
tgtaaaacgacggccagtCAAATGGGACTGGAGGAAGT Forward Exon 3A
caggaaacagctatgaccGTTTGCTGCTGTTCTTGCTT Reverse Exon 3A
tgtaaaacgacggccagtCAGAAGGACACTCAAAAGCATG Forward Exon 3A
caggaaacagctatgaccTTGCTGCTCTAAAGCTGGG Reverse Exon 3A
tgtaaaacgacggccagtGAGAATCCACCTGCAAGCTG Forward Exon 3A
caggaaacagctatgaccTTTCACAAGACACAAGCATCG Reverse Exon 3A
tgtaaaacgacggccagtGGCCACATTTTCCTAATAGATCAGTCCA Forward Intron 3B/3C
caggaaacagctatgaccCTGCTTTGTGTGTGAAGGCTG Reverse Intron 3C/4
tgtaaaacgacggccagtTTCATTTCTCAGGATGTGGTCATAG Forward Intron 3C/4
caggaaacagctatgaccCCAATTCTCAGGGTCAGATTTACA Reverse Intron 4/5
tgtaaaacgacggccagtGTTGCCCTAATTGTGATCTAAACATG Forward Intron 4/5
caggaaacagctatgaccAGATTGGGCTTTCCTATCAGTGG Reverse Intron 5/6
tgtaaaacgacggccagtGGGTTCTACTTAACTGGGTATTTTCCA Forward Intron 5/6
caggaaacagctatgaccAGCTTACCAAGATATGTCATATTGTTCAC Reverse Intron 6/7
tgtaaaacgacggccagtGGATTCAAAATGTAAGGGAATAATC Forward Intron 6/7
caggaaacagctatgaccGCAAGTGGTTTCAACAATTAAGAGGA Reverse Intron 7/8
tgtaaaacgacggccagtCCATGTCAAGATATTTGCTCTATTTTGT Forward Intron 7/8
caggaaacagctatgaccCAGCCATGTGGAACTGTGAGTC Reverse Intron 8/9
tgtaaaacgacggccagtCCACCAACACAAATCTGAATACTGA Forward Intron 8/9
caggaaacagctatgaccAAGTTGATGGGGGCAAAACC Reverse Intron 9/10
tgtaaaacgacggccagtTCTTTGCTTAATGGGTGTCGTATATC Forward Intron 9/10
caggaaacagctatgaccTTGGGTATTCTGATTCAAAAGCC Reverse Exon 10
tgtaaaacgacggccagtCCAGCCCTATGAACTTCTATTCCA Forward Exon 10
caggaaacagctatgaccCGGAGCTGCACTGTAGTTATGG Reverse Exon 10
tgtaaaacgacggccagtCAAACATGGACTATAAAAATGGTGAAC Forward Exon 10
caggaaacagctatgaccAAGACGAGGGAGATCCTGGTG Reverse Exon 10
tgtaaaacgacggccagtGCCGTGGCTCCAACTCAT Forward Exon 10
caggaaacagctatgaccGTGACCTTTCCCCACTGCC Reverse Exon 10
tgtaaaacgacggccagt Forward Universal sequencing primer
caggaaacagctatgacc Reverse Universal sequencing primer
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Primers for genescan analysis of TET2















tgtaaaacgacggccagt FAM-labeled Forward All
caggaaacagctatgacc FAM-labeled Reverse All
Primers for pyrosequencing of TET2
Primers for amplification Forward/
reverse
Primers for sequencing UPN Mutation
GGTTCCAGCAGCAATTTG forward CCTGGTGGCAGCTCT 75 c.1102G>T
AGCGCTGCTCCGGTTCATAGATTGAACACTGAGCTTTGCTTGAAGTA reverse
GACGGGACACCGCTGATCGTTTATGGCAGCTCTGAACGGTATTT forward TAGTGAACACTGAGCTTT 44 c.1147C>T
TGTGGTAGTGGCAGAAAAGGAAT reverse
AATTGCTTCTTTCTCCCCCTCC forward TCCTCTTCCACAGGTT 50 c.1249C>T
AGCGCTGCTCCGGTTCATAGATTCCACCATTCAGAGTGCTTTTTC reverse
GCAGGGACAATGACTGTTCCA forward CCATTGTGTTCTGAGAAA 59 c.1516A>T
AGCGCTGCTCCGGTTCATAGATTGGTGGGTTATGCTTGAGGTGTT reverse






GACGGGACACCGCTGATCGTTTAATTGAAGGCCCCTCGTTT forward TTTAGATGGGATTCCG 81 c.1720delC
AGTGATGCCTCATTACGTTTTAGA reverse
GACGGGACACCGCTGATCGTTTATCAACCCAATCTCTCCAATCAAA forward CCCAGGCATGTTGGAA 86 c.1821delA
TGTGTTGTTTTCTGGGTGTAAGC reverse
GACGGGACACCGCTGATCGTTTATGCAGTCACTGTGTGGCACTA forward TCTGCTCTTTGTTGAAAA 100 c.2045_2046insA
GCTGTTTCAACACTGGGGACAT reverse





c.2526C>A  and 
c.2477delGGGGTCTTGTTTCCTGCAAAAAGT reverse
AGGTGGCATCTCTTACAGAAGCA forward TGGCATCTCTTACAGAAG 46 c.2881G>T
AGCGCTGCTCCGGTTCATAGATTAAGACTCAGTTTGGGGTTGCT reverse




GTGTTTCTGTGGGTTTCTTTAAGG forward GGTTTCTTTAAGGTTTGG 74 c.3508delC
AGCGCTGCTCCGGTTCATAGATTGAGAACTTTTGCCTTCTTTACCAG reverse



























































GACGGGACACCGCTGATCGTTTAAGTGAAACGGGAGCCTGCT forward TGATGAAACGCAGGTA 7 c.5885C>T
GGTCCTTTCGGCAAGAGACTT reverse
Primers for confirmation TET2 splice variants
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Primers and probe for isoform-specific quantitative TET2 PCR
Primer/probe (5’to 3’) Forward/ 
reverse
Location Isoform specificity
AATTTATTGGATACACCTGTCAAGACTC Forward Exon 3A 1,2,3
GATAAACGCCATGTGTCTCAGTACA Reverse Exon 3B 2
ACCTGCTCCTAGATGGGTATAAAAAG Reverse Exon 3C 1
TTTACCCTTCTGTCCAAACCTACAC Reverse Exon 3A/4 3
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Aberrations of the Ten-Eleven-Translocation 2 (TET2) gene have been implicated in a variety of 
hematopoietic malignancies in adults, but not in childhood malignancies. We studied a cohort 
of childhood acute myeloid leukemia (AML) and precursor B-cell acute lymphoblastic leukemia 
(B-cell ALL) for the presence of mutations in TET2. In total 104 childhood AML and 47 childhood 
precursor B-cell ALL cases were included. TET2 mutations were detected in 4 of the 104 AML 
samples tested (3,8%). No TET2 mutations were found in the precursor B-cell ALL cohort. The 
observation of the presence of TET2 mutations in childhood AML may be instrumental for the 
design of novel targeted therapies.
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The Ten-Eleven-Translocation 2 (TET2) gene has recently been implicated in a variety of hematopoietic 
malignancies in adults. Mutations and deletions were detected in myelodysplastic syndromes (MDS), 
acute myeloid leukemias (AML) and other myeloid malignancies1-5. 
 So far, the presence of TET2 mutations has not been reported in childhood leukemia. Precursor B-cell 
ALL and AML represent the most frequently occurring hematopoietic malignancies in children. During 
the past decades, the survival rates of children with these malignancies have improved considerably, but 
a substantial subset of the patients still suffers from relapses and treatment-related mortality. Genetic 
abnormalities may provide insights into the mechanisms underlying the etiology of leukemia and the 
development of therapy resistance. In addition, they may provide novel clues for the development of 
targeted therapies. TET2 mutations are found in 8-19% of adult AML2, 5. Thus far, the incidence of 
TET2 mutations in adult ALL has not been reported. TET2 expression is high in granulocytes where it is 
increased during myeloid differentiation, and in normal B-cells as compared to other hematopoietic and 
non-hematopoietic cells2. Here, we set out to assess a cohort of childhood AMLs and precursor B-cell 
ALLs for the presence of mutations in TET2.
 In total 104 childhood AML and 47 childhood precursor B-cell ALL cases were included in this 
study. All patient material was obtained with informed consent through the Dutch Childhood Oncology 
Group (DCOG). Patient characteristics are listed in Supplemental Table 1. DNA was isolated from 
peripheral blood or bone marrow cells at diagnosis. Sequence analyses were carried out as reported before 
using primers covering all exons of the TET2 gene, including its intron-exon boundaries2. All sequence 
analyses were performed bi-directionally and all sequence variations were confirmed independently. In 
order to establish whether the observed mutations were acquired, DNA from remission material was 
analyzed whenever available. All sequence variations were compared to those published in the literature 
and listed in public databases.
 Novel TET2 mutations were detected in 4 of the 104 AML samples tested (3.8%) Figure 1a, Table 
1). In addition, 16 SNPs were found, some of which have not been reported before (Figure 1a). One of 
the patients carrying a TET2 mutation, a 3-month old girl (UPN AML51), suffered from AML-M0. A 
conversion of cytosine to guanine at position 1526 of the TET2 gene led to the formation of a premature 
stop codon. A second patient, a 17-year-old boy (UPN AML60), suffered from AML-M2. In his case, 
the TET2 mutation (c.3001A>T) gave rise to a premature stop codon as well. In both cases the mutations 
were not detected in DNA obtained during remission. Both premature stop codons were located in the 
N-terminal moiety of the protein, upstream of the two conserved domains BOX1 and BOX2 (Figure 
1a). The two other patients with TET2 mutations suffered from AML-M4. In one of them, a 14-year-
old girl (UPN AML07), the mutation (c.1379C>T) led to a conversion of a serine to a phenylalanine, 
again upstream of the two conserved domains in the protein. Unfortunately, remission DNA from this 
patient was not available for analysis, but literature and database searches revealed that this mutation 
has been reported before and was shown to be acquired5. In the fourth patient, the diagnosis sample 
showed a homozygous mutation of one base-pair upstream of the GT-splice-donor site of intron 5. This 
mutation, an insertion of a thymine, was absent in remission material (Figure 2a). In addition to the 
mutation, we detected two SNPs which were homozygous in the diagnosis sample, but heterozygous in 
the remission sample (Figure 2a), indicative for the presence of either a deletion or a region of acquired 
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Figure 1: Schematic representation of the TET2 protein showing the localization of the conserved domains BOX1 
and BOX2, and the mutations and SNPs found in pediatric AML (a) and precursor B-cell ALL (b) 
Table 1: Characteristics of the four TET2-mutated patients
UPN AML51* AML60 AML07** AML19#
TET2 mutation cDNA c.1526C>G c.3001A>T c.1379C>T 4190 +2_3 ins T
TET2 mutation protein p.Ser509X p.Lys1001X p.Ser460Phe unknown
Age at diagnosis (years) 0 17 14 11
Sex female male female female
Blasts bone marrow (%) 85 48 85 87
Blasts peripheral blood (%) 95 46 86 83
Subtype M0 M2 M4 M4
CNS involvement yes no no no
Cytogenetics
47,XX,+19 [8]/ 







Co-occurence of other mutations no* unknown no**
NPM1 and 
FLT3 ITD*
TET2 mutation previously 
described (references) yes (3, 4) no yes (5) no
*  mutation screening negative for CEBPalpha, NPM1, WT1, c-KIT, N-RAS, K-RAS, FLT3 ITD, FLT3 TKD, PTPN11
** mutation screening negative for NPM1 and MLL-PTD
# mutation screening positive for NPM1 (exon 12 CCTG, type D) and FLT3 ITD. 
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uniparental disomy (aUPD) affecting the TET2 gene. Subsequent SNP array-based genomic profiling of 
the respective DNA samples indeed confirmed the presence of an aUPD of the long arm of chromosome 
4 harboring the TET2 gene (Figure 2b).
 No TET2 mutations were found in the precursor B-cell ALL cohort (Figure 1b). The locations of 14 
TET2 SNPs are depicted in Figure 1b. In two patients we detected sequence variations leading to amino-
acid substitutions in the isoform 2 of TET2. Remission material of these patients was not available 
for analysis, but considering the fact that these variations only affect the short TET2 isoform lacking 
the two conserved domains BOX1 and BOX2, we consider that the functional consequences of these 
variations may be limited. One of the variations (p.Gly1160Glu) was also encountered in a cohort of 
adult AML patients (unpublished results), and was found to be present in remission material. Therefore, 
we concluded that this variation represented a SNP. 
 Compared to the incidence of TET2 mutations in adult AML, its incidence in childhood AML 
seems to be lower (8-19% versus 3.8%). In adult AML TET2 mutations appear to correlate with a poor 
prognosis (5, unpublished results). As yet, however, our childhood AML cohort is too small to draw any 
firm conclusions on its prognostic implications.
In our precursor B-cell ALL cohort no TET2 mutations were found. Previously, we and others performed 
SNP array-based analyses on precursor B-cell ALLs6, 7 and identified recurrent deletions, duplications 
and aUPDs affecting various regions on the genome, but the 4q24 region encompassing the TET2 gene 
was not affected. 
Figure 2: A homozygous TET2 splice site mutation in a child with AML. 
(a) Sequence analysis in leukemic and remission samples of patient UPN AML19 revealed two heterozygous SNPs with ac-
quired homozygosity in the diagnosis sample and a homozygous mutation in the splice donor site of exon 5 (c.4190+2_3insT). 
(b) Genotyping plot showing the allelic difference of all SNPs on chromosome 4, with acquired uniparental disomy of a segment 





The mechanism by which TET2 mutations contribute to the etiology of myeloid malignancies 
is, as yet, poorly understood. Tahiliani et al. have implicated that the TET2 homolog TET1 may 
be involved in epigenetic gene regulation8. Specifically, they found that TET1 plays a role in the 
transition of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC). Very recently TET2 
was reported to possess similar enzymatic activity9. Considering the co-occurrence of TET2 
mutations with other mutations such as FLT3 ITD, TET2 mutations are probably type II mutations.
In conclusion, we have detected novel TET2 mutations in 3.8% of pediatric AML patients. This 
observation may be instrumental for the design of novel targeted therapies in pediatric acute myeloid 
leukemia.
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Supplementary Table 1: Patient characteristics
AML ALL
Number of patients 104 47
Time of diagnosis 1982 to 2009 1992 to 1996
Age at diagnosis, median (range) 6 (0-17) 4 (0-14)
Sex (male / female / unknown) 69 /34 / 1 29 / 18
Blasts bone marrow, median (range) 80 (15-97) 90 (64-99)
Blasts peripheral blood, median (range) 66 (2-95) 37 (0-95)
Subtype AML   
M0 9  
M1 9  
M2 22  
M3 10  
M4 23  
M5 24  
M6 1  
M7 3  
RAEBt 1  
unknown 2  




CNS involvement (Y/N/unknown) 9 / 61 / 34 0 / 34 / 13
Cytogenetics   
normal 19 0
   
high hyperdiploidy (>50) 1 13
triple trisomy (4,10,17) 0 7
hypodiploidy (<46) 6 5
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In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate 
with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that 
EZH2, located at 7q36.1 is frequently targeted in MDS. Analysis of EZH2 deletions, missense and 
frameshift mutations strongly suggests that EZH2 is a tumor suppressor. As EZH2 functions as a 
histone methyltransferase, abnormal histone modification may contribute to epigenetic deregulation 
in MDS.
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Myelodysplastic syndromes comprise a heterogeneous group of acquired clonal hematopoietic 
disorders characterized by dysplasia of the myeloid, erythroid and/or megakaryocytic lineages. 
MDS is one of the most frequent hematopoietic malignancies, particularly in the elderly1. In the 
majority of affected individuals, a cure for the disease cannot be achieved and most die from severe 
cytopenias. Identification of the underlying genetic aberrations may promote proper classification and 
prognostication of disease and, eventually, the development of targeted therapy. 
Conventional cytogenetic techniques detect large chromosomal aberrations in 40-60% of 
individuals with MDS, of which deletions of chromosome 5 or 5q (15%) and 7 or 7q (10%) are 
the most frequent2. Several genes have been implicated on chromosome 5, but the relevant genes on 
chromosome 7 have remained elusive. 
Previously, we applied single nucleotide polymorphism (SNP) arrays on a cohort of 102 
subjects to identify genomic aberrations in MDS. The complete overview of SNP array lesions has 
been published3. Using DNA-sequencing, we and others identified the perturbation of the TET2 
gene located at chromosome 4q24, in 26% of the individuals with MDS3, 4. Here, the same cohort 
was used to identify affected genes on chromosome 7. SNP array analysis revealed chromosome 7 
deletions in 14 out of 102 subjects and loss of heterozygosity due to uniparental disomy (UPD) in 
two subjects (Figure 1a). In subject 87, we found a monoallelic microdeletion of 130 kb at 7q36.1. 
This region was shared by 13 out of 14 subjects with deletions, as well as by the two subjects with 
UPD and encompassed two genes, CUL1 and EZH2 (Figure 1a and Supplementary Figure 1). 
Genomic sequence analysis of subject 87 covering the coding region and splice sites of the remaining 
copy of these genes showed no aberrations in CUL1. However, a frameshift mutation in exon 7 
(703delGinsAA, nomenclature as described5) introducing a premature stop codon was found in EZH2 
(Table 1, Supplementary Figure 2 and Supplementary Figure 3). The presence of this mutation 
implied that no intact copy of EZH2 was left in the malignant bone marrow cells of this individual. 
Because large segmental regions of UPD may harbor acquired homozygous mutations, we sequenced 
EZH2 in the bone marrow cells of the two subjects who showed UPD at 7q (Figure 1a, subjects 97 
and 103). EZH2 mutations were not detected in subject 103, but a homozygous missense mutation 
was present in subject 97 (Table 1). 
To assess the prevalence of EZH2 mutations in individuals with MDS, we sequenced the gene 
in all 102 subjects from the initial cohort and 24 additional individuals with MDS (Supplementary 
Table 1). EZH2 missense, donor-splice-site and frameshift mutations predicting truncated proteins 
were observed in 8 out of 126 subjects (6%, Table 1 and Figure 1b). In three individuals we could 
show that mutations were biallelic. In case 87, one allele was deleted whereas the other contained 
a point mutation.  In subject 97, a point mutation was found that was homozygous due to UPD, 
and in subject 96 two different point mutations were found that resided on two different alleles 
(Supplementary Figure 4). To investigate whether these mutations were somatically acquired, we 
analyzed DNA of non-neoplastic T cells from the same individuals. Polyclonal T cell cultures were 
generated from viably frozen cells of subjects 10, 40 and 73 (Supplementary Methods). None of 
the four mutations detected in the malignant cells were found in these T cells, confirming these 
were acquired mutations (Table 1). For two additional subjects who carried missense mutations 
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Figure 1:  EZH2 is recurrently affected in individuals with MDS.
(a) Genomic aberrations of chromosome 7 detected in 102 individuals with MDS by high-resolution SNP arrays. Numbers on the 
right are unique patient numbers. Two subjects carried large areas of UPD (blue bars), fourteen subjects carried deletions (red bars) 
and six showed duplications (green bars, asterisks represent four different subjects). Subject 87 showed a 130-kb microdeletion at 
7q36.1, which contains CUL1 and EZH2. CNA, Copy Number Alterations; UPD, Uniparental disomy. (b) Protein localization 
of ten different EZH2 point mutations found in 8 out of 126 subjects with MDS. The ruler indicates the number of amino acids. 
The catalytic SET domain, a C-rich domain and the two SANT domains are indicated. Numbers in the boxes indicate unique 
patient numbers (UPN)
Table 1: Aberrations of EZH2 at chromosome 7q36.1 were detected in 29 bone marrow samples of 126 individuals 
with MDS.
Genomic sequencing of the coding region and the splice donor and acceptor sites revealed missense mutations, donor-splice-site 
mutations, deletions and insertions, predicting amino acid substitutions and truncations. Sequences were compared to the 
reference genomic sequence NT_007914.15 and the deduced protein sequences to reference NP_004447.2. In subjects 44 
and 104, the 7q deletion that was identified on SNP array was missed by karyotype analysis. In subject 43, the 7q deletion 
that was revealed by karyotype analysis was not detected by SNP array analysis. To assess whether mutations were acquired, 
T cells from the same individuals were analyzed or allelic discrimination assays were applied to show that the mutations were 
absent in a cohort of 250 unaffected donors (Supplementary Methods, Supplementary Table 2 and Supplementary Figure 5). 
Detected SNPs are summarized in Supplementary Table 3. UPN, Unique Patient Number; FAB, French-American-British 
classification; WHO, World Health Organization classification; IPSS, International Prognostic Scoring System; N/A, Not 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(subjects 96 and 97), we designed allelic discrimination assays (PCR using allele-specific probes and 
high-resolution melting analysis, HRM) and tested a cohort of 250 unaffected individuals (controls) 
(Supplementary Methods and Supplementary Table 2). None of these mutations were found in any 
of the unaffected subjects (Table 1 and Supplementary Figure 5). In three individuals, we examined 
whether the mutant mRNA was expressed (Supplementary Figure 6 and Supplementary Methods). 
In subject 73 (who harbored a heterozygous splice-donor-site mutation in intron 12), only wild-type 
mRNA was detected. No aberrant splice variants could be detected using primers  from exon 11 to 
exon 13, or when exon 11 to 20 primers were used (Supplementary Methods). In subjects 10 and 
127, mutant mRNA was detected, but pyrosequencing and Genescan analysis showed that the mutant 
sequences were expressed at lower levels than wild-type sequences, suggesting a decreased stability of 
the mutant transcript. Although we could readily detect EZH2 protein in cell lines and in primary T 
cells, no EZH2 protein expression could be measured in total bone marrow of individuals with MDS, 
irrespective of the presence or absence of EZH2 mutations. Therefore, more detailed expression studies 
in bone marrow subfractions of MDS patients are warranted. In addition to the eight subjects with 
EZH2 point mutations, the EZH2 locus at 7q36.1 was entirely deleted at one allele in 22 subjects by 
7 or 7q (micro)deletions. Collectively, deletions and point mutations of EZH2 were present in 23% 
of the affected subjects. In 5 out of 8 subjects with an EZH2 mutation, a TET2 mutation was present 
(ref. 3 and Supplementary Table 1).  Overall, in 40% of the subjects showing 7q36.1 aberrations 
or EZH2 mutations, TET2 was affected as well. This is notable, as both EZH2 and the Tet family of 
proteins have been implicated in epigenetic regulation of gene transcription6-10. 
The cohort harboring EZH2 aberrations was too small to detect a clear association with a 
specific French-American-British (FAB), International Prognostic Scoring System (IPSS) or World 
Health Organization (WHO) classification of MDS (Table 1). Subjects carrying 7 or 7q deletions 
showed a significantly worse survival compared to patients without any EZH2 abnormalities (p<0.001, 
Supplementary Figure 7). The adverse effect of chromosome 7 and 7q deletions on the prognosis in 
MDS is well known1. We show here that EZH2 point mutations result in a similar adverse tendency 
in overall survival (p=0.076 when measured from the date of diagnosis and p=0.026 when measured 
from the time of bone marrow sampling), but a larger cohort from a prospective clinical trial should 
be analyzed to assess this properly. 
EZH2 encodes the histone methyltransferase that constitutes the catalytic unit of the 
Polycomb Repressive Complex 2 (PRC2)7-10. This complex initiates dimethylation and trimethylation 
of lysine 27 of histone H3 (H3K27), an epigenetic modification associated with gene silencing. 
All the mutations detected here disrupt highly conserved amino acids (Supplementary Figure 8). 
Notably, the SET domain, essential for the methyltransferase activity of EZH28-10, was either altered 
or truncated in at least one allele in all affected subjects (Figure 1b and Supplementary Figure 8). 
We conclude that EZH2 is targeted by various types of deletions and mutations in MDS, probably 
leading to loss-of-function of the gene. Recently, a recurring mono-allelic EZH2 point mutation in 
the SET domain (Tyr641; Tyr646 in NM_004456.3) leading to loss-of-function has been described 
in lymphomas11. Together with our data, this suggests that EZH2 may acts as a tumor suppressor. 
This is in line with recent investigations showing that Drosophila E(z) as well as other PRC1 and 
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PRC2 components may exhibit tumor suppressor activity by silencing the mitogenic JAK-STAT12 
and Notch13 signaling pathways. In contrast, in various malignancies, overexpression of EZH2 has 
been reported14, suggesting that EZH2 might also act as an oncogene. This indicates that deregulation 
of EZH2 in cancer may not be generalized into one simple mechanism. We postulate that changes 
in epigenetic modifications caused by defective EZH2 may result in tumor promotion by different 
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Supplementary information
Supplementary Figure 1: 250k SNP array profile of chromosome 7 showing a microdeletion at 7q36.1.
Genomic profile of chromosome 7 in subject 87 showed a microdeletion located on 7q36.1 (red circle). This microdeletion 
encompassed the CUL1 and EZH2 genes (see also Figure 1a). Relative intensities of individual (red dots) and 10 consecutive 
SNPs (blue line) on chromosome 7 are indicated. For this patient, no T cells could be obtained to show that the deletion was 
acquired. However, this region was never found to be affected in a large control cohort of 1015 healthy controls that were 
individually hybridized. 
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Supplementary Figure 2: EZH2 exon organization and sequence primers.
Exon organization of EZH2 according to GenBank: EZH2 isoform 1, NM_004456.3, representing the longest isoform. 
Localization of the primers is indicated in the table. M13 sequence primers are indicated in lower case.
Exon
 
Amplification primer sequence (5’ to 3’) Forward / 
Reverse
Location  Sequence primersequence (5’ to 3’) 
2 tgtaaaacgacggccagtAAGTGTTTTAAGGATTTAACCATGCA Forward intron 1 tgtaaaacgacggccagt
  caggaaacagctatgaccCCTTTATATTTAGGGAGGCATTTCTG Reverse intron 2 caggaaacagctatgacc
3 tgtaaaacgacggccagtGTCAACAAAGAAAGGATGGCAAT Forward intron 2 AAGAGTATGTTTAGTTCCA
  caggaaacagctatgaccAGCTAATAGTGTGATCTACAGCAGTCATT Reverse intron 3 caggaaacagctatgacc
4 tgtaaaacgacggccagtGGGTAGGCAGCATCTCTTTACAATAT Forward intron 3 tgtaaaacgacggccagt
  caggaaacagctatgaccAATTTATACTGTCTTGATTCACCTTGACA Reverse intron 4 caggaaacagctatgacc
5 tgtaaaacgacggccagtTTTTCTCAGATATGCTTATTGGTGAGA Forward intron 4 tgtaaaacgacggccagt
  caggaaacagctatgaccGTTCAGTCCCTTATAGTTCAGTGCAA Reverse intron 5 caggaaacagctatgacc
6 tgtaaaacgacggccagtTTGCCTAACACCAGTCCTGAAA Forward intron 5 tgtaaaacgacggccagt
  caggaaacagctatgaccTCCCAAGTGCTAGGATTACAGAGTTAG Reverse intron 6 caggaaacagctatgacc
7 tgtaaaacgacggccagtGTAGCAGAGCTGGGAGTAGAACCTA Forward intron 6 tgtaaaacgacggccagt
  caggaaacagctatgaccGTAATGCAGAGTACCACAAGTACACATG Reverse intron 7 caggaaacagctatgacc
8 tgtaaaacgacggccagtAATTTGATTCTTGATAACACCATGCA Forward intron 7 tgtaaaacgacggccagt
  caggaaacagctatgaccCAGAGCAATCCTCAAGCAACAAA Reverse intron 8 caggaaacagctatgacc
9 tgtaaaacgacggccagtGAGGAGGAATGGAGAATACGTTGT Forward intron 8 tgtaaaacgacggccagt
  caggaaacagctatgaccGAAACAGCATGGGTGAGAAAGC Reverse intron 9 caggaaacagctatgacc
10 tgtaaaacgacggccagtATGAGTTTTAGAACTTTGCCCTGATG Forward intron 9 tgtaaaacgacggccagt
  caggaaacagctatgaccCACAACACGAACTTTCACAGAACAG Reverse intron 10 caggaaacagctatgacc
11 tgtaaaacgacggccagtTGTGAACTACGATGGGTTAGTGTTTT Forward intron 10 tgtaaaacgacggccagt
  caggaaacagctatgaccTTAAAAGTCTACATTGGGGAAATTCTG Reverse intron 11 caggaaacagctatgacc
12 tgtaaaacgacggccagtGCATCACAGTTCTTGACCAGAATATAA Forward intron 11 tgtaaaacgacggccagt
  caggaaacagctatgaccAGTTCTGTTTTTGATGGCAGTTTAAG Reverse intron 12 caggaaacagctatgacc
13 tgtaaaacgacggccagtAGCCTGAGCCATCAAGCTGTT Forward intron 12 tgtaaaacgacggccagt
  caggaaacagctatgaccCCAGTCAGCCTCCACTTTACAGA Reverse intron 13 caggaaacagctatgacc
14 tgtaaaacgacggccagtCCGTGCTTTAGATGGAACTCATAA Forward intron 13 tgtaaaacgacggccagt
  caggaaacagctatgaccGCCTCACACACACAGACACACA Reverse intron 14 caggaaacagctatgacc
15 tgtaaaacgacggccagtCGCTGTTAATACTTCCATTTCCTTGT Forward intron 14 tgtaaaacgacggccagt
  caggaaacagctatgaccACACTTTCTCATCAGTTGCACCTTT Reverse intron 15 caggaaacagctatgacc
16 tgtaaaacgacggccagtACAGGTCTGAGGATTTACAGTGATAGC Forward intron 15 tgtaaaacgacggccagt
  caggaaacagctatgaccCAGTTTATGGCAATTCATTTCCAAT Reverse intron 16 caggaaacagctatgacc
17 tgtaaaacgacggccagtTGGGAAAGAGAACTTGGCTGTAGT Forward intron 16 tgtaaaacgacggccagt
  caggaaacagctatgaccCCAGTTCCTTTCAAGCAAGCA Reverse intron 17 caggaaacagctatgacc
18 tgtaaaacgacggccagtAACAATAGTGTGTTCTTCCAAATGTCA Forward intron 17 tgtaaaacgacggccagt
  caggaaacagctatgaccCTGGTGTCAGTGAGCATGAAGAC Reverse intron 18 caggaaacagctatgacc
19 tgtaaaacgacggccagtCCTTTGACGTGAGAATTGGAACT Forward intron 18 tgtaaaacgacggccagt
  caggaaacagctatgaccCTGTCAACAGCAGGGTGAGAAAT Reverse intron 19 caggaaacagctatgacc
20 tgtaaaacgacggccagtACCCACTATCTTCAGCAGGCTTT Forward intron 19 TCAGCACATGTTGGATGG
  caggaaacagctatgaccCTTCCACATATTCACAGGCAGTATTAGT Reverse downsteam of exon 20
caggaaacagctatgacc
              CAGCTGTTTCAGAGGAGGGGG
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Supplementary Figure 3:  Sequence analysis of genomic DNA from subject 87.
SNP array analysis revealed a 130-kb microdeletion at 7q36.1, containing the CUL1 and EZH2 genes, in subject 87 (Fig. 
1a). Subsequent sequence analysis of genomic DNA from this subject showed a c.703delGinsAA mutation in the remaining copy 
of EZH2, predicting the formation of a truncated protein.
Supplementary Figure 4: Bi-allelic point mutations in subject 96.
A PCR product covering EZH2 exons 17 and 18 from subject 96 was cloned and individual clones were sequenced (Supplementary 
Methods online). Clones contained either the c.1983delA mutation in exon 17 (e.g. clone 16) or the c.2068C>T  mutation in 




Supplementary Figure 5: Missense mutations are absent in healthy donors.
Allelic discrimination assays (Supplementary Table 2 and Supplementary Methods online) were performed to screen ge-
nomic DNA from white blood cells of healthy donors (n = 250). (a) Representative result of allelic discrimination assays 
(PCR with allele-specific probes). The missense variant c.2025C>A (exon 17, subject 97) is absent in 250 healthy donors as 
determined by this assay. Blue dots represent subject 97 carrying this mutation (triplicate). Red dots represent 80 healthy donor 
samples and two MDS patients without this mutation (subjects 63 and 73, both in triplicate). Green dots represent 1:1 DNA 
mixtures of subject 97 and subject 63 (triplicate) and of subject 97 and subject 73 (triplicate) creating artificial heterozygotes. 
The black dot represents the No Template Control. Variants were auto-called by the SDS 2.3.2. allelic discrimination program 
(Applied Biosystems). (b) Representative result of allelic discrimination assays (PCR followed by HRM analysis). The missense 
variant c.2068C>T (exon 18,  subject 96) is absent in 250 healthy donors. Blue lines represent 83 healthy donor samples and 
two MDS patients without this mutation (subject 63 and subject 73, both in triplicate). Red lines represent subject 96 carrying 
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Supplementary Figure 6: Expression of wild-type and mutant alleles in subjects 10 and 127.
(a-h) Expression of wild-type and mutant alleles in subjects 10 and 127. (a-c) Subject 10 harbored a heterozygous mutation 
c.2195+1G>A in the donor splice site of intron 19. This resulted in aberrant mRNA splicing as shown by agarose gel electrop-
horesis and sequence analysis of RT-PCR products (Supplementary Methods online). (a) Bone marrow cDNA from subject 
10 was amplified using primers directed against the exon 18/19 boundary and exon 20. The PCR product demonstrated the 
presence of two different transcripts. Amplification of cDNA from the non-neoplastic T cells showed the presence of only one 
transcript. (b) Sequence analysis of the cloned PCR products revealed an aberrant transcript in bone marrow cells, containing 
an insertion of four intronic base pairs G>A, T, T and G between exon 19 and 20. Wild-type transcripts were present in both 
bone marrow cells and non-neoplastic T cells. (c) Wild-type RNA was spliced at the r.2195+1 donor splice site. Mutant RNA 






(d-e) Subject 10 harbored the heterozygous missense mutation c.745G>A in exon 8. Transcripts carrying this mutant were 
expressed as determined by pyrosequencing (Supplementary Methods online). (d) Bone marrow cDNA from subject 10 was 
amplified using primers directed against exon 7 and exon 8 (green arrows), spanning the c.745G>A mutation (indicated in 
red). Pyrosequencing of the PCR products was performed using a nested primer directed against the exon 7/8 boundary (yellow 
arrow). (e) Pyrosequence analysis revealed the presence of both wild-type transcripts (83 %) and mutant transcripts (17 %), as 
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(f-h) Subject 127 carried the heterozygous deletion c.1212-1216delGAAGA in exon 10 resulting in a frameshift. Transcripts 
carrying this mutant were expressed as determined by Genescan and sequence analysis of RT-PCR products (Supplementary 
Methods online). (f ) Bone marrow cDNA from subject 127 was amplified using primers directed against exon 9 and exon 11. 
Genescan analysis unveiled the presence of two different transcripts: a wild-type transcript of the expected 288 bp and a mutant 
transcript of 283 bps (ratio = 2.5 : 1). Genescan analysis of amplified cDNA from bone marrow cells of two healthy donors 
(controls 1 and 2)  showed the presence of the wild-type transcript only. (g) Bone marrow cDNA from subject 127 was amplified 
using primers directed against exon 10 and exon 11. Genescan analysis detected two different transcripts: a wild-type transcript 
of the expected 188 bp and a mutant transcript of 183 bp (ratio = 1.8 : 1). Genescan analysis of cDNA from bone marrow cells 






(h) Sequence analysis of the cloned PCR products confirmed the presence of two different transcripts in the bone marrow cells of 
subject 127. The deleted nucleotides are marked.
Supplementary Figure 7: Aberrations of 7q36.1 correlate with poor survival in MDS.
Kaplan-Meier analysis showing overall survival of MDS patients with and without EZH2/7q36.1 aberrations. Since diagnosis 
material was not available in a subset of patients, overall survival was calculated from the date of diagnosis (a and b) as well 
as from the date of bone marrow (BM) sampling (c and d). p-values were calculated comparing patients with a deletion or 
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Supplementary Figure 8: Alignment of orthologous EZH2 proteins and summary of point mutations.
Alignment of EZH2 orthologs in various species. Blue boxes represent two the SANT domains and the SET domain res-
pectively. Positions of donor splice site and frameshift mutations are indicated in red. In case of donor splice site mutation 
c.1505+1G>T, the first amino acid of the next exon is highlighted in red, since the deduced protein sequence is unknown. 















































Xenopus_laevis 439 ASLFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIISPVIAEDVDTPPRKKKRKHRLWAAHCRKI Drosop-
hila_melanogaster 452 QALYRVLHKVYLKNYCAIAHNMLTKTCRQVYEFAQKEDAEFSFEDLRQDFTPPRKKKKKQRLWSLHCRKI
 
Supplementary	  Figure	  8:	  Alignment	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  EZH2	  proteins	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  summary	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  point	  mutations.	  
  
Alignment  of  EZH2  orthologs  in  various  species.  Blue  boxes  represent  two  the  SANT  domains  and  the  
SET  domain  respectively.  Positions  of  donor  splice  site  and  frameshift  mutations  are  indicated  in  red.  In  
case  of  donor  splice  site  mutation  c.1505+1G>T,  the  first  amino  acid  of  the   ext  exon  is  highlighted  in  
red,  since  the  deduced  prot   sequence  is  unknown.  Missense  mutations  are  indicated  in  green.  
Homo_sapiens               1 M TGKKSEKGPVCWRKRVKSEYMRLRQLKRFR ADEVKSMFS NRQKILERTEI E KQR IQPVHI 
Equus_caballus            1 M TGKKSEKGPVCWRKRVKSEYMRLRQLKRFR ADEVKSMFS NRQKILERTEI E KQR IQPVHI 
Bos_tauru                 1 M TGKKSEKGPVCWRKRVKSEYMRLRQLKRFR ADEVKSMFS NRQKILERTEI E KQR IQPVHI 
Mus_musculus              1 M TGKKSEKGPVCWRKRVKSEYMRLRQLKRFR ADEVKTMFSSNRQKILERTETLNQEWKQRRIQPVHI 
Xenopus_laevis            1 M TGKKSEKGPVCWRKRVKSEYMALRQLK FR ADEVKSMFNTNRQKIMERTEILNQEWKQRRIQPVHI 
Drosophila_me nogaster    1 ---MNSTKVPPEWKRRVKSEYIKIRQQ YKRAD IKEAWIRNWDE HNVQDLYCESKVWQAKPYDP 
 
 
Homo_sapiens              71 LTSV SLRGTRECSVTSDLDFPTQVIPLKTLN VASVPIMYSWSPLQQNFMV DETVLHNIPYMGDEVLD 
Equus_caballus           71 LTSV SLRGTRECSVTSDLDFPTQVIPLKTLN VASVPIMYSWSPLQQNFMV DETVLHNIPYMGDEVLD 
Bos_tauru                71 LTSV SLRGTRECSVTSDLDFPTQVIPLKTLN VASVPIMYSWSPLQQNFMV DETVLHNIPYMGDEVLD 
Mus_musculus             71 M SLRGTRECSVTSDLDFPAQVIPLKTLNAVASVPIMY WSPLQQNFMVEDETVLHNIPYMGDEVLD 
Xenopus_laevis           71 M RG VTSDLD PKQV PLKTLTAVASVPIMY WSPLQQNFMVEDETVLHNIPYMGDEVLD 
Drosophila_me nogaster   66 PH AEVTSYNGIPSGPQKVPICVINAVTPIPTMYTWAPTQQNFMVEDETVLHNIPYMGDEVLD 
 
 
Homo_sapiens             41 Q EELIKNYDGKVH F VELVNALG --------------QYND 
Equus_caballus          41 Q EELIKNYDGKVH F VELVNALG --------------QYND 
Bos_tauru               41 Q EELIKNYDGKVH F VELVNALG --------------QYND 
Mus_musculus            41 Q EELIKNYDGKVH F VELVNALG --------------QYND 
Xenopus_laevis           141 QDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALA---------------------------QYSD 
Drosophila_melanogaster  134 KDGKFIEELIKNYDGKVHGDKDPSFMDDAIFVELVHALMRSYSKELEEAAPGTATAIKTETLAKSKQGED 
 
 
Homo_sapiens             184 D---DDDDDGDD--PEEREEKQKDLEDHRDDKESRPPR-----------------KFPSDKIFEAISSMF 
Equus_caballus           184 D---DDDDDGDD--PDEREEKQKDLEENRDDKESCPPR-----------------KFPSDKIFEAISSMF 
Bos_taurus               184 D---DDDDDGDD--PDEREEKQKDLEESREDKESRPPR-----------------KFPSDKIFEAISSMF 
Mus_musculus             184 D---DDDDDGDD--PDEREEKQKDLEDNRDDKETCPPR-----------------KFPADKIFEAISSMF 
Xenopus_laevis           184 Y---EDDEDGDDNQDDEQDDTAKDQDDNMEDKETQPLR-----------------KFPSDKIFEAISSMF 
Drosophila_melanogaster  204 DGVVDVDADGESPMKLEKTDSKGDLTEVEKKETEEPLETEDADVKPDVEEVKDKLPFPAPIIFQAISANF 
 
 
Homo_sapiens             232 PDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHRKCN 
Equus_caballus           232 PDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLH---- 
Bos_taurus               232 PDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLH---- 
Mus_musculus             232 PDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLH---- 
Xenopus_laevis           234 PDKGTSEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRPCFKYDCFLH---- 
Drosophila_melanogaster  274 PDKGTAQELKEKYIELTEHQDP-ERPQECTPNIDGIKAESVSRERTMHSFHTLFCRRCFKYDCFLHR--- 
 
 
Homo_sapiens             302 YSFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPS 
Equus_caballus           298 -PFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPS 
Bos_taurus               298 -PFHATPNTYKRKNTETALDNKPCGPHCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPS 
Mus_musculus             298 -PFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPS 
Xenopus_laevis           300 -PFHATPNTYKRKNNEAANDGKPCGPHCYQLLEGAREFAAALTAERIKTPPKRPSGRRRGRLPNNTSRPS 
Drosophila_melanogaster  340 LQGHAGPNLQKRRYPELKPFAEPCSNSCYMLIDGMKEKLAADS----KTPPIDSCN-------EASSEDS 
 
 
Homo_sapiens             372 TPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAE 
Equus_caballus           367 TPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAE 
Bos_taurus               367 TPTINVLESKDTDSDREAGAETGGESNDKDEEEKKDETSSSSEANSRCQTPIKMKPNTEPPENVEWSGAE 
Mus_musculus             367 TPTISVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAE 
Xenopus_laevis           369 TPTVNVSEAKDTDSDREAGTETGGESNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAE 
Drosophila_melanogaster  399 NDSNSQFSNKDFN--HENSKDNGLTVN----------SAAVAEINSIMAGMMNITS-----TQCVWTGAD 
 
 
Homo_sapiens             442 ASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKI 
Equus_caballus           437 ASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKI 
Bos_taurus               437 ASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSVIAPAPAEDVDTPPRKKKRKHRLWAAHCRKI 
Mus_musculus             437 ASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPVPTEDVDTPPRKKKRKHRLWAAHCRKI 
Xenopus_laevis           439 ASLFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIISPVIAEDVDTPPRKKKRKHRLWAAHCRKI 


































The characteristics of MDS patients (n = 102), the collection of blood and/or bone marrow 
after obtaining informed consent and the isolation of cells have been described previously3. The 
characteristics of 24 additional MDS patients are described in this paper (Supplementary Table 
1 online). Consecutive subjects from the Radboud University Nijmegen Medical Center (n = 107) 
belonging to all different WHO and IPSS categories and cytogenetic subgroups were included, 
if bone marrow was available, as well as a second cohort of karyotypically normal cases from the 
University Hospital Leuven (n = 19). For control experiments, blood from 250 healthy individuals 
and bone marrow from two healthy donors was obtained after informed consent. Cells were frozen 
in liquid nitrogen until further use. For SNP array analysis and genomic sequencing, DNA was 
extracted from FACS-sorted lymphocyte-depleted bone marrow (n = 41) and Ficoll density gradient– 
isolated mononuclear cells from bone marrow (n = 85). DNA from healthy donors (controls, n = 250) 
was isolated from white blood cells after NH4Cl lysis. RNA from healthy donors (controls, n = 2) 
was isolated from total bone marrow as described.
 
Homo_sapiens             12 Q Y PCDHPRQPCDS CPCVIA NFCEKFCQCS ECQNRFPGCRCKAQCNTKQCP YLA 
Equus_caballus          07 Q Y PCDHPRQPCDS CPCVIA NFCEKFCQCS ECQNRFPGCRCKAQCNTKQCP YLA 
Bos_tauru               07 Q Y PCDHPRQPCDS CPCVIA NFCEKFCQCS ECQNRFPGCRCKAQCNTKQCP YLA 
Mus_musculus             07 Q Y PCDHPRQPCDS CPCVIA NFCEKFCQCS ECQNRFPGCRCKAQCNTKQCP YLA 
Xenopus_laevis          09 Q Y PCDHPRQPCDS CPCVIA NFCEKFCQCS ECQNRFPGCRCKAQCNTKQCP YLA 
Drosophila_me anogaster  2 Q SNH P HPCDMNCSCIQTQNFCEKFCNCSSDCQNRFPGCR KAQCNTKQCPCYLA 
 
 
Homo_sapiens             82 VRECD TC DSKNVSCKNCSIQRGSK HL APSDVAGWGIFI PVQKNEFI I 
Equus_caballus          7 VRECD TC DSKNVSCKNCSIQRGSK HL APSDVAGWGIFI PVQKNEFI I 
Bos_tauru               7 VRECD TC DSKNVSCKNCSIQRGSK HL APSDVAGWGIFI PVQKNEFI I 
Mus_musculus             7 VRECD TC DSKNVSCKNCSIQRGSK HL APSDVAGWGIFI PVQKNEFI I 
Xenopus_laevis          79 VRECD TC DSKNVSCKNCSIQRGSK HL APSDVAGWGIFI DTVQKNEFIS E  
Drosophila_me anogaster  92 VRECD TCKN L KHL MAPSDIA WGIFLKEGAQKNEFI I 
 
 
Homo_sapiens             52 SQD Y CSFL NDFV DATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAI 
Equus_caballus          47 SQD Y CSFL NDFV DATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAI 
Bos_tauru               47 SQD Y CSFL NDFV DATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAI 
Mus_musculus             47 SQD VY KYMCSFLFNLNNDFV DATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAI 
Xenopus_laevis          49 SQD Y CSFL NDFV DATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAI 
Drosophila_me anogaster  61 SQD Y CSFL NDFV DATRKGNKIRFANHSINPNCYAKVM VTGDHRIGIFAKRAI 
 
 
Homo_sapiens             2 Q FFDYRYSQADALKYVGIEREMEIP 
Equus_caballus          17 Q FFDYRYSQADALKYVGIEREMEIP 
Bos_tauru               17 Q FFDYRYSQADALKYVGIEREMEIP 
Mus_musculus             17 Q FFDYRYSQADALKYVGIEREMEIP 
Xenopus_laevis          19 Q FFDYRYSQADALKYVGIEREMEIP 
Drosophila_me anogaster  31 Q G FFDYRYGPTEQLKFVGIEREMEI
p.Y733LfsX6 
p.N675K p.V662CfsX13 p.R690C p.L674K 
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106 RA RA int-2 45,XY,-7[6]/46,XY[4] no
107 RARS RCMD-RS int-1 46,XX,t(3;3)(q21;q26)[10] no
108 RAEB RAEB-1 int-1




109 RA RCMD int-1 45,X,-Y [4]/46,XY[16] no
110 RARS RCMD-RS int-1 normal yes
111 RA 5q- unknown 46,XY, 5q- no





113 RAEB RAEB-1 int-2 45,XX, -7 [8]/46,XX[2] no
114 RA RCMD int-2 46,XY,der(7)t(1;7)(p10;q10)[9]/46,XY[1] yes
115 RAEB RAEB-2 int-2 normal no
116 RA RA int-1 normal no
117 RAEB-t RAEB-2 int-2/high no metaphases, FISH: no deletion 5/7 or trisomy 8/21
no
118 RA RCMD low normal no
119 RAEB RAEB-1 int-2 46,XX,del(5)(q15q33),der(7)del(7)(p11)add(7)(q3?3) [8]/46,XX [2]
no
120 RARS RARS low normal no
121 RAEB RAEB-1 int-2
44~47,XY,-2,-2,-4, del(4)(q31),-5,-7,+15,-







122 RARS RARS low normal no
123 RA RCMD int-1 46,X,t(Y;11;20)(q11;p15;p11)[10] no
124 RA 5q- int-1 46,XX,del(5)(q12q33) [7]/46,XX [3] yes
125 RAEB RAEB-1 int-1 normal yes
126 RA RCMD int-2 47,XX,-7,+21,+22[5] no
127 RA RA low normal no












The SNP array analysis of genomic DNA from 102 MDS patients was performed and described 
previously3. 
Sequence analysis
DNA was extracted using Qiagen spin-columns and DNA quality was checked by gel analysis 
and nanodrop ND-1000 spectrophotometer analysis. We conducted bidirectional sequence 
analysis on PCR-amplified genomic DNA fragments spanning the entire coding region and splice 
sites (Supplementary Fig. 3 online). Sequence variations were confirmed by independent PCR-
amplification and sequencing of the original DNA. To analyze whether the observed variants 
were acquired, DNA from cultured non-neoplastic T cells was amplified and sequenced, whenever 
available (n = 3). To minimize the chance that the remaining putative variants represent SNPs, 
we compared the observed variants with public databases (NCBI SNP and EST database) and 
investigated the presence of missense variants in healthy donors (n = 250) by allelic discrimination 
assays. Detected mutations were described according to the nomenclature explained at http://www.
hgvs.org/mutnomen5.
Cloning of variant sequences
Subject 96 harbored two heterozygous variants (c.1983delA in exon 17 and c.2068C>T in exon 18) 
in close proximity, enabling DNA amplification using primers spanning both variants: forward 
primer 5’ - tgtaaaacgacggccagtTGGGAAAGAGAACTTGGCTGTAGT - 3’ (intron 16) and 
reverse primer 5’- caggaaacagctatgaccCTGGTGTCAGTGAGCATGAAGAC - 3’ (intron 18). The 
generated amplicon was cloned into the pDrive cloning vector (Qiagen). To determine whether the 
variants were mono- or bi-allelic, individual clones were sequenced using primers
5’ -TGGGAAAGAGAACTTGGCTGTAGT - 3’ (forward primer, intron 16),
5’ -CCAGTTCCTTTCAAGCAAGCA- 3’ (reverse primer, intron 17),
5’ -AACAATAGTGTGTTCTTCCAAATGTCA- 3’ (forward primer, intron 17) and
5’- CTGGTGTCAGTGAGCATGAAGAC - 3’ (reverse primer, intron 18).
T cell cultures
To obtain DNA from non-malignant cells, we conducted in vitro expansion of polyclonal T cells from 
frozen blood or bone marrow samples. These samples were depleted of myeloid cells by adherence to 
tissue culture flasks. The remaining cells were cultured for 7-14 days in IMDM (Gibco Invitrogen 
Corporation) supplemented with human serum (10%, PAA Laboratories GMBH), IL-2 (100 IU/
ml) and CD3/CD28 coated beads (Dynabeads, Invitrogen). The purity of T-cells was determined by 
FACS analysis of CD3+ cells. DNA was extracted from T cells when the purity was > 90%. 
155
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Allelic discrimination assay: PCR with allele-specific probes
We examined DNA obtained from 250 healthy donors for the presence of the identified homozygous 
missense variant c.2025C>A (subject 97). Probes (Supplementary Table 2 online) were designed 
for recognition of the variant (FAM-MGB probes, Applied Biosystems) and wild-type (VIC-MGB 
probes, Applied Biosystems) sequences. Primers (Supplementary Table 2 online) spanning the 
site of variation were used in combination with these probes to generate a PCR product of 115 
bp using the 7900HT Fast Real-Time PCR System (Applied Biosystems). MDS samples without 
this mutation (subjects 63 and 73) and the MDS sample with this homozygous missense mutation 
(subject 97) were included in each run in triplicate. Artificial heterozygotes were created by 1:1 
mixing of DNA from subject 97 and subject 63 (triplicate) and subject 97 and subject 73 (triplicate). 
End point VIC/FAM measurements were performed and values were corrected for passive reference 
ROX values. Corrected values were plotted automatically by the SDS 2.3.2. allelic discrimination 
program (Applied Biosystems).
Supplementary Table 2: Primers and probes for allelic discrimination.
UPN Variant Assay Amplification primer and probe




















TCAACTTGAACAATGGT Probe VIC / MGB Wild-type exon 17 - intron 17











exon 18 - intron 18
Allelic discrimination assay: PCR followed by high-resolution melting (HRM) analysis. 
We examined the DNA of 250 healthy donors for the presence of the newly identified missense variant 
c.2068C>T (subject 96). Primers (Supplementary Table 2 online) spanning the site of variation and 
the MeltDoctor™ HRM Master Mix (Applied Biosystems) were used to generate a PCR product of 
123 bp using the 7500 Fast Real-Time PCR System (Applied Biosystems). MDS samples without 
this mutation (subjects 63 and 73) and the MDS sample containing this heterozygous missense 
mutation (subject 96) were included in each run in triplicate. Melting temperatures of the generated 
amplicons were recorded during the subsequent dissociation stage by the 7500 System SDS Software. 
Variants were auto-called and grouped by the HRMv1.0 software (Applied Biosystems).
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Present in T-cell 
fraction 
     
c.87C>T  synonymous p.L29L   1/126 (  0,8) N/A
c.396T>C rs61732845 synonymous p.P132P   3/126 (  2,4) N/A
c.553G>C rs2302427 non synonymous p.D185H 20/126 (16,0) N/A
c.623A>G rs61753264 non synonymous p.D208G   1/126 (  0,8) N/A
c.933T>C  synonymous p.Y311Y   1/126 (  0,8) N/A
c.1457C>T  synonymous p.P486P   2/126 (  1,6) N/A
c.1731G>A rs41277437 synonymous p.P577P   7/126 (  5,6) N/A
c.2113-6C >T  non-coding region non-coding region   2/126 (  1,6) yes
c.2113-9A>G  non-coding region non-coding region   1/126 (  0,8) yes
c.2276+6T >G rs41277434 non-coding region non-coding region 12/126 (  9,5) N/A
RNA isolation and reverse transcriptase reactions. 
RNA was extracted from total bone marrow or expanded T cells using TRIzol Reagent (Invitrogen) 
or RNA-Bee (Bio-Connect). Traces of genomic DNA were depleted from the isolated RNA by 
DNAse I treatment (Invitrogen) according to the manufacturer’s instructions. Reverse transcriptase 
(+RT) reactions on 1 µg of RNA were performed using M-MLV reverse transcriptase (Invitrogen). 
Negative controls containing no reverse transcriptase (-RT) were included to detect remaining traces 
of genomic DNA.
Confirmation of the c.2195+1G>A mutation (subject 10) at the transcript level
Subject 10 carried a heterozygous donor splice site mutation in intron 19 (c.2195+1G>A). To 
determine the effect on splicing, we designed PCR primers spanning the affected intron: forward 
primer 5’ - CCAAACTGCTATGCAAAAGTTATGAT - 3’ (exon 18/19 boundary) and reverse 
primer 5’ - CAGATGTCAAGGGATTTCCATTTC - 3’ (exon 20). PCR reactions were performed 
on cDNA (-RT and +RT). PCR products were analyzed by agarose gel (2%) electrophoresis and by 
sequence analysis of products that were cloned into the pDrive cloning vector (Qiagen).
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Confirmation of the c.745G>A mutation (subject 10) at the transcript level
Subject 10 carried a heterozygous missense mutation in exon 8 (c.745G>A). To determine the presence 
of this mutation in RNA transcripts, we designed primers for amplification and pyrosequencing of 
cDNA, spanning the c.745G>A mutation:
forward amplification primer (exon 7)   
5’ - AATGTTTCCAGATAAGGGCACAG - 3’
reverse amplification primer (exon 8)   
5’ - TTAGCATTTGGTCCATCTATGTTG - 3’
forward pyrosequencing primer (exon 7/8 boundary) 
5’ - AGGAAAAATATAAAGAACTC - 3’
Confirmation of the c.1505+1G>T mutation (subject 73) at the transcript level
Subject 73 carried a donor splice site mutation in intron 12 (c.1505+1G>T). To determine 
the effect on splicing, we designed two PCRs. For the 1st PCR, we used primers spanning the 
affected intron: forward primer 5’ - GGACCAAAACATGTAGACAGGTGTA - 3’ (exon 11/12 
boundary) and reverse primer 5’ - GCAGTGTGCAGCCCACAA - 3’ (exon 13). For the 2nd PCR, 
we used primers spanning the entire 3’ coding region (exon 11/12 to exon 20): forward primer 5’ 
- GGACCAAAACATGTAGACAGGTGTA - 3’ (exon 11/12 boundary) and reverse primer 5’ - 
CAGATGTCAAGGGATTTCCATTTC - 3’ (exon 20). PCR reactions were performed on cDNA 
(-RT and +RT). PCR products were analyzed by agarose gel (2%) electrophoresis and by sequence 
analysis of PCR products.
Confirmation of the c.1212-1216delGAAGA mutation (subject 127) at the transcript level
Subject 127 harbored a heterozygous c.1212-1216delGAAGA mutation in exon 10. To assess the 
presence of this mutation, we designed two PCR assays spanning the affected exon:
forward primer A 5’ - GACCACAGTGTTACCAGCATTTG - 3’ (exon 9), forward 
primer B 5’-AAGAGGACGGCTTCCCAATAA-3’ (exon 10) and reverse primer 
5’-TGTTTGACACCGAGAATTTGCT - 3’ (exon 11, coupled to a 5’ 6FAM label). PCR reactions 
were performed on cDNA (-RT and +RT). PCR products were analyzed by agarose gel (2%) 
electrophoresis and by sequence analysis of products that were cloned into the pDrive cloning 
vector (Qiagen). GeneScan analysis was performed using the 6FAM-coupled PCR products in 







Myelodysplastic syndromes are known as a group of heterogeneous hematopoietic stem cell disorders, 
sharing a dysplastic morphology of erythroid, myeloid or megakaryocytic cells. Multiple classification 
systems are currently in use, or are being developed, to define distinctive subgroups sharing similar 
characteristics. These classification systems are primarily based on morphological features, not on 
differences and similarities in the pathogenesis of the various disease subtypes. Finding specific genes 
or groups of genes that are commonly affected in patients with MDS provides a way to gain more 
insight into the origin of these diseases and eventually to develop novel, targeted therapies. 
Gene expression analysis
In trying to define genes involved in MDS pathogenesis, analysis of mRNA expression patterns has 
drawn a lot of attention. These studies took a flight after the development of micro-array technologies, 
enabling researchers to study the expression of thousands of genes at the same time. It has led to the 
identification of commonly deregulated pathways in MDS, but it has proven difficult to pinpoint 
how these pathways exactly contribute to the development of this disease. In contrast to examining 
global gene expression, the research described in chapter 2 of this thesis focuses on genes involved 
in apoptosis, a process which has often been implicated in the pathogenesis of MDS. We aimed at 
finding similarities between different groups of MDS patients. We restricted the analysis to apoptosis-
related genes, used a microfluidic card platform, which is more sensitive than micro-array analysis, 
and studied three hematopoietic cell populations. In contrast to our expectations, distinct expression 
patterns distinguishing patients from healthy controls or patients with indolent and aggressive forms 
of MDS were not seen. The activity of single genes, such as BIK, could play a role in defining different 
MDS subgroups, but this would require further research. Moreover, studying expression levels of genes 
may increase insight into pathways that are important in MDS pathogenesis, but it does not answer the 
question what mechanisms lie beneath these differences in gene expression. 
Using SNP-arrays to detect genomic aberrations
In the second part of this thesis, a different strategy has been used to define common aberrations 
in MDS patients. The study described in Chapter 3 focuses on finding commonly occurring 
DNA aberrations in MDS. Single Nucleotide Polymorphism (SNP) arrays served as a novel tool 
to study the MDS genome with a higher resolution than had ever been possible before. The aim 
of performing SNP-array analysis in MDS patients was to find small, commonly affected genomic 
regions, which would subsequently lead to the identification of individual genes involved in the 
pathogenesis of MDS. Before focusing on novel chromosomal lesions, we first studied the ability of 
the array technology to detect the known ones. SNP-arrays do not allow the detection of balanced 
chromosomal abnormalities, except copy number (CN) neutral loss of heterozygosity (LOH). Thus, 
translocations or inversions found by karyotyping in our cohort could not be confirmed by SNP-
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array analysis. In some cases, however, one of the genes involved in the translocation could be 
identified because of a microdeletion at the breakpoint (i.e. ETV6 on chromosome 12 in UPN2 
and, likely, MDS1 on chromosome 3 in UPN40). In about 25% of the patients one or more of the 
monosomies or trisomies detected by karyotyping could not be confirmed by SNP-array analysis. 
This applied in particular to trisomies and other aberrations that were only present in a subclone of 
the metaphases analyzed. Taking these observations into consideration, SNP-array based genomic 
profiling cannot be regarded as a complete replacement of karyotype analysis with regard to 
facilitating diagnosis of MDS. However, the capacity of SNP-arrays to detect small deletions and 
amplifications and CN neutral LOH complements the information obtained by karyotype analysis. 
Thus, SNP-arrays may facilitate the diagnosis and prognostic evaluation of MDS patients, but the 
impact on clinical decision making (e.g. should patients with a CN neutral LOH be treated similar 
to patients with a deletion of 7q) remains, as yet, to be determined. In some cases it proved to be 
difficult to compare SNP-arrays and karyotyping because of the presence of marker chromosomes in 
the karyotype. In addition, chromosomal aberrations may have been missed due to ‘contamination’ 
of the samples with non-malignant cells. The SNP-array analysis revealed a large number of novel, 
potentially interesting affected chromosomal regions. Frequently recurring novel micro-deletions or 
amplifications, as have been described in SNP-array analysis of other hematopoietic malignancies, 
were not found. But, by combining the results of patients with large and small genomic aberrations, 
we were able to identify the 4q24 and 7q36 regions, leading to the identification of mutations in 
the TET2 and EZH2 genes (chapters 3 and 5). Of note, the smallest-affected-area that led to these 
genes, was in both cases determined by a single patient, whilst the others carried large chromosomal 
abnormalities. The possible consequences of aberrations in the TET2 and EZH2 genes are discussed 
in the next section. It is not possible without further research to conclude which of the other novel 
regions may be implicated in the pathogenesis of MDS. We attempted to exclude non relevant 
regions by comparing the data with a large panel of controls and the database of normal variants 
to exclude neutral copy number variations (CNVs). We did not include non-malignant cells (such 
as fibroblasts) in the analysis of the bone marrow sample of each individual patient. This may have 
facilitated the discovery of relevant defects. Lymphocytes are in general not regarded as part of the 
malignant clone in MDS and we used these as a control in a subset of patients. However, as discussed 
in the next section, it has been published that (a subclone of) lymphocytes may carry the same 
genetic abnormality as the myeloid cells, thus complicating the interpretation of the relevance of 
possible aberrations found in both cell populations. Perhaps even more difficult than determining the 
disease-specificity of novel aberrations is to determine the extent to which they contribute to disease 
pathogenesis. A substantial part of MDS patients showed complex chromosomal abnormalities. 
Some of these may have been early events in the pathogenesis of the disease, whereas others may 
have arisen due to genetic instability of the malignant MDS clone. To distinguish these so called 
driver and passenger defects requires extensive functional studies. Thus, the interpretation of the 
importance of novel genomic aberrations requires careful evaluation. 
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Copy number (CN) neutral loss of heterozygosity (LOH): which regions count?
CN neutral LOH of partial or entire chromosomes may contribute to the development of MDS, since 
this may lead to homozygosity of mutated genes or transcriptionally repressed or activated (e.g. hyper- 
or hypomethylated) genes. The frequency of partial CN neutral LOH reported in MDS differs. When 
first performing SNP-array analysis we included areas consisting of ≥ 70 consecutively homozygous 
SNPs. In this way, many areas of CN neutral LOH were found, however, in those patients of whom 
T-cells were available, these areas appeared to be identical. Also, small areas of CN neutral LOH were 
frequently found in our healthy controls. We also assessed whether certain chromosomal regions are 
more prone to homozygosity in MDS patients compared to controls by comparing the frequency with 
which (areas of 10 consecutive) SNPs showed homozygosity. This did not lead to the identification of 
single affected genes. In other studies, different criteria have been used to define potentially relevant 
areas of CN neutral LOH. These vary from only the telomeric regions to areas based on their size, e.g. 
>2Mb. In our final analysis, described in chapter 3, we included only large telomeric regions of CN 
neutral LOH. Concerning the areas of CN neutral LOH on chromosomes 4 and 17, we have shown 
that they contain the homozygously mutated TET2 and TP53 genes. The CN neutral LOH detected 
on chromosome 7 led to the identification of homozygous mutations in EZH2, though not in all 
patients. We did not focus on the affected regions on chromosomes 1 and 6, although aberrations in 
these regions have been found by others as well. To answer the question what the role of, in particular, 
the segmental non-telomeric regions of CN neutral LOH is in the pathogenesis of MDS, analysis of 
matched malignant and non-malignant cells of the patients is again essential.
TET2 mutations in malignant hematopoiesis
Using SNP-array technology we identified a commonly affected area in MDS patients on chromosome 
4q24 encompassing the TET2 and PPA2 genes (described in chapter 3). TET2 was shown to be 
mutated on the remaining allele of patients carrying a 4q24 deletion and also in a substantial number 
of patients without 4q24 copy number abnormalities. Overall, TET2 aberrations were detected in 
26% of patients with MDS. Studies performed by other groups have reported an 11-23% incidence 
of TET2 mutations in MDS (Table 1)1-5. Notably, it has recently been reported that TET2 mutations 
can be detected in T-cells of MDS patients as well, though at a lower level than in CD34+ cells 
or whole bone marrow5. Thus, the incidence of TET2 mutations in our and other patient cohorts 
may be an underestimation. We found that TET2 mutations occurred most frequently in patients 
with MDS categorized as IPPS category low or intermediate 1, although the difference was not 
statistically significant. Other groups have shown different patterns of distribution, although all 
report a low frequency in the IPSS high risk category (Table 1)3-5. TET2 mutations have been found 
in patients with other malignancies apart from MDS (Table 2) (chapter 4). Thus finding a TET2 
mutation is not specific for MDS, but could contribute to its diagnosis, especially in the IPSS low 
and intermediate risk groups.
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TET2 mutations in IPSS subgroups  
low int-1 int-2 high
This thesis 102 26% 12/29 (41%) 10/35 (29%) 3/24 (13%) 2/14 (14%)
2 115 23% 4/35 (11%) 13/39 (28%) 8/26 (31%) 1/15 (7%)
3 35 11% 1/11 (9%) 2/8 (25%) 0/4 (0%) 1/7 (14%)
4 59 22% 2/17 (12%) 8/23 (35%) 3/12 (25%) 0/7 (0%)
5 320 12% ns ns ns ns
1 439 21% ns ns ns ns
NS: Not specified
Table 2: TET2 mutations in hematopoietic malignancies
Hematopoietic malignancy TET2 mutations overall Reference
Myeloproliferative neoplasms   
Chronic myeloid leukemia 
(only accelerated phase/blast crisis)
14-20% 65
polycythemia vera 10-16% 2, 6, 66, 67
primary myelofibrosis 8-27% 2, 6, 66, 67 
essential thrombocythemia 2-10% 2, 6, 66, 67
mastocytosis 29% 68
Myeloid/lymphoid neoplasms associated with 
eosinophilia and abnormalities of PDGFRA, PDGFRB, 
FGFR1
absent 68
Myelodyplastic/Myeloproliferative neoplasms  
chronic myelomonocytic leukemia 20-50% 2, 5, 6, 69-74
juvenile myelomonocytic leukemia absent 74-76
RARS-T* 9-26% 2, 74, 77, 78
Myelodysplastic syndromes 11-26%
This thesis,
 2-5, 74, 79 1
Acute myeloid leukemia 12-27%
This thesis,
4, 6, 22, 23, 25, 79, 80
Blastic plasmacytoid dendritic cell neoplasm
53%
 (in 13 patients)
81
B-cell lymphoma 2% 18
T-cell lymphoma 12% 18
Acute lymphoblastic leukemia absent This thesis
* RARS-T is provisionally catagorized as a MDS/MPN 




Tet proteins are involved in hydroxylation of 5-methylcytosine
The family of mammalian Tet proteins consists of Tet1, Tet2 and Tet3 (Figure 1). Tet1, the founding 
member of the Tet proteins, was independently identified by several groups as a fusion partner of MLL 
in patients with acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Mutations of 
the TET1 and TET3 genes have not been described6. The Tet proteins share two C-terminal highly 
conserved regions, which are also present in their orthologues in a variety of species. Tahiliani et al. 
discovered that these conserved regions are partly homologous to the predicted oxygenase (2OGFeDO) 
domain of the trypanosome proteins JBP1 and JBP27. These proteins are involved in the hydroxylation 
of the methyl group of thymine in trypanosomes. Tet1 was shown to be involved in the hydroxylation 
of 5-methylcytosine (5-mC). Subsequent studies showed that Tet2 and Tet3 are involved in the same 
process8, 9. In order to execute their function, Tet proteins must bind iron (Fe2+) and 2-oxoglutarate 
(or ketoglutarate). The functional consequences of 5-mC hydroxylation are an ongoing subject of 
studies. On the one hand, 5-mC hydroxylation may lead to passive demethylation. In this case, the 
methyltransferase DNMT1 no longer methylates its target cytosine when the complementary strand 
contains a 5-hydroxy-methylcytosine (5-hmC) instead of 5-mC. As a result, methylation patterns are 
no longer conserved in dividing cells. On the other hand, Tet proteins have been implicated in active 
demethylation. In this model, hydroxylation of 5mC is the first step in a number of modifications 
(Figure 2). After formation of 5-hmC, conversion to 5-carboxylcytosine (5-caC), 5-formylcytosine 
(5-fC) and 5-hydroxyuracil (5-hmU) may take place, leading, via interaction with various glycosylases 
and proteins of the base excision repair pathway to cytosine10-12. To date, not much is known about the 
presence of 5-hmC in healthy and malignant hematopoietic cells. Ko et al. showed that 5-hmC levels 
are reduced in those patients with myeloid malignancies, in whom TET2 mutations were detected9. 
However, some patients in whom TET2 was not mutated carried low 5-hmC levels as well, indicating 
that other proteins may affect the function of Tet2 or are involved in 5-mC hydroxylation themselves. 
Two of these proteins may be Isocitrate dehydrogenases (Idh) 1 and 2. Idh1 and Idh2 normally 
catalyze the conversion of isocitrate to 2-oxoglutarate. When mutated, they gain a novel function, 
namely the conversion of 2-oxoglutarate to 2-hydroxyglutarate (2-HG)13, 14. This may disrupt the 
function of 2-oxoglutarate-dependent proteins, such as Tet2. Considering the clinical heterogeneity of 
the diseases associated with TET2 aberrations and the fact that TET2 mutations co-occur with many 
other genetic defects, it seems unlikely that TET2 mutations alone cause hematopoietic malignancies 
(Tables 2 and 3). Studies in TET2 conditional knockout mouse models, have shown that loss of 
the TET2 gene leads to expansion of the hematopoietic stem cell compartment and eventually a 
phenotype mostly resembling CMML 15-19. In conclusion, mutations in the TET2 gene are thought 
to lead to aberrant DNA methylation patterns, disturbing the expression of genes that influence cell 
differentiation and survival. Which genes are affected by these aberrant methylation patterns, and how 
this leads to the development of diverse malignancies, requires combined analysis of Tet2’s target genes 
and their expression levels. There is also little known about the differences in function between the 
Tet1, Tet2 and Tet3 proteins. The results of knock-down experiments suggest that these proteins are 
not mutually exclusive. If formation of 5-hmC physiologically leads to demethylation and if defects 
in the Tet proteins disturb this process, this is in agreement with the hypothesis that hypermethylation 
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contributes to development of myeloid malignancies. As described in the introduction of this thesis, 
demethylating agents are available in clinical practice and are currently under investigation in clinical 
trials.  It is not known if patients with defects of Tet proteins show a specific response to these agents. 
The largest study, performed in 86 MDS patients (13 carrying a TET2 mutation) treated with 
azacitidine, reported a better response rate in patients carrying a TET2 mutation, but found  no 
differences in response duration or overall survival20. 
Figure 1: Tet family of proteins
Schematic representation of the three Tet proteins. Box 1 and Box 2 are conserved regions between the Tet orthologues and 
homologues and contain a Cys-rich region and the 2-oxoglutarate (2OG) and iron (Fe2+ binding domain. Tet1 is distinguished 
by the DNA binding CXXC domain.
Figure 2: Role of the Tet proteins in active demethylation
Tet1, Tet2 and Tet3 are involved in the hydroxylation of 5-methylcytosine. When this process has taken place, 5-hydroxy-
methylcytosine is thought to be converted to either 5-hydroxyuracil (5hmU),  5-carboxylcytosine (5caC) or 5-formylcytosine 
(5fC) and subsequently to cytosine. AID: activation-induced deaminase. APOBEC: apolipoprotein B mRNA-editing enzyme 
complex. DNMTs: DNA methyltransferases.
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Tabel 3: Mutations co-occurring with TET2 mutations*
Gene Function Hematopoietic malignancy
JAK2 Signal transduction MDS, MPN (PV, ET, PMF), MDS/MPN1, 2, 5, 6, 25, 57, 66-68, 71, 74, 78, 82
KIT Signal transduction MPN (systemic mastocytosis), (secondary) AML68, 80, 83
MPL Signal transduction MPN (PMF), MDS/MPN (RARS-T)2, 6
Flt3 Signal transduction (secondary) AML, MDS/MPN (CMML)14, 22, 23, 25, 80, 82, 83
RAS Signal transduction MDS, MDS/MPN (CMML), (secondary) AML1, 25, 57, 69-71, 80, 82, 83 
PTPN11 Signal Transduction MDS/MPN (CMML)70
MLL Histone methylation AML80
EZH2 Histone methylation MDS, MDS/MPN (CMML)1, 57, 69, 82 (this thesis)
UTX Histone demethylation MDS/MPN (CMML)69
DNMT3A DNA methylation MDS/MPN (CMML)69, 80
ASXL1 Chromatine remodelling MDS, MPN, MDS/MPN, (secondary) AML1, 4, 57, 69, 70, 72, 80, 82, 84 
c-Cbl E3 ubiquitin ligase MDS, MPN (MPN-U), MDS/MPN, (secondary) AML 1, 25, 57, 65, 69, 71 
NPM1 Nucleo-cytoplasmic transport MDS, MDS/MPN (CMML), (secondary) AML 1, 4, 22, 23, 25, 57, 80, 83 
RUNX1 Transcription factor MDS, MDS/MPN (CMML), (secondary) AML1, 25, 57, 70, 71
CEBPalpha Transcription factor (secondary) AML14, 23, 25, 80 
WT1 Transcription factor (secondary) AML14, 23, 83 
PHF6 Regulation transcription AML14 
TP53 Apoptosis, DNA repair, cell 
cycle regulation
MDS, AML1, 14 
IDH1/IDH2 Isocitrate dehydrogenase MDS, MPN, MDS/MPN, (secondary) AML 23, 25, 69, 70, 85, 86
*Of note, co-occurrence has been described in individual patients, in most cases it has not been proven that co-occurrence occurs 
in the same cell.
Influence of TET2 aberrations on prognosis
In the MDS patient cohort described in this thesis, no significant difference in overall survival between 
TET2 mutated and wild type patients was found. In the literature, there is no consensus regarding the 
impact of TET2 mutations on prognosis. Kosmider et al. found a significantly better overall-, leukemia-
free and event-free survival of TET2 mutated MDS patients (n=88)21. When studying separate IPSS 
(international prognostic scoring system) groups, the overall survival of TET2 mutated patients was 
significantly better than TET2 wt patients in the IPSS low and int-1 risk groups, but not (significantly) 
in the int-2 and high risk populations. Another study by Smith et al. showed no significant difference in 
overall survival5. Interpretation of survival data in MDS is difficult due to the heterogeneity of the disease 
and of the treatment patients receive. We did not find a statistically significant correlation between 
TET2 allelic burden and WHO classification or IPSS classification in MDS patients. However, it must 
be noticed that the sequencing technique we used is not sensitive enough to detect TET2 mutations 
in small subpopulations. The effect of the TET2 allelic burden may of course be influenced by the 
co-occurrence of other genetic defects. In two Tet2 knockout mouse models, it was shown that both 
homozygous and heterozygous deletions of the TET2 gene resulted in a similar phenotype16, 19. A third 
study showed a more profound phenotype in the homozygous knockout17. 
In AML, studies performed so far mostly indicate a negative impact of TET2 mutations on prognosis. 
Nibourel et al. reported no significant difference in overall and disease free survival in a cohort of 
111 AML patients. However, their cohort contained only patients who achieved complete remission, 
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which may have influenced the outcome22. Metzeler et al. found an unfavorable prognostic impact 
of TET2 mutations in the ELN (European Leukemia Network) favorable AML group (normal 
karyotype + CEBPamut/NPM1mut, not Flt3mut), but not in the remainder of their karyotypically 
normal AML cohort23. Chou et al. found a worse prognosis in patients with TET2 mutations and 
intermediate risk cytogenetics24. In addition, Weissman et al. described a worse prognosis in AML 
patients with  normal karyotypes if TET2 mutations were present25.
EZH2 mutations in malignant hematopoiesis
Although the role of Tet2 in epigenetics has only recently been partially elucidated, the function of 
Ezh2 has been the subject of various studies prior to the detection of mutations in hematological 
malignancies. The SET-domain of Ezh2 possesses methyltransferase activity which enables it to 
add methyl groups to lysines in histones. In case of Ezh2, histone 3 lysine 27 (H3K27) is its main 
substrate. H3K27 can be mono-, di- or trimethylated. Trimethylation of H3K27 is associated with a 
more compact chromatin structure and ultimately gene silencing. Ezh2 cannot perform this activity 
by itself, but needs to be incorporated in the polycomb repressive complex 2 (PRC2)26-29(Figure 3). 
Mutations in other components of the PRC2, SUZ12, and EED, have been described in a small 
number of MDS/MPN patients30. Additional proteins have been described that are not part of 
PRC2 itself, but are able to modulate its activity. For example, Jarid2, belonging to the jumonji 
family of proteins, interacts with Ezh2. The target genes of Jarid2 and PRC2 show a large degree of 
overlap. JARID2 was one of the genes which we found to be deleted in multiple patients using SNP-
array analysis (Chapter 3). Point mutations of the JARID2 gene have not been found in our patient 
cohort 31, but they have been described in 2% of MDS/MPN patients30. Ezh2 expression patterns 
have been studied in various cell populations during normal hematopoiesis. In addition to a role of 
Ezh2 in early hematopoietic differentiation, it has been implicated in B- and T-cell development32-37. 
PRC2 mediated modification of histones is important to establish and maintain gene expression 
patterns during various stages of development, such as stem cell maintenance, lineage commitment 
and senescence. Accordingly, an increase or decrease in the activity of the PRC2 or changes in its 
substrate specificity may result in severe disruption of these processes. In normal and malignant 
hematopoietic cells, Ezh2 expression was shown to correlate with increased proliferation38. In the 
past, overexpression of Ezh2 has been linked to various malignancies, including carcinomas of the 
prostate, breast, stomach, liver, lung and bladder39-43. Overexpression of Ezh2 in these malignancies 
has been related to increased aggressiveness of the tumor and poor clinical outcome. Support for the 
hypothesis that Ezh2 was involved in oncogenesis was found in experiments in which knockdown 
of Ezh2 in cancer cells resulted in growth arrest44, 45, diminished tumor growth46 and metastasis47, 
whereas ectopic overexpression induced growth factor independence45. 
The mechanisms leading to increased Ezh2 expression in malignancies have been partially 
elucidated. In a subset of cancers, the EZH2 genomic locus is amplified39, 40, 44, 48 directly leading 
to overexpression. Alternatively, expression of EZH2 is disturbed by defects in EZH2 regulating 
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factors. For example, micro-RNA 101 has been shown to inhibit EZH2. In a subset of prostate and 
bladder carcinoma cells, levels of micro-RNA 101 were found to be reduced, either by somatic loss 
of the genomic locus or by other mechanisms, leading to increased EZH2 levels49, 50. In addition, 
molecular pathways, such as those involving pRB-E2F and P53, have been shown to suppress EZH2 
expression, an activity that might be lost in cancer where these pathways are frequently found to be 
disturbed39, 51.
In 2010, mutations of the EZH2 gene were reported in follicular and diffuse large B-cell lymphomas52. 
The mutations all resulted in replacement of a tyrosine on position 641 in the SET domain of 
Ezh2 (Y641). In vitro assays measuring trimethylation activity of four different mutants showed 
that the ability of the mutants to trimethylate the H3K27 peptide was markedly reduced. Thus, 
it appeared that loss of Ezh2 function contributed to the pathogenesis of these malignancies, in 
contrast to the Ezh2 overexpression reported in many other types of cancer. However, subsequent 
studies have reported a decreased ability of the Ezh2 Y641 mutants to trimethylate unmethylated 
or monomethylated substrates but an increased ability to trimethylate dimethylated H3K27. As 
long as a wild type copy of Ezh2 is present, it compensates for the mutant’s decreased affinity for 
unmethylated and monomethylated substrates. Overall, this results in an increase of H3K27Me3, in 
line with the expected increase in H3K27Me3 in cells overexpressing Ezh253, 54.
We detected various mutations located in different regions of the EZH2 gene in MDS. Although part 
of the mutations are missense mutations, which may result in a similar change of substrate specificity 
of Ezh2 as reported for the Y641 mutation, nonsense mutations predicted to lead to a truncated 
protein were identified as well. Since all predicted truncated proteins lack (part of) the SET domain, 
which confers Ezh2’s catalytic activity, these mutations most likely lead to loss of function. Several 
other groups have reported similar mutations in myeloid malignancies (Table 4). These findings are 
in contrast with the reports of increased Ezh2 activity in diverse malignancies. Although studies have 
Figure 3: Schematic representation of the Polycomb repressive complex 2
PRC2 consisting of the core components EZH2, SUZ12, EED and RBB4/7. 




thus far shown that Ezh2 depletion leads to decreased proliferation and tumor growth, in specific 
circumstances, reduced expression of Ezh2 may contribute to leukemogenesis. For example, it has 
been shown that in hematopoietic stem cells, several genomic regions carry both active (H3K4me2 
and H3K4me3) and repressive (H3K27me3) histone marks55. During differentiation, the balance 
between these marks shifts, favoring either activation or repression of specific genes. In some cases 
the bivalent pattern persists during differentiation. A shift in this balance by defects in the EZH2 
gene, may lead to increased expression of genes involved in oncogenesis.
Table 4: EZH2 mutations in hematopoietic malignancies
Hematopoietic malignancy EZH2 mutations overall Reference
Myeloproliferative neoplasms   
chronic myelogenous leukemia (only atypical and 
accelerated phase/blast crisis)
0-13% 56
polycythemia vera 3% 56
primary myelofibrosis 6-13% 56, 82, 87
essential thrombocythemia absent 56
mastocytosis absent 56
Myeloid/lymphoid neoplasms associated with 
eosinophilia and abnormalities of PDGFRA, 
PDGFRB, FGFR1
absent 56
Myelodyplastic/Myeloproliferative neoplasms  
chronic myelomonocytic leukemia 11-13% 56, 57, 82
Myelodysplastic syndromes 6% This thesis, 1, 56
Acute myeloid leukemia absent 56 6, 79
Lymphomas
Immunodeficiency-related NHL (exon 15)
(2xTyr641, 1x other locus within SET domain)
3% 88
follicular lymphoma (Tyr641) 7-12% 52, 89
splenic B-cell mariginal zone lymphoma 
(entire gene)
absent 90
diffuse large B-cell lymphoma (Tyr641) 10% 52
mantle cell lymphoma, small lymphocytic 
lymphoma, peripheral T-cell lymphoma (Tyr641)
absent 52
Influence of EZH2 aberrations on prognosis
The EZH2 gene is located on the long arm of chromosome 7. Deletions of the long arm of 
chromosome 7 have been associated with a worse prognosis in MDS patients. In our patient cohort, 
we also observed that overall survival in this group was reduced. The contribution of the deletion 
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of the EZH2 gene to this phenomenon is unknown. However, patients with an EZH2 mutation 
without a 7(q) deletion appeared to have a worse prognosis as well, although this must be interpreted 
with caution, since we did not study this effect in a prospective study of a homogeneously treated 
patient population. Similar results, pointing towards a worse prognosis in MDS and MDS/MPN 
patients carrying EZH2 mutations, have been found by others1, 56, 57.
TET2 and EZH2
The detection of mutations in the TET2 and EZH2 genes implicates two novel genes, involved 
in epigenetics, in the pathogenesis of MDS. In our MDS patient population, co-occurrence of 
TET2 and EZH2 mutations was frequently detected, pointing towards defects in both DNA and 
histone methylation. Loss of Tet2 protein function may lead to DNA hypermethylation, whereas 
the mutations found in EZH2 are proposed to lead to decreased H3K27 trimethylation. This raises 
the question if and how these processes are related. It has been hypothesized that binding of the 
PRC2 complex to DNA leads to recruitment of DNA methyltransferases and subsequent de novo 
methylation58-60 in cancer cells. This phenomenon might explain increased DNA methylation in 
case of Ezh2 overexpression. However, in MDS we assume that normal Ezh2 function is lost. In 
contrast to the hypothesis mentioned above, other studies have found that several well known 
targets of DNA hypermethylation, such as CDKN2A, show no H3K27 trimethylation, and, 
likewise, not all H3K27 trimethylated genes show DNA hypermethylation. Also, inactivation of 
Ezh2 leads to reactivation of genes silenced by H3K27 trimethylation, but not of genes silenced by 
DNA methylation61-63. In case of Tet1 it has been suggested that its binding to genomic targets in 
embryonic stem cells partly co-occurs with both activating and repressing (such as H3K27) histone 
modifications64. However, in genome wide studies it proves difficult to determine if all modifications 
occur on the same DNA strand. Processes involving DNA and histone methylation thus seem to be 
intertwined, but to what extent, under which circumstances and at which genomic regions remains 
to be elucidated. Combining techniques such as Chip-sequencing and RNA-sequencing may in the 
future resolve some of these questions.
Conclusion 
This thesis describes the identification of genetic aberrations in patients suffering from MDS. Two 
novel defects, those in the TET2 and EZH2 genes are studied in more detail in patients with MDS 
and other hematopoietic malignancies. Both defects are thought to result in deregulation of the 
epigenetic processes of DNA and histone methylation. In what way this deregulation results in 
aberrant differentiation, proliferation and cell death remains to be elucidated. 
171
Overview and Discussion
Table 5: Mutations co-occurring with EZH2 mutations


























MDS, MDS/MPN (CMML)1, 57
MPN, MDS/MPN (CMML)57, 82
MDS, MDS/MPN (CMML)57, 82, This thesis
MDS, MDS/MPN (CMML)1, 57
MDS1
MDS, MDS/MPN (CMML)1, 57
MDS1
MDS1 
MDS, MDS/MPN (CMML)1, 57
*Of note, co-occurrence has been described in individual patients, in most cases it has not been proven that co-occurrence occurs 
in the same cell.
Figure 4: Possible role of EZH2 and TET2 in gene expression
An active configuration of chromatin, represented in (a) lacks trimethylation of histone H3K27 and contains unmethylated 
DNA. Trimethylation of H3K27 by EZH2 (as part of PRC2) and methylation of cytosines are thought to lead to a more con-
dense chromatin structure and decreased gene expression (b). Cytosine methylation is thought to be reversed by a multistep process 
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Het menselijk lichaam kan niet zonder goed functionerende bloedcellen. Er zijn drie soorten 
bloedcellen te onderscheiden: rode bloedcellen (erythrocyten), witte bloedcellen (leukocyten) en 
bloedplaatjes (trombocyten). De rode bloedcellen zijn nodig voor het zuurstof transport naar alle 
organen, zoals hart en hersenen. Personen met een tekort aan goed werkende rode bloedcellen 
hebben bloedarmoede (anemie). De witte bloedcellen zijn nodig voor de afweer tegen bacteriën, 
virussen, schimmels en parasieten. Functioneren deze cellen niet goed, dan heeft een persoon 
een vergrote kans op (ernstige verlopende) infecties. De bloedplaatjes zorgen voor de stolling 
van bloed. Dus, bij een tekort hieraan krijgen mensen eerder blauwe plekken, neusbloedingen 
en blijven wonden langer en heftiger nabloeden. De verschillende soorten bloedcellen worden 
gemaakt in het beenmerg en ontstaan daar uit dezelfde voorloper cel, of stamcel. Bij mensen die 
lijden aan een myelodysplastisch syndroom (MDS) verloopt de ontwikkeling van stamcel naar rijpe 
bloedcellen niet naar behoren. Hierdoor ontstaan tekorten aan rijpe bloedcellen en functioneren 
de gevormde bloedcellen niet adequaat. Sommige personen met MDS ontwikkelen na verloop van 
tijd leukemie. Wat er precies ten grondslag ligt aan deze abnormale bloedcelvorming is niet goed 
bekend. Dit is het onderwerp van het onderzoek beschreven in dit proefschrift.
Bij een groot deel van de personen met MDS is in het verleden aangetoond dat er weliswaar 
rode en witte bloedcellen en bloedplaatjes worden aangemaakt in het beenmerg, maar dat veel 
van deze cellen sterven voordat ze het bloed bereiken. In hoofdstuk 2 van dit proefschrift wordt 
onderzocht of dit komt door abnormale activiteit van genen die betrokken zijn bij apoptose. 
Genen zijn stukjes van het DNA die de code vormen voor eiwitten. Eiwitten op hun beurt zijn 
verantwoordelijk voor de uitvoering van alle processen die zich in een cel afspelen, zoals het 
stimuleren van celgroei of juist het remmen hiervan. Apoptose wordt ook geprogrammeerde 
celdood genoemd. Hiermee wordt bedoeld dat een cascade van reacties in de cel in gang wordt 
gezet, onder controle van verschillende factoren, die er uiteindelijk toe leidt dat een cel sterft. In 
voorgaand werk door andere onderzoekers wordt gesuggereerd dat apoptose gestoord is bij MDS, 
waardoor cellen sneller sterven. Dit heeft geleid tot het onderzoek dat is beschreven in hoofdstuk 
2, waarin de activiteit van verschillende genen, zowel genen die apoptose bevorderen als remmen, 
gemeten is.  Bij deze experimenten zijn beenmergcellen van patiënten met MDS vergeleken met 
die van gezonde mensen.  Hieruit bleek dat er, op basis van de activiteit van alle genen samen, 
geen duidelijk onderscheid te maken is tussen personen met en zonder MDS. Wel konden enkele 
specifieke genen, zoals het gen BIK, onderscheiden worden waarvan de activiteit verschilde tussen 
de onderzochte groepen. 
Een verstoorde activiteit van genen, zoals de apoptose-genen, kan bijdragen aan het ontstaan van 
MDS. Echter, de vraag blijft waardoor deze verstoring veroorzaakt wordt. Om hier meer inzicht 
in te krijgen, richt het onderzoek in hoofdstuk 3 van dit proefschrift zich niet op de activiteit van 
genen, maar op de genen zelf. Zoals beschreven zijn genen stukjes van het DNA. DNA is een code, 
door wetenschappers weergegeven door vier verschillende letters: A, T, G en C. Het DNA van de 
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mens bestaat uit miljoenen A’s, T’s, G’s en C’s.  Tezamen vormen zij de blauwdruk voor het lichaam. 
Het DNA is georganiseerd in 46 chromosomen.  De chromosomen worden aangeduid met nummers 
(1 tot en met 22, van elke chromosoom twee kopieën) en, in het geval van geslachtschromosomen, 
met letters (X en Y bij mannen, X en X bij vrouwen). De helft van deze chromosomen erft een 
persoon van zijn vader, de andere helft van zijn moeder. Als een cel in het lichaam zich deelt, moet 
het DNA behouden blijven. Dus, voorafgaand aan een celdeling, wordt het DNA verdubbeld. 
Vervolgens wordt het gelijk verdeeld over de twee nieuwe cellen die uit de deling voortkomen. Soms 
ontstaan er ongewild veranderingen in de DNA code van een cel. Een “C” wordt bijvoorbeeld 
veranderd in een “G”. Dit noemen we een mutatie.  Als zo’n verandering eenmaal ontstaan is, wordt 
hij bij deling van de cel doorgegeven aan de nieuwe cellen die uit de deling voortkomen. Dit is 
niet de enige verandering die kan optreden. Zo kunnen er bij het verdubbelen van het DNA en het 
verdelen van chromosomen tijdens een celdeling ook grotere stukken van de DNA code verloren 
gaan (een deletie) of juist teveel DNA in de nieuwe cel eindigen (duplicatie of amplificatie). Een 
bijzonder soort van afwijkingen dat tijdens de celdeling kan ontstaan, noemen we uniparentale 
disomie. Hierbij wordt (een deel van) een chromosoom dat oorspronkelijk afkomstig is van de vader 
vervangen door een kopie van (een deel van) het chromosoom van de moeder. Een cel bevat dan nog 
steeds in totaal twee kopieën van het betreffende chromosoom, maar omdat de chromosomen die 
van vader en moeder afkomstig zijn, nooit helemaal exact dezelfde ATGC code bevatten, kunnen 
ook hierdoor problemen ontstaan. In hoofdstuk 3 wordt de zoektocht beschreven naar DNA 
afwijkingen in de bloedcellen van personen die lijden aan MDS. Om deze DNA afwijkingen op 
het spoor te komen, is gebruik gemaakt van zogenaamde “SNP (Single Nucleotide Polymorphism)-
arrays”. Met deze techniek is het mogelijk om het DNA van een patiënt te vergelijken met het DNA 
van gezonde mensen. Zo kan men bepalen of er een stukje van het DNA van een persoon ontbreekt 
(een deletie) of juist teveel is (duplicatie of amplificatie). Ook kunnen gebieden met uniparentale 
disomie worden opgespoord. Mutaties, daarentegen, kunnen niet worden opgespoord met de SNP-
arrays. De analyses met de SNP-arrays brachten een groot aantal DNA afwijkingen aan het licht in 
het beenmerg van personen met MDS (hoofdstuk 3, figuur 1). Door de afwijkingen van een groot 
aantal patiënten te vergelijken, kan een schatting worden gemaakt over het belang van de afwijking. 
Als een afwijking bij veel patiënten voorkomt, is de kans groot dat deze betrokken is bij het ontstaan 
van de ziekte. Het vervolg van het onderzoek in hoofdstuk 3 heeft zich geconcentreerd op een van 
deze vaker voorkomende afwijkingen, namelijk een afwijking van chromosoom nummer 4. In de 
beenmergcellen van twee personen bleek een stuk van een van de twee chromosomen nummer 4 te 
ontbreken.  Een vergelijkbaar gebied was bij vier andere personen betrokken bij uniparentale disomie. 
Bij het vergelijken van alle afwijkende gebieden op chromosoom 4, bleek er een klein stukje DNA bij 
al deze patiënten aangedaan te zijn: het stuk dat het TET2 gen bevat. Vervolgens is onderzocht bij 
alle patiënten in de studie, dus ook degenen zonder grote, met de SNP-array zichtbare, afwijkingen 
op chromosoom 4, of er mutaties in het TET2 gen opgetreden waren. Dit bleek inderdaad het geval. 
In totaal was bij 26% van de patiënten het TET2 gen afwijkend. Hoewel dit misschien niet veel lijkt, 
is er niet eerder een gen beschreven dat bij zoveel MDS patiënten is aangedaan. 
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Het TET2 gen bleek actief te zijn in verschillende soorten bloedcellen, waaronder twee soorten 
witte bloedcellen, granulocyten en B-cellen. Om te onderzoeken of het TET2 gen ook gestoord is 
bij andere aandoeningen dan MDS, zijn daarom twee andere ziektebeelden onderzocht, waarbij 
de vorming van (onder andere) granulocyten en B-cellen onderdrukt is, namelijk acute myeloide 
leukemie (AML) en acute lymfatische leukemie (ALL). Omdat het laatst genoemde ziektebeeld 
relatief vaak bij kinderen voorkomt, is eerst het TET2 gen onderzocht in het beenmerg van 
kinderen met AML of ALL. Dit wordt beschreven in hoofdstuk 4. Bij 4% van de kinderen met 
AML werden afwijkingen in het TET2 gen gevonden. Bij de kinderen met ALL konden geen 
TET2 veranderingen worden aangetoond. Ook in AML blijkt het TET2 gen dus gestoord te zijn, 
hoewel bij een kleiner deel van de patiënten in vergelijking met MDS. 
Mede naar aanleiding van de door ons en anderen beschreven mutaties, heeft ook de functie van 
het TET2 eiwit veel aandacht gekregen. Hoewel de DNA volgorde (de A, T, C en G) de opbouw 
van de eiwitten bepaalt, kan er in het DNA molecuul ook nog een code worden gestopt die mede 
bepaalt of dat stuk van het DNA wel of niet wordt afgelezen. Deze code bepaalt dus mede of 
genen op dit stuk DNA actief zijn. Andere onderzoekers hebben laten zien dat het TET2 eiwit 
is betrokken bij het chemisch veranderen van het DNA molecuul. Hoewel het nog niet helemaal 
duidelijk is, lijkt deze verandering betrokken te zijn bij het opnieuw leesbaar maken van DNA dat 
door andere eiwitten was afgesloten. Bij afwijkingen in het TET2 gen, kan het TET2 eiwit niet 
meer normaal functioneren. Hierdoor kan de leesbaarheid van DNA en dus de activiteit van vele 
andere genen mogelijk beïnvloed worden.  
In hoofdstuk 5 tenslotte wordt een andere afwijking belicht die gevonden is in het DNA van 
MDS patiënten met behulp van de SNP-arrays. Het betreft een afwijking op chromosoom 7. 
Afwijkingen op een deel van chromosoom 7 zijn in het verleden vaker gevonden bij personen 
met MDS. Deze personen blijken vaker een slechtere prognose te hebben dan degenen zonder 
deze afwijkingen. Het was echter niet bekend in welk gen of welke genen op chromosoom 7 zich 
afwijkingen bevonden die betrokken kunnen zijn bij het ontstaan van MDS. Door opnieuw de 
SNP-array resultaten van alle patiënten met een afwijking op chromosoom 7 te vergelijken, is het 
gelukt om een klein gebied op te sporen dat bij al deze patiënten overlapt. Dit gebied bevat het 
EZH2 gen.  Het eiwit waar dit gen voor codeert is, net als TET2, betrokken bij het reguleren van 
de leesbaarheid van het DNA. Alleen EZH2 doet dit op een andere manier. Het DNA zit strak 
ingepakt in eiwitten, genaamd histonen, en is daarmee niet altijd even bereikbaar voor andere 
eiwitten die genen kunnen activeren. EZH2 zorgt voor een chemische verandering van een van 
de histonen, waardoor de manier waarop het DNA is ingepakt verandert. Het uitschakelen van 
EZH2, bijvoorbeeld door de mutaties die wij hebben gevonden, heeft grote gevolgen voor dit 
proces. Hoewel dat niet in onze studie is aangetoond, is de verwachting dat hierdoor ook de 
activiteit van andere genen in de cel veranderd kan zijn. 
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Nederlandse samenvatting
Samengevat laat dit proefschrift zien dat er bij patiënten met MDS frequent veranderingen 
voorkomen in de TET2 en EZH2 genen en dat hierdoor mogelijk de activiteit van andere genen 
in de bloedcellen verandert, wat bij kan dragen aan het ontstaan van MDS en AML. Een van de 
groepen genen, waarvan een veranderde activiteit beschreven is bij MDS zijn de apoptose genen. 






Vele mensen hebben een bijdrage geleverd aan het tot stand komen van dit proefschrift en nu we op 
de laatste pagina’s zijn aangekomen, wil ik hen dan ook bedanken. 
Beste Theo, in 2001 spraken wij elkaar voor het eerst over de mogelijkheden van onderzoek binnen 
de hematologie. Jij regelde toen dat ik stage kon gaan lopen bij de groep van John Tisdale op het 
NIH. Toen ik in 2005 opnieuw langskwam, maar nu voor onderzoek in Nijmegen zelf, hielp je mij 
weer op weg. Ik heb veel geleerd van jouw kennis over myelodysplastische syndromen, je enthousi-
asme en inzet voor de kliniek en het laboratorium en het stimuleren van een nauwe samenwerking 
tussen beiden.
Beste Joop, de afgelopen jaren heb je een belangrijke rol gespeeld bij het begeleiden van het MDS 
onderzoek.  Ik heb enerzijds kunnen profiteren van je praktische kennis over experimenten en je ei-
genschap om altijd de rode draad in het onderzoek te kunnen blijven zien, maar heb ook meer kunnen 
leren over ‘de business’ van het onderzoek doen, zoals het schrijven van beursaanvragen. Ik hoop dat je 
in de toekomst in de positie zult zijn om vele AIO’s op deze manier te kunnen begeleiden.
Beste Bert, vanaf de eerste werkbesprekingen heb je altijd actief meegedacht over de mogelijkheden 
binnen het MDS onderzoek. Je volgde alle literatuur op de voet en je kwam dan ook regelmatig met 
een artikel langslopen. Ik hoop dat er nooit iets van dat enthousiasme verloren gaat. 
Beste Roland, de SNP-arrays spelen een belangrijke rol in dit proefschrift en vanaf het begin ben jij 
hierbij betrokken geweest. Ook heb je de studie naar TET2 mutaties bij kinderen met leukemie bege-
leidt.  Ik wil je bedanken voor je hulp en kritische blik bij het analyseren en interpreteren van de data.
Beste Ruth, bij elk onderzoek in dit proefschrift ben jij als analist betrokken geweest. Ik heb, net als 
vele andere AIO’s en postdocs, gebruik kunnen maken van jouw laboratoriumervaring. Maar los van 
het praktische werk, heb ik zowel de leuke als de minder leuke aspecten van het doen van onderzoek 
met je kunnen bespreken. Jij bent de stabiele factor in een onderzoeksgroep die steeds van samenstel-
ling wisselt. En die stabiele factor heb ik graag naast mij als paranimf op de dag van mijn promotie.
Beste Thessa, jij bent als student bij de TRIAD/GFI groep begonnen, maar gelukkig daarna naar de 
TET groep overgestapt. Jouw manier van werken is een aanwinst voor het lab. Helaas is ons laatste 
‘klimuitje’ al weer een tijd geleden, maar ik hoop dat we in de toekomst weer wat mooie routes kun-
nen uitzoeken. Ik vind het erg fijn dat je paranimf bij mijn promotie wilt zijn.
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Dankwoord
Beste Mariam, jij was mijn eerste student op het lab en in de tijd dat we de eerste TET2 mutatie 
vonden. We hadden toen nog geen idee wat dat gen deed, maar vonden het des te spannender om dit 
uit te gaan zoeken. Jij bent nu nog druk bezig om onderzoek te doen naar de functie van TET2. Dat 
is niet makkelijk gezien de toenemende concurrentie, maar ik weet zeker dat je je onderzoek tot een 
goed einde zal brengen.
Beste Gorica, er is volgens mij geen proef die je niet kan. Al je ervaring als analist stop je nu in je pro-
motieonderzoek, dat ongetwijfeld een uitstekend proefschrift op zal leveren. Ik hoop dat het EZH2 
artikel, waaraan we samen werkten, een mooie ‘functionele’ opvolger krijgt.
 Beste dames en heer van de moleculaire diagnostiek. Eigenlijk vind ik dat de naam ‘moleculaire di-
agnostiek’ tekort doet aan de bijdrage die jullie leveren aan het onderzoek. Een groot deel van jullie 
heeft meegewerkt aan het onderzoek in dit proefschrift en jullie allemaal dragen bij aan de goede sfeer 
die ik altijd ervaren heb als ik weer eens eventjes binnen liep. Bedankt voor jullie hulp bij onder meer 
het sequencen van TET2 en/of EZH2. Patricia, ik zie ons nog zitten om met een lineaaltje de pieken 
te meten. Gelukkig zijn er meer betrouwbare technieken. Louis, dank voor alle hulp met de CARDs 
en het  ‘primer-en-probe’ ontwerpen.
Beste Leonie,  Sylvie en Maaike, het was heel fijn om op het lab met mensen zoals jullie samen te 
werken. Sylvie, je bent inmiddels naar Canada verhuist om je als post-doc op een nieuw onderzoek 
te storten.  Als je dit met het doorzettingsvermogen doet waarmee je in de klimhal een route blijft 
proberen totdat je aan de top zit, komt het helemaal goed. Leonie, wij blijven hopelijk in de toekomst 
diezelfde klimroutes proberen. Dan zal ik het niet meer over Darwin hebben. Maaike, als jij jezelf een 
doel stelt, dan ga je daar volledig voor met een inzet waar ik alleen maar bewondering voor kan heb-
ben. Je wordt ongetwijfeld een uitstekende kinderarts. 
Beste Sas1 (of toch 2?), wij zijn kort na elkaar op het lab begonnen en inmiddels ben je een ervaren 
analiste. Er zijn niet veel mensen met wie ik 7 dagen en nachten vrolijk in de trein kan zitten, maar 
aan onze reis met de transmongolië-express heb ik alleen maar goede herinneringen.
Beste Aswin,  Elke, Jeannet,  Jurgen, Liesbeth en Sake, jullie werkten al een tijd op het lab toen ik 
ineens ‘op de stoep stond’. Ik wil jullie bedanken voor alle gezelligheid tijdens het eerste deel van mijn 
AIO-tijd. Leilei, Jimmy en Davide, jullie zijn later op het lab gekomen en inmiddels zelf ook bezig met 
het laatste deel van het AIO-schap. Ik wens jullie veel succes bij het afronden van jullie proefschrift.
Beste Roderick, net als Mariam en Leonie heb jij als student meegewerkt aan het TET-project. Hoewel 
de resultaten van jouw inspanningen uiteindelijk niet in dit proefschrift staan, heb je me veel werk uit 
handen genomen tijdens je stage.
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Chapter 7
Beste Marieke, jij hebt je een jaar lang met de TET2 mutatie analyses bezig gehouden en hierdoor een 
belangrijke rol gespeeld bij het tot stand komen van het eerste TET2 artikel. Rob en Jeroen, bedankt 
voor het vele helpen met het sorteren van de beenmergcellen die voor de studies in dit proefschrift 
gebruikt zijn. Christian en Jan, bedankt voor de hulp met de statistische analyses. Eveline en Simon, 
bedankt voor de hulp met de SNP-arrays. Reinier, dank voor de kritische inbreng bij de werkbespre-
kingen.
Beste dames en heren van ‘de morfologie’, ‘immuunfenotypering’ en ‘BMT-unit’; zonder de samen-
werking met jullie was nooit de basis gelegd voor het onderzoek in dit proefschrift, namelijk het 
verzamelen en karakteriseren van patiëntenmateriaal. 
Beste Peter, Estelle en Anne,  dank voor de fijne samenwerking vanuit Leuven. De patiëntsamples met 
de nauwkeurig verzamelde klinische data hebben een belangrijke bijdrage geleverd aan het onderzoek 
in dit proefschrift. 
Beste Marius en Petra, dankzij jullie is mijn beeld van ‘de patiënt met MDS’ niet beperkt gebleven 
tot het DNA. Jullie hebben mij, samen met Theo, de kans gegeven om op de polikliniek hematologie 
MDS patiënten te begeleiden binnen klinische studies. Daarnaast heb ik veel geleerd over de moge-
lijkheden en beperkingen van de diagnostiek naar MDS. Dit is een belangrijk onderdeel van mijn 
‘opvoeding’ tot arts-onderzoeker. 
Beste Fred, dank voor de snelle, uitvoerige en kritische beoordeling van mijn proefschrift.
Naast alle mensen met wie ik op het lab en in de kliniek heb samengewerkt, mogen nog een aantal 
anderen niet in dit dankwoord ontbreken. 
Beste Carien, Lynn, Remco, Renate, Ruth, Surayda en Susan. Tijdens en na onze geneeskunde studie, 
hebben we vele leuke momenten gedeeld. Jullie hebben tijdens mijn onderzoek en nu specialisatie 
voor de nodige afleiding gezorgd. 
Lieve papa en mama, ik wil jullie bedanken voor alle steun in de afgelopen jaren. Ik kan jullie zeg-
gen dat ik heel wat ‘correcties Langemeijer’ heb moeten uitvoeren voorafgaand aan publicatie van dit 
proefschrift. Het is fijn om te weten altijd op jullie te kunnen rekenen. 
Lieve Laurens, ik kan je nooit in een paar regels genoeg bedanken voor alles wat je voor me doet en 
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